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Dissertation Title: Investigating the genome of Anaplastic Lymphoma Kinase-positive Anaplastic Large 
Cell Lymphoma 
Name: Hugo Larose 
Anaplastic Large Cell Lymphoma (ALCL) is a T cell Non-Hodgkin Lymphoma, mainly presenting in 
paediatric and young adult patients. The majority of cases express a chimeric fusion protein resulting 
in hyperactivation of Anaplastic Lymphoma Kinase (ALK) as the consequence of a chromosomal 
translocation. Patients diagnosed with ALCL are still treated with toxic multi-agent chemotherapy and 
as many as 25-50% of patients relapse. It is clear that continued adaption of current therapies will likely 
not improve these statistics and for progress to be made, integration of biology with the design and 
implementation of future clinical trials is required. 
To understand disease pathology and to uncover novel targets for therapy, Whole-Exome Sequencing 
(WES) of ALK+ ALCL was performed, as well as Gene-Set Enrichment Analysis. This revealed that the 
Notch pathway was the most enriched in mutations. In particular, variant T349P of Notch1, which 
confers a growth advantage to cells in which it is expressed, was detected in 12% of ALK+ and ALK- 
ALCL patient samples. Furthermore, we demonstrate that the nucleophosphomin 1-Anaplastic 
lymphoma kinase (NPM-ALK) chimeric protein promotes Notch1 expression through binding of Signal 
Transducer and Activator of Transcription 3 (STAT3) upstream of notch1. Moreover, inhibition of 
Notch1 with γ-secretase inhibitors (GSI) or silencing by shRNA leads to apoptosis; co-treatment in vitro 
with the ALK inhibitor crizotinib led to additive/synergistic anti-tumour activity suggesting this may be 
an appropriate combination therapy for future use in the circumvention of ALK inhibitor resistance. 
Indeed, crizotinib-resistant and sensitive ALCL cells were equally sensitive to GSIs. In conclusion, we 
show a variant in the extracellular domain of Notch1 that provides a growth advantage to cells and 
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“Imagination is not only the uniquely human capacity to envision that which is not, and therefore the 
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1.1 The history of ALCL 
The history of Hodgkin Lymphoma (HL) can be traced back to the 17th century with a report from 1666 
(Malpighi, 1666), though it took until the 19th century for Thomas Hodgkin to publish his now famous 
paper on “Some morbid appearance of the absorbent glands and spleen” (Hodgkin, 1832), where he 
detailed historical clinical mentions of a similar disease and his own findings. In 1865, Sir Samuel Wilks 
further characterized the disease and named it in his paper “Cases of Enlargement of the Lymphatic 
Glands and spleen (or Hodgkin’s Disease) with Remarks” (Reviewed by Bonadonna, 2000). This was 
followed by large amounts of research on the characterization of the different tumour types 
throughout the 20th century (Reviewed in Bonadonna, 2000; Lakhtakia & Burney, 2015a; Canellos et 
al, 2014). There were a number of attempts to standardize classification of Hodgkin’s Lymphomas and 
other tumour types (including Non-Hodgkin Lymphomas), but the differentiation between Hodgkin 
and Non-Hodgkin Lymphoma (NHL) only crystallized in 2001 with the publication of the World Health 
Organisation (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues (WHO, 2001; 
Lakhtakia & Burney, 2015b; Bonadonna, 2000). 
The path to the identification of Anaplastic Large Cell Lymphoma (ALCL) as a distinct lymphoma entity 
began in 1982, with the discovery by Stein and colleagues of the antigen CD30 (also called Ki-1 or Berh-
H2) consistently expressed on Hodgkin Reed-Sternberg cells (Stein et al, 1982; Schwab et al, 1982). 
Reed-Sternberg cells are giant cells, often derived from B-lymphocytes, named after Dorothy Reed 
Mendenhall and Carl Sternberg, who in the early 20th century observed and described the microscopic 
feature of HL, before publishing these findings for the first time (Sternberg, 1898; Reed Mendenhall, 
1902). CD30 expression was seen not only on Reed-Sternberg cells of HL but also on cells within 
tumours showing an unusually large morphology. The tumours in which these cells resided were 
initially named Ki-1-positive Large Cell Lymphomas due to this unique, unusually large morphology. 
The name Anaplastic Large Cell Lymphoma itself was used in a number of publications (Krc et al, 1987), 
but was not widely adopted until the end of the 1980s (Pallesen & Hamilton-Dutoit, 1988; Rimokh et 
al, 1989; Herbst et al, 1989; Le Beau et al, 1989; Delsol et al, 1988). 
In 1988, a cell line shown to carry the t(2;5)(p23;q35) translocation was established from a Ki-1-positive 
tumour (Fischer et al, 1988; Rimokh et al, 1989; Le Beau et al, 1989). In 1994, Morris and colleagues 
reported the results of cloning and identification of the t(2;5) translocation breakpoints seen in ALCL 
samples from patients; the gene involved was named anaplastic lymphoma kinase (alk), a gene with 
sparse expression outside of the brain or developmental tissue (Morris et al, 1994). The catalytic 
domain of ALK was found to be transposed next to the amino terminus of nucleophosphomin 1 (npm1). 
NPM-ALK has since been characterised as an 80 kDa protein, present in both the cytoplasm and the 
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nucleus of ALCL tumour cells (Pulford et al, 1997). NPM-ALK homodimerizes via the NPM 
oligomerization domains, mimicking ligand binding, which in turn activates the ALK catalytic domain. 
NPM-ALK can also dimerize with wild-type NPM1, a protein involved in cellular trafficking, which is 
thought to explain the dual cytoplasmic/nuclear localization of the chimeric protein (Mason et al, 
1998). 
Not every patient presents with an ALK-encoding translocation, however, leading to a distinction 
between cases presenting with the ALK chimera and those without (Bitter et al, 1990; Lamant et al, 
1996; Yee et al, 1996; Benharroch et al, 1998). As such, there are two recognised subtypes of systemic 
ALCL, ALK+ or ALK-, which are listed in the revised 2008 WHO classification as distinct tumour types 
(WHO, 2008). While npm1 is the most common partner with alk in children with ALCL (70-75% of 
cases),  a number of alternative partner genes besides npm1 have also since been identified in ALK+ 
ALCL, such as tropomycin 3 (tpm3), atic, trk-fused gene (tfg), cltc, alo17 or tnf-receptor-associated 
factor 1 (traf1) (Lamant et al, 1999; Rosenwald et al, 1999; Liang et al, 2004; Trinei et al, 2000; Cools 
et al, 2002), but NPM-ALK remains the predominant translocation product, as it is present in three 
quarters of ALCL, ALK+ cases (Brugières et al, 2009).  
The 2008 WHO Classification also lists five histomorphology subtypes of ALK+ ALCL: common, small-
cell, lymphohistiocytic, Hodgkin-like and composite morphologies (WHO, 2008). As the name indicates, 
common patterns are the most frequently observed, in over half of ALCL cases. The lymphohistiocytic 
sub-type represents about a tenth of ALCL cases, and are identified by the presence of histiocytes 
which may sometimes mask tumour cells (Pileri et al, 1990). Small-cell patterns, represent less than a 
tenth of ALCL cases and are identifiable by the presence of small anaplastic cells with irregular nuclei 
and clear cytoplasm (Kinney et al, 1993). Hodgkin-like patterns of ALCL are so similar to HL that the 
two are easily confused, but represent just 3% of ALCL  (Vassallo et al, 2006).  
 
1.2 NPM-ALK 
The ALK protein is sparsely expressed in healthy human tissues, mostly concentrated in neural and 
endothelial cells, although alk mRNA is seen in a few other organs (Morris et al, 1994; Bilsland et al, 
2008). ALK itself is a receptor tyrosine kinase with an extracellular ligand-binding domain, a 
transmembrane domain and an intracellular tyrosine kinase domain (Iwahara et al, 1997), although its 
function remains largely unclear. However, some of ALK’s ligands have recently been described (Guan 
et al, 2015). The subcellular localization of the chimeric ALK in ALCL depends on its fusion partner. 
NPM-ALK in particular is distributed between the cytoplasm and nucleus; this is due to the ability of 
NPM-ALK to form complexes with wild-type NPM1 which contains a nuclear localization motif (Bischof 
et al, 1997).   
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NPM1 is a ribonucleic shuttle protein ubiquitously expressed at high levels in healthy cells, and has 
been shown to promote cell growth, but also to act as an oncogene in some contexts (Jiang & Yung, 
1999; Zeller et al, 2001; Feuerstein et al, 1988; Lim & Wang, 2006). Since alk is expressed at low levels 
in human tissues, it is thought that npm’s constitutively activated promoter is the driver behind 
aberrant npm-alk expression in ALCL. NPM1 has also proven to be the reason for NPM-ALK’s 
constitutive activation, while both NPM1 and ALK’s intracellular tyrosine kinase domain are required 
for downstream signalling (Bischof et al, 1997).  
NPM-ALK activates numerous downstream signalling pathways: it recruits the SH2 domain of PI3K, 
which in turn activates the Akt pathway (Bai et al, 2000). The Akt pathway is well-known for promoting 
cell growth and survival, and for being oncogenic if constitutively activated. PI3K also phosphorylates 
p27 (also called Kip1), targeting it for degradation, which mediates the downstream cell growth 
observed (Slupianek & Skorski, 2004; Rassidakis et al, 2005). In addition, NPM-ALK has been shown to 
recruit the SH2 domain of PLC-γ, which along with PI3k/Akt, is thought to be responsible for the 
mitogenic phenotype observed in NPM-ALK positive cells (Bai et al, 1998). Finally, Signal Transducer 
and Activator of Transcription 3 and 5 (STAT3 and STAT5) are also important targets of NPM-ALK, 
protecting NPM-ALK positive cells from apoptotic inducers (Zhang et al, 2007; Nieborowska-Skorska et 
al, 2001; Zamo et al, 2002). Numerous other proteins may be involved in signalling downstream of 
NPM-ALK, such as Shp2, Grb2, grb2-associated binding protein (Gab2) and Src, to name but a few, but 
the major signalling pathways downstream of NPM-ALK thought to lead to oncogenesis are 
summarised in Figure 1.1; indeed the targets of NPM-ALK signalling have been extensively reviewed 
(Chiarle et al, 2008; Lim & Wang, 2006; Webb et al, 2009).  
It should be said, however, that the aforementioned genes are but the main mitogenic pathways which 
are influenced by the NPM-ALK chimera and lead to the anaplastic phenotype observed in ALCL. 
Indeed, research groups, including our own, have shown NPM-ALK to be sufficient for the development 
of Lymphomas in NPM-ALK transgenic mice (Chiarle et al, 2003; Jäger et al; Turner et al, 2003, 2006). 
In addition to this, cloning NPM-ALK into primary cells leads to aberrant proliferation, invasiveness and 
























Figure 1.1: Major signalling pathways downstream of NPM-ALK. There are three main signalling 
pathways downstream of NPM-ALK: (1) Phosphoinositide 3-kinase (PI3K) and the Akt pathway, (2) the 
Ras/Extracellular signal-regulated kinase (ERK)-Mitogen Activated Protein Kinase (MAPK) pathway, 
and (3) the STAT3 pathway. (1) NPM-ALK recruits PI3K, which activates Akt1 and Akt2; this leads to 
enhanced survival and proliferation of NPM-ALK positive cells, by increased mammalian Target of 
Rapamycin (mTor) and B-cell lymphoma 2 (BCL2)-Associated Agonist of Cell Death (BAD) activity, as 
well as decreased Cyclin p27 activity. (2) NPM-ALK can also promote Ras activity by recruiting proteins 
such as Src homology region 2 (SH2)-containing protein tyrosine phosphatase (Shp2), Src and Growth 
factor receptor-bound protein 2 (Grb2). Ras then activates the Ras/MAPK pathway, leading to 
increased proliferation by activation of Cyclins. In parallel, NPM-ALK recruits Phospholipase C-γ (PLC-
γ), which activates the Protein Kinase C pathway (PKC). The PKC pathway overlaps with Ras/MAPK and 
leads to the same increase in cellular proliferation. (3) Finally, NPM-ALK activates STAT3 directly and 
via Janus Kinase 3 (JAK3). STAT3 activates downstream effectors which inhibit apoptosis and ensure 
cell survival. Parallel to this, the JAK2/STAT5 pathway has a similar effect, and is also activated by NPM-
ALK (Modified from Chiarle et al, 2008). 
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1.3 Treatment options 
Discovered by Wilhelm Röntgen (Röntgen, 1896), X-rays were quickly put to good use: anecdotal 
evidence suggesting their involvement in cancer therapy as early as 1896 (News of Science, 1957). 
Indeed already in 1902 was radiation therapy reportedly used on a HL patient; this is the first published 
evidence of non-symptomatic cancer treatment (Pusey, 1902). Radiotherapy was refined through trial 
and error throughout the 20th century, particularly by Gilberts and colleagues first, in France, and 
Peters and her colleagues in Toronto (Gilbert & Babaiantz, 1931; Peters, 1950). The advent of chemical 
warfare in the two World Wars led to the discovery of chemotherapy (starting with the discovery of 
mustard gas’ properties as a potent haematopoiesis suppressor), and in the 1970s radiation therapy 
was combined with chemotherapeutic agents for the first time (Mechlorethamine, Vincristine, 
Procarbazine and Prednisone, or MOPP protocol; Rosenberg & Kaplan, 1975; Devita et al, 1970). These 
efforts were greatly helped by the fact that Hodgkin Lymphoma’s Reed-Sternberg cells are unusually 
sensitive to both radiotherapy and chemotherapy. Due to the toxicity of the first iteration of 
chemotherapy regimens, a number of alternative drug combinations were trialled, and the protocols 
CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone) or CHOEP (CHOP plus 
Etoposide) were determined to be the best options for NHL, as less toxic yet as effective (Fisher et al, 
1993). 
Several trials attempted to refine the chemotherapy regimen, first for B- and T-cell NHL, and then 
specifically for ALCL. ALCL, not initially being recognised as an independent entity, as explained earlier, 
was treated as B- or T-cell NHL until the 1990s - indeed, retrospective studies have shown that a 
number of ALCL cases were treated within the B- and T-cell NHL trials (all these trials have been 
extensively reviewed in Prokoph et al, 2018). Some of the best results for ALCL were obtained by the 
NHL Berlin-Frankfurt-Münster (NHL-BFM) working group, which recommended the use of 
methotrexate along with the CHOP backbone (Seidemann et al, 2001). Unfortunately, this was 
associated with a number of serious short-term adverse events, hence the NHL-BFM95 study 
attempted shorter doses with short-pulses, and found this to be not inferior but less toxic (Woessmann 
et al, 2005). 
The European Inter-group for Childhood NHL (EICNHL) led the first and largest international ALCL-
specific clinical trial initiated in 1999 for patients under the age of 22: ALCL99 (NCT00006455), which 
recruited 352 children in 11 European countries and Japan. (Mori et al, 2014; Attarbaschi et al, 2011). 
The protocol’s objectives were to test two different methods of delivering methotrexate and to test 
the efficacy of the addition of vinblastine in high risk patients. Indeed, CHOP was still seen as too toxic,  
particularly in the paediatric setting, and so the search remained for less aggressive alternatives. 
Vinblastine, originally extracted from the Madagascar periwinkle (Brown, 1965), had been investigated 
as part of the ABVD backbone (Adriamycin, Bleomycin, Vinblastine, Dacarbazine), and was found to be 
 
24/172 
significantly less toxic than MOPP (Santoro et al, 1987; Bonadonna et al, 1975). ALCL99 used the 
recommended NHL-BFM90 protocol, with either a 24-hour methotrexate infusion (with intrathecal 
injection), or a higher 3-hour dose of methotrexate without intrathecal injections respectively for arms 
MTX1 or MTX3 (1g/m2 over 24 hours with intrathecal injections versus 3g/m2 over 3 hours without 
injections). These protocols were then supplemented with weekly Vinblastine for randomized high-
risk patients, followed by Vinblastine weekly, on its own for 52 weeks, as a maintenance treatment. 
Maintenance could be given on an outpatient basis, thereby greatly improving quality of life. 
The Event-Free Survival (EFS) for patients on the trial were not significantly improved over those 
obtained in previous trials, though it did demonstrate that 3g/m2 short-pulse methotrexate without 
intrathecal injections was less toxic than the alternative arm. The trial reported a 2-year Overall 
Survival (OS) of 92%, and a 2-year EFS of 74%; ALCL99 as a front-line regimen has since become the 
gold standard for paediatric ALK+ ALCL (Brugières et al, 2009; Seidemann et al, 2001; Wrobel et al, 
2011). The addition of Vinblastine for high-risk patients showed no improvement in the 2-year EFS 
compared to patients who did not receive vinblastine, although these data suggest that the 1-year 
maintenance phase delays relapse (Le Deley et al, 2010). Whilst OS using this trial protocol is excellent, 
EFS remains sub-optimal and acute toxicity remains significant, with 60% of patients reporting grade 4 
neutropenia, 20% with weight gain and 15% mucositis (Wrobel et al, 2011).  
In North America, different chemotherapeutic backbones were used. The Paediatric Oncology Group 
(POG) and the Children’s Cancer Group (CCG; later combined into the Children’s Oncology Group; COG) 
ran two concurrent studies: POG9315 and CCG5941. POG9315 trialled a year-long regimen based on 
the APO chemotherapy backbone (Adriamycin, Prednisone and Vincristine) (Laver et al, 2005), while 
CCG5941 tested one year of chemotherapy (Vincristine, Prednisone, Cyclophosphamide,  Daunomycin, 
Asparaginase for induction, along with 6-thioguanine, cytarabine and methotrexate for consolidation 
and maintenance) designed to treat T lymphoblastic lymphoma (Lowe et al, 2009). The trials found 
similar results to the European trials, with a 4-year EFS of 72% for the POG trial, versus a 5-year EFS of 
68% for the CCG trial. It should be noted that only advanced stage III and IV patients were included in 
both of these trials, as opposed to the European trials which were open to all ALCL patients possibly 
accounting for the lower OS observed. Later came COG trial ANHL0131 which assessed the efficacy of 
vinblastine when combined with the APO regimen of POG9315. The trial led the COG to the same 
conclusion as the EICNHL, with a similar 3-year EFS of 76% and no benefit to the addition of vinblastine 
(Alexander et al, 2014). Currently, both APO and ALCL99 could be considered standard chemotherapy 
for children with ALCL. That said, as ALCL99 has potentially less long-term toxicity (especially cardiac) 
than APO and in order to facilitate wider international collaboration, the ALCL99 backbone was 
adopted by the COG in their current clinical trial.   
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Due to the relatively small number of relapsed or refractory patients, it has been difficult to design and 
conduct a trial for this group of patients. Instead, a number of retrospective studies by European and 
Japanese groups assessed the success with which small cohorts of patients had been treated, using 
either allogeneic or autologous Stem Cell Transplantation (SCT). There is some evidence to show that 
allogeneic SCT yields better outcomes for relapse patients, yet there is no consensus on this, nor on 
the type of conditioning which should be used, although radiotherapy seems to be the most common 
option (Reviewed in Prokoph et al, 2018). Some of the more recent trials, however, have shown 
promise. Perhaps most interestingly, the EICNHL trial ALCL-Relapse (NCT00317408) has shown that 
allogeneic SCT yields a higher survival rate for relapsed patients but is inconclusive as far as refractory 
patients are concerned. In addition, single-agent vinblastine achieved high remission rates for both 
relapsed and refractory patients (Woessmann et al, 2012; Ruf et al, 2015). Hence, vinblastine is a 
potential option as a single-agent therapy, although only with a low-dose, long-term regimen 
(Woessmann et al, 2012).  
 
1.4 A ceiling has been hit - the need for biomarkers and prognostic factors 
The success of prior trials with OS varying from 80-92% has in itself resulted in difficult ethical 
considerations for trialling new drugs, particularly for low risk patients (Minard-Colin et al, 2015). This, 
combined with the relatively low incidence of ALCL, which represents just 15% of childhood and young 
adult NHL presents dilemmas in the design and conduct of new trials. Indeed, data from British 
Columbia suggests an incidence of diagnosed ALCL cases of under 4 per million children and young 
adults (Alessandri et al, 2002). In Europe, this represents fewer than 100 new cases per year (Shiramizu 
et al, 2016). In contrast to OS rates, EFS rates are lower, ranging from 59-76%, depending on the 
treatment protocol used (Prokoph et al, 2018; Minard-Colin et al, 2015). Unfortunately, this means 
that not only do 10-15% of children not survive a diagnosis of ALCL, but many survivors suffer from the 
late effects of intensive therapies and/or transplantation required to cure them. Therefore, there is a 
clear need for new therapies facilitated by bench-side biological research into ALCL and the 
development of predictive biomarkers. Targeted therapies, for instance, may well prove significantly 
less toxic than the current gold standards, as often having less off- or un-intended targets, and hence 
fewer side-effects. 
What is clear is that some children respond well to treatment and have a low risk of relapse, whilst 
others fail therapy and/or suffer multiple relapses. It is therefore likely that we are over-treating some 
children and as a consequence exposing them to unnecessary toxicities. In order to identify these 
children, biomarkers are required that are clinically actionable. Some clinical factors such as visceral 
or mediastinal disease and bone marrow involvement initially showed promise as predictors of 
treatment failure (Lamant et al, 2011; Mussolin et al, 2005; Le Deley et al, 2008). Other potential 
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biomarkers such as circulating tumour cells in bone marrow or peripheral blood may have prognostic 
value (Damm-Welk et al, 2007). Tumour cells in peripheral blood, or minimal disseminated disease 
(MDD) has gained traction in recent years as a biomarker for ALCL. Indeed, studies have shown 
significant differences in progression-free survival when retrospectively stratified using a combination 
of MDD and anti-ALK autoantibody titres, the latter being another promising biomarker for ALCL 
(Mussolin et al, 2013). Anti-ALK autoantibodies can be identified and quantified in a majority of 
patients, and may on their own help to predict risk of relapse (Ait-Tahar et al, 2010; Knörr et al, 2018). 
Other potential biomarkers for relapse risk are microRNA (miRNA) detected in exosomes within the 
peripheral blood of patients. In particular, miR-103a-3p and miR-223-3p when detected in exosomes 
are predictive or relapse, potentially because they are thought to increase the invasiveness of ALCL 













Figure 1.2: Main biomarkers thought to be predictive of relapse risk or prognosis in ALCL . The most 
obvious prognostic biomarkers are of a clinical nature, including bone-marrow or mediastinal 
involvement. Minimal residual disease is also a predictive biomarker. More recent liquid biopsy-based 
biomarkers show promise, though have yet to be validated in prospective clinical trials, these include 
exosomes (and miRNA profiles), circulating tumour cells (MDD), circulating DNA and anti-ALK 




Studies have also shown MDD and minimal residual disease (MRD) to be a potential combination to 
stratify ALCL patients according to risk, although MDD may be a valid prognostic factor on its own when 
employing the highly sensitive technique of digital droplet PCR (Damm-Welk et al, 2018). However, it 
remains to be seen whether prognostic markers predicting response to established chemotherapy 
schedules will apply to therapeutic protocols involving new targeted agents. The potential of 
biomarkers based on liquid biopsies is immense, yet all require validation in prospective clinical studies 
(Figure 1.2). MDD and ALK autoantibody titres may be predictive of response to therapy with the ALK 
inhibitor crizotinib or the anti-CD30 drug conjugate brentuximab vedotin (BV) when given in 
combination with an ALCL99 backbone although full results are not expected until 2019 and 2022 
(Rolland et al, 2018; Lowe, 2018).  
 
1.5 Current avenues for treatment - breaking the ceiling 
A number of different chemotherapy regimens have been trialled, but none have been able to breach 
an OS of 90% and 70% EFS (Prokoph et al, 2018; Lowe & Lim, 2013). It is therefore unlikely that 
modifying current trial protocols further will improve these statistics, but modifications could improve 
the acute side-effects of therapy. EICNHL therefore aims to launch a trial of single-agent vinblastine as 
a front-line therapy for standard-risk patients, to test whether this could replace ALCL99 and thus 
drastically reduce toxicity, though whether this will improve OS or EFS remains to be seen. In addition, 
although a prolonged course of vinblastine is a significant commitment for parents and their families, 
the fact that this can be given as an outpatient may significantly improve the patients’ qualify of life. 
High risk patients (defined using a biomarker yet to be determined) would continue to receive the 
current standard of care. 
Progression on therapy carries an extremely negative prognosis, with only 25% of these patients 
estimated to survive, even when given aggressive salvage therapies (Woessmann et al, 2006, 2011). 
This is a salient issue, particularly given the lack of consensus on the treatment of relapsed or refractory 
ALCL. Latent toxicity is also an issue, as methotrexate has a number of side-effects, not to mention 
possible long-term effects for the survivors (Oeffinger et al, 2006). Indeed, long-term morbidity for 
survivors of NHL is significantly higher than healthy controls - survivorship and long-term follow-up 
should be kept in focus when developing new therapies (Burkhardt & Woessmann, 2018; Ehrhardt et 
al, 2018). Consequently, novel trial designs are required incorporating bench-side research to risk-
stratify patients towards dose reduction for low risk patients, while the introduction of novel, targeted 
agents is needed for high risk children - but also to facilitate a better distinction between children more 
likely to suffer an event from those for whom therapy will be curative.  
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ALK is arguably the ideal target for ALK-positive diseases due to tumour addiction to its expression – 
inhibition of NPM-ALK alone in cell and murine models leads to tumour regression - and its near-absent 
expression in healthy tissue. Unfortunately, the rarity of ALCL has meant little interest from 
pharmaceutical companies in developing a small molecule inhibitor for this indication. Indeed, only 
after being identified in Non-Small Cell Lung Cancer (NSCLC) did interest peak in ALK as a therapeutic 
target and in 2008, Pfizer launched a phase I trial for crizotinib, an ALK/cMet/ROS1 inhibitor – and was 
awarded breakthrough approval in 2011 for the treatment of NSCLC (Camidge et al, 2012). Other ALK 
inhibitors have since been developed, although none have so far been approved for use in paediatric 
ALCL. However, their use is starting to be trialled in a number of settings, including ALCL (Reviewed in 
Prokoph et al, 2018). Results are promising, particularly for refractory adult ALCL patients, for whom 
odds of survival have improved significantly from 30% to 73% (Gambacorti Passerini et al, 2014). 
Recent data in a paediatric setting have also shown encouraging outcomes, with response rates for 
refractory and relapse ALCL patients of between 80 and 90% depending on dosage (Mossé et al, 2017). 
Unfortunately, trial data on the use of ALK Tyrosine Kinase Inhibitors (TKIs) as a front-line treatment 
for ALCL is so far missing, although trials are in progress (Prokoph et al, 2018). Unfortunately, given the 
objectively high OS rates observed in ALCL patients, clinicians are understandably wary to trial ALK TKIs 
as a stand-alone therapy, and therefore these trials have started by combining ALK TKIs with standard 
therapy – rather than to facilitate dose-reduction of chemotherapy. The COG trial ANHL12P1 
(NCT01979536) is currently testing the addition of BV or crizotinib to ALCL99 chemotherapy for newly 
diagnosed patients with ALCL. The trial also includes prospective analysis of MDD, MRD and ALK 
autoantibodies, to assess whether these have prognostic value. Patients have been randomized to 
receive either BV (1.8 mg/m² once per cycle), or crizotinib (165 mg/m² for 21 days each cycle) along 
with the ALCL99 backbone. The trial opened in November 2013 in 135 institutions and is reaching 
accrual as of time of writing. As a change to previous COG trials, the current one includes stage II 
patients, who have been shown to have similar outcomes to those of stages 3-4 in previous trials. A 
further phase II trial of crizotinib combined with vinblastine could provide a further option for 
treatment of relapsed and refractory ALCL (CRISP trial, ITCC053).  
As with other TKIs, resistance is expected, and has indeed been observed, sometimes with aggressive 
relapses in isolated cases (Gambacorti-Passerini et al, 2016; Sharma et al, 2018). It may be that ALK 
TKIs should be given on a long-term basis, possibly on a metronomic schedule to improve control of 
tumour progression (Amin et al, 2015). It may also be that combination therapies could alleviate the 
risk of relapse, indeed recent data in experimental settings show synergies between either Notch 
inhibitors and ALK TKIs (Larose et al, 2018), or ALK TKIs and BV (Hudson et al, 2018). Combination 
approaches require further study, although the latter combination demonstrating synergy is 
somewhat surprising given the fact that inhibition of NPM-ALK leads to downregulation of CD30 
expression, thus robbing BV of its target (Hsu et al, 2006). In addition, it has been reported that 
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chemotherapeutic drugs such as doxorubicin may act antagonistically to crizotinib (Hudson et al, 
2018). 
An alternative target for the treatment of ALCL - regardless of ALK status - is CD30, which is consistently 
present on ALCL cells, and which expression is restricted to activated T and B-cells under homeostatic 
conditions, thereby limiting the risk of off-target effects. Early attempts at developing antibody-based 
drug delivery of toxins such as saporin-6 or pseudomonas exotoxin A, or radioisotopes such as iodine-
131 to CD30-positive cells proved too toxic for the paediatric setting (Pasqualucci et al; Klimka et al, 
1999; Schirrmann et al, 2014; Schnell et al, 2005). The arrival of the anti-CD30 antibody SGN-30 
conjugated to the anti-microtubule agent monomethyl auristatin E (BV, or SGN-35), which targets 
CD30-positive cells and delivers the antimitotic drug has shown promise. BV was approved by the Food 
and Drug Administration (FDA) in 2011, but only for use in chemo-resistant, relapsed adult ALCL 
patients (FDA, 2011). A number of adult HL and NHL trials have since published their results, including 
some incorporating adolescent and young adult patients (Sekimizu et al, 2018), but it wasn’t until 2012 
that a paediatric-specific phase I/II trial for relapsed or refractory ALCL patients began (NCT01492088). 
Early results from this study have recently been reported, and are disappointing; only 53% of ALCL 
patients achieved an overall response, and all patients on the study experienced adverse events, with 
44% suffering at least one grade 3 or worse treatment-related side-effect (Locatelli et al, 2018). In 
addition, questions remain as to how to treat patients failing BV, as this has been shown to be 
associated with a very poor outcome (Chihara et al, 2018). An alternative therapy targeting CD30 may 
be Chimeric Antigen Receptor T (CAR-T) cells (cells engineered with an ectopic T-cell receptor targeting 
a specific antigen). A number of trials are planned for adult relapsed CD30-positive lymphoma, but no 
data for the paediatric setting has yet been published.  
The importance of the immune response to ALCL has been highlighted by the role of anti-ALK 
autoantibodies in treatment outcome. However, tumour cells also evade the immune response by 
downregulating CD48, thereby promoting immune evasion, a process that is reversed by inhibiting ALK 
(Wu et al, 2018). Immune evasion is also facilitated by NPM-ALK-induced expression of Programmed 
Cell-Death Ligand 1 (PDL-1) on the surface of ALCL cells, which has been confirmed in patient tumours 
(Yamamoto et al, 2009; Marzec et al, 2008). Given the role of PDL-1, PDL-2 and receptor PD-1 in 
tumour-driven immune suppression of T-cells, immunotherapy holds potential promise for the 
treatment of ALCL. Following case reports of adolescent or young adult patients with relapsed ALCL 
responding to nivolumab (anti-Programme cell Death protein-1 or PD-1; which also reported minimal 
toxicity) (Rigaud et al, 2018; Hebart et al, 2016), the checkpoint inhibitor was entered into clinical trials 
for both adult and paediatric relapsed and refractory ALK+ ALCL (NCT03703050, trial ‘Nivo-ALCL’). 
Perhaps the main caveat for check-point inhibitors such as nivolumab, is the lack of agreed biomarkers. 
Studies have shown that strength of expression of PDL-1 does not predict response to treatment; not 
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only do patients with strong PDL-1 not necessarily respond, but some patients without strong PDL-1 
expression have shown excellent responses (Grigg & Rizvi, 2016).  
As depicted in Figure 1.3, the timespan between bench-side discoveries and development at the 
bedside has accelerated in recent years, though unfortunately is mostly driven by developments to 
















Figure 1.3: Timeline of the main discoveries relevant to ALCL. The most ground-breaking bench-side 
studies of ALCL are depicted in the timeline and point to, where relevant, the main clinical trials 





































FDA approval for specific 
indications in Hodgkin 
Lymphoma and ALCL31-year span to 1st paediatric 
ALCL trial
17-year span to 1st
paediatric ALCL trial







Table 1.1: Targets for which therapies exist along with corresponding current trials. The treatment 
protocols and doses for the targeted agents are also detailed (BV: Brentuximab Vedotin, VBL: 
Vinblastine, IV: Intra-venous, RP2D: Recommended Phase-II Dose). 
 
 
Target Therapy Trial Phase Patients Schedule Dose Notes 
ALK 
crizotinib 
NCT00939770 I/II Relapsed/Refractory 
Orally, twice 
daily 
Determining RP2D  







UMIN000028075 I/II Relapsed/Refractory 
Orally, twice 
daily 
Determining RP2D  
ITCC053 I-B Relapsed/Refractory Twice Daily Determining RP2D 
Combination 
with VBL 











patients under 18 
 
alectinib UMIN000016991 II Relapsed/Refractory 
Orally, twice 
daily 
300mg, except for 
patients <35kg, 
who got 150mg 
for at least one 
year 
 
ceritinib NCT02729961 I/II Frontline 
Orally, once 







NCT02729961 I/II Frontline 
IV (30 mn) 
every three 





NCT01492088 II Relapsed/Refractory 
IV (30 mn) 





NCT01979536 II Frontline stages II-IV 
IV (30 mn) 
every three 






SGN-30 NCT00354107 I/II Relapsed 






PD-1 nivolumab NCT03703050 II Relapsed 
IV, every 2 
weeks for 8 
weeks, then 
every 4 weeks 




imatinib NCT02462538 I/II 
Relapsed/Refractory 
patients of at least 18 
years of age 
Orally, for up to 
48 weeks 
200 mg daily, up 





1.6 Developing our understanding of the biology of ALCL to identify novel therapeutic targets 
A number of potential therapeutic targets have been identified in the laboratory, but most have yet to 
make headway at the bedside. For example, the signalling pathways active in ALCL have been 
extensively studied and documented providing multiple potential targets for therapy. The PI3-Kinase, 
Akt, Mouse double minute 2 homologue (MDM2), c-Jun N-terminal Kinase (JNK), STAT3 and PLCγ 
pathways are all activated by NPM-ALK and have been shown to drive cell survival in experimental 
settings (Bai et al, 1998, 2000; Turner & Alexander, 2006; Slupianek & Skorski, 2004; Chiarle et al, 2005; 
Leventaki et al, 2007; Marzec et al, 2007; Turner et al, 2007; Zhang et al, 2002; Cui et al, 2009). Perhaps 
more advanced in its clinical progress is the platelet derived growth factor receptor beta (PDGFR β) 
which has been shown to be a promising therapeutic target in the treatment of ALCL both at the bench 
and bedside (in adult patients; Laimer et al, 2012; Garces de los Fayos Alonso et al, 2018a). PDGFRβ 
expression in ALCL is mediated by MAPK, in particular the Activator Protein (AP-1) transcription factors 
Jun and JunB (Garces de los Fayos Alonso et al, 2018b; Leventaki et al, 2007). Indeed, AP-1 transcription 
factors themselves are attractive therapeutic targets in ALCL since patient tumours express high levels 
of the transcription factors basic leucine zipper ATF-like transcription factor (batf and batf3) (Liang et 
al, 2018).  
Overall, the limitations to conducting paediatric ALCL trials are not the science and discovery of new 
targets, but clinical development, which requires intelligent trial design to develop protocols with small 
patient number, lower toxicities and higher EFS rates. The road from the bench to the bedside for ALCL 
has been slower than for many cancers. Indeed, seventeen years separate the discovery of NPM-ALK 
and the approval of the first drug targeting it – and still we are waiting for its approval for the treatment 
of paediatric ALCL. CD30 is a similar story, with nineteen years spanning its first description in ALCL 
and the FDA approval of a targeted agent. Indeed, while in many cancers academics may struggle to 
keep up with the rate of new clinical trials and drug development, at least in the paediatric setting the 
reverse is often seen, as access to new agents is more difficult.  
Fortunately, there is movement from regulatory agencies to facilitate treatment for children with ALCL. 
In the USA, legislation such as the RACE for Children Act, signed into law as part of the FDA 
Reauthorization Act of 2017 may yet change the equation by requiring paediatric trials for drugs of 
interest already being trialled in adults (Walden, 2017). In Europe, the ACCELERATE platform, formed 
in 2013 as part of the European Network for Cancer research in Children and Adolescents is steered by 
a number of representatives from patient advocacy groups, academia, industry and regulatory bodies. 
The platform aims to identify bottlenecks and hurdles to speed up the arrival of drug at the patient 
bedside (Pearson et al, 2016; Vassal et al, 2015). Laboratory research into ALCL has greatly improved 
our understanding of the oncogenic nature of the disease (Reviewed in Larose et al, 2019). We hope 
that this extensive knowledge coupled with the cooperation of clinicians, researchers, pharmaceutical 
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companies and regulatory agencies will allow all children who develop ALCL to be cured with minimal 
toxicity in the very near future. 
 
1.7 The Notch pathway 
One pathway thought to be important for the biology of ALCL is the Notch pathway (Larose et al, 2018). 
The notch gene was stumbled upon while studying Drosophila melanogaster just over a century ago, 
when Morgan and colleagues observed notches on flies following genetic mutations leading to loss of 
function of the notch gene (Morgan, 1917). This family of genes have since been found to encode large 
(300 KDa) proteins. Notch proteins are transmembrane receptors made up a number of different 
domains; the main extracellular ones are the 36 epidermal growth factor (EGF)-like repeats and the 
Negative Regulatory region (NRR) which, in wild-type setting, prevents ligand-independent activation 
of the receptor, though mutations to the notch family of genes may override this. The intracellular 
domains are made up of a Recombination Signal Binding Protein Jκ (RBP-Jκ)-Association Molecule 
(RAM), 6 Ankyrin repeats (ANK; which contain the two nuclear localization signals), a Transactivation 
(TAD; also known as Heterodimerization) domain and a sequence rich in Proline, Glutamic Acid, Serine 
and Threonine (PEST) as depicted in Figure 1.4A. 
Members of the Notch family of receptors are activated by one of five ligands; Jagged1 or 2, Delta -
like1, 3 or 4 (Jag1, Jag2, DLL1, DLL3 and DLL4), which leads to cleavage of the intracellular domain of 
Notch (ICN) by γ-secretase (a protease complex which cleaves proteins with an intramembrane 
domain). The ICN then is transported to the nucleus where changes in gene expression are effected by 
binding of ICN to RBP-Jκ, displacing corepressors and thus preventing RPB-Jκ from inhibiting Notch 
target genes (Reviewed in Borggrefe & Oswald, 2009 and summarized in Figure 1.4B) – though it 
should be noted that there is also evidence for signalling outside the RBP-Jκ pathway (Reviewed in 
Heitzler, 2010). 
A number of genes are directly targeted, but the main ones include the hairy enhancer of split family 
(hes and hey), the hes-related repressor protein family (herp), ptcra, nrarp, deltex E3 ubiquitin ligase 1 
(dtx1) and cyclin-dependent kinase (cdk)-related genes involved in cell cycle regulation (Davis & Turner, 
2001; Iso et al, 2003; Rangarajan et al, 2001; Krebs et al, 2001; Deftos et al, 2000; Reizis & Leder, 2002). 
Some of the main pathways effected by Notch include Nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB), Akt/mTOR and Wingless-type (Wnt) (Reviewed in Ayaz & Osborne, 2014). The 
Notch pathway regulates a number of key biologic functions (Reviewed in Greenwald, 1998), one of 
which is haematopoiesis and T-cell development. Indeed, Notch1 expression in bone marrow lymphoid 
progenitors instruct these cells to adopt a T cell fate: inactivation of the protein or of RBP-Jκ leads to 





seen by a significant increase in the amount of B cells present in the thymus) - and constitutive 
activation of Notch has the opposite effect (Wilson et al, 2001; Pui et al, 1999; Kawamata et al, 2002). 
There is yet no overarching consensus as to the exact role Notch has to play in T cell differentiation 
beyond this (the topic has been extensively reviewed in Amsen et al, 2015; and Radtke et al, 2013). 
 
 
Figure 1.4: The Notch protein structure. (A) Structure of the Notch1 receptor. EGF-like repeats (EGF-LR), 
Negative Regulatory Region (NRR), LIN12/Notch Repeats (LNR), Heterodimerization Domain (HDD), 
RBP-Jκ Association Molecule (RAM), Ankyrin Repeats (ANK), Nuclear Localization Signals (NLSs), 
Transactivation Domain (TAD), Polypeptide enriched in proline, glutamate, serine and Threonine 
(PEST). (B) Schematic Notch signalling cascade including Notch ligand families Jag and DLL, release of 




As far as cancers are concerned, the evidence is mixed; indeed in some cell types, Notch has an 
oncogenic role (T cell acute lymphoblastic leukaemia, or T-ALL, for example), while in others (Acute 
myeloblastic leukaemia, AML, for example) a tumour suppressor effect has been observed (Reviewed 
in Hernandez Tejada et al, 2014). A number of lymphoma and leukaemia have also shown Notch 
mutations driving cancer, including paediatric T cell lymphoma (Grabher et al, 2006) – the role of Notch 
in ALCL will be detailed in subsequent chapters. 
 
1.8 Next-Generation Sequencing and the ALCL genomic landscape 
The genetics and epigenetics of ALCL have been sparsely studied. Evidence shows that the genome of 
ALCL is relatively stable, although there are indications that a higher frequency of chromosomal 
imbalances may be indicative of a poorer prognosis (Youssif et al, 2009; Salaverria et al, 2008; Eckerle 
et al, 2009). Some genetic events of ALCL, ALK- have also recently been identified, such as the 
involvement of the JAK/STAT pathway, or miRNA-155 overexpression, but there is still only limited 
data as to the therapeutic applications of these findings (Crescenzo et al, 2015; Merkel et al, 2010, 
2015). Whilst the above described data provide obvious targets for therapy, delving deeper into the 
biology of ALCL can provide more findings not immediately apparent as therapeutic targets. Indeed, 
other molecules can regulate cell survival in ALCL including, for example, non-coding RNAs. The miRNA 
profile of ALCL tumours is highly dependent on NPM-ALK expression levels (Garbin et al, 2018) 
suggesting that some might be regulated directly by NPM-ALK activity, for example,  miRNA-150 has 
been shown to be silenced in ALCL and that restoring expression hinders tumour cell growth (Hoareau-
Aveilla et al, 2015).  
It is not clear whether miRNA-150 is silenced in an NPM-ALK-dependent manner, but there is evidence 
that NPM-ALK affects the epigenome of ALCL, which in turn may explain downstream signalling despite 
a stable genome. Indeed, NPM-ALK has been shown to epigenetically silence a whole raft of genes, by 
signalling through STAT3, for instance (Ambrogio et al, 2009). Indeed, STAT3 has been shown to induce 
dna methyltransferase (dnmt1) expression, an important epigenetic silencer (Zhang et al, 2006, 2005). 
Some examples of genes silenced in ALCL include stat5a and il-2r whose rescue has been shown to 
inhibit NPM-ALK expression in a manner which is tumour suppressive (Zhang et al, 2007, 2011). NPM-
ALK is also increasingly thought to be the cause of a number of epigenetic changes (Reviewed in Ducray 
et al, 2019). This has led to new potential therapeutic avenues by reactivating silenced genes; there 
already exists proof-of-concept evidence for this approach in vitro (Hassler et al, 2012). A number of 
these epigenetic changes are thought to be mediated by modulating CpG island methylation; studies 
show that ALCL cell lines have increased methylation at such islands (Eberth et al, 2010; Piazza et al, 
2013; Watanabe et al, 2008; Nishikori et al, 2003). Long non-coding RNA have also recently been 
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implicated in ALCL, such as LINC01013, which has been shown to promote invasiveness of ALCL cells 
(Chung et al, 2017). 
NGS is increasingly used to understand the genetics of tumours and identify risk factors. The genetics 
of ALCL for example have revealed a multitude of ALK fusion partners (Reviewed in Ducray et al, 2019). 
This has also been helpful in ALK- ALCL, some subtypes of which have been identified, as mentioned. 
Two main types of analyses are being employed to identify driver mutations; either examining driver 
genes by looking for frequently mutated genes (at varying positions), or by looking for specific point  
mutations, deletions and insertions that are mutated in a constant manner in several different 
tumours. The former technique is mostly employed to identify driver oncogenes or lost tumour 
suppressors, or genes consistently indicative of poor prognosis (Lasorsa et al, 2016). However the latter 
technique has been used to identify a number of mutations involved in malignancy (Ho et al, 2013; 
Wang & Armstrong, 2007). Not only do these Single Nucleotide Polymorphism (SNP) chips or panels 
lead to intriguing cancer detection possibilities by DNA sequencing, they also pave the way for 
prognosis prediction.  
 
1.9 Aims of this study 
As explained, second-line treatment and combination therapies for relapse patients are still required 
– as well as predictive markers to allow dose de-escalation for patients who would react well to the 
current gold-standard, often children who could benefit from a less toxic treatment than ALCL99. Many 
breakthroughs in other cancer types have come from the study of the genome of these malignancies, 
by identifying oncogene addiction or driving mutations and/or pathways. Since relatively little is known 
of the genomic profile of ALCL, this necessarily limits both our understanding of the biology of ALCL, 
and our ability to posit about new therapies and predictive biomarkers.  
This thesis describes work conducted performing whole exome sequencing (WES) of ALK+ ALCL, 
pooling different cohorts together, analysing a total of 25 ALK+ ALCL tumours genomes, further 
validating the variants identified in another 78 cases of ALCL to understand disease pathology and to 
uncover novel targets for therapy. The main mutated pathways in ALCL were then assessed, along with 
the genomic profile more broadly, in the context of what is known of paediatric cancer genomes. Gene 
Set Enrichment Analysis (GSEA) is employed here to enable pathway analyses, combining results from 
different algorithms to form robust conclusions. The biological significance of any identified and 
validated variant or significantly mutated pathway is then analysed to both improve our understanding 
of ALCL biology and to uncover new potential treatment options, as well as to look for prospective 
predictive biomarkers of either relapse or poor prognosis.   
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2. Materials and Methods 
 
2.1 Cell culture 
Routine culture and passaging 
The cell lines HEK293FTs, ALK+ ALCL cell lines (Karpas 299, SU-DHL1, SUP-M2, DEL), ALK- ALCL lines 
(MAC2A, FEPD), an acute T-cell leukaemia cell line (CD4 and CD8 negative Jurkat), and mouse feeder 
cell lines (wild-type or DLL-1 expressing OP9) were cultured in a humidified 37⁰ C incubator, at 5% CO₂. 
ALK+ ALCL and Jurkat cell lines were obtained from the DSMZ, while FEPD were obtained from 
Annarosa Del Mistro at the University of Padua, and Mac2A were obtained from Olaf Merkel at the 
Medical University of Vienna. OP9 cells were obtained from Alison Michie, in Glasgow, and HEK293FT 
were obtained from Nick Coleman, at the University of Cambridge.  
HEK293FT is an adherent line grown in Dulbecco’s Modified Eagle’s Medium (DMEM; ThermoFisher 
Scientific, Cat# 11995065) supplemented with 10% Fetal Bovine Serum (FBS, Sigma-Aldrich, Cat# 
F9665) and 1% Penicillin-Streptomycin (Sigma-Aldrich, Cat# P4333). ALCL cell lines are all suspension 
cell lines and were cultured in Roswell Park Memorial Institute (RPMI) 1640 (ThermoFisher Scientific 
Cat# 21875091) medium supplemented with 10% FBS and 1% Penicillin-Streptomycin. OP9 cells were 
transduced to express the Notch1 ligand DLL-1 (expressed using the pMIGR-1 plasmid, see chapter 
2.6). OP9 cells are adherent and were grown in α-Modified Eagle’s Medium (α-MEM) medium 
(ThermoFisher Scientific, Cat# 12561056), supplemented with 20% FBS.  
Every two to three days, suspension cells were collected by centrifugation at 100 g for 5 min at room 
temperature and were seeded to reach either a density of 100,000 cells per mL, or to the density 
required for the subsequent experiment. Every 6 months, cell lines were tested for Mycoplasma, using 
an EZ-PCR Mycoplasma test kit (Geneflow, Cat# 20-700-20), according to the manufacturers’ 
instructions. Every two to three days, adherent cell lines were detached by incubating in 0.05% Trypsin-
Ethylenediaminetetraacetic acid (Trypsin-EDTA; ThermoFisher Scientific, Cat# 2530054) for 5 min in a 
cell culture incubator. Cells were then collected by centrifugation at 100 g for 5 min at room 
temperature, before diluting cells to reach a confluency of 20%, or were seeded to a confluency 
depending on the needs of the subsequent experiment. 
OP9-DL1 co-culturing 
OP9-DL1 cells were seeded at 20% confluency as described above. Two days later, the media was 
removed and replaced with either media containing HEK293FTs, which were also seeded at 20% 
confluency, or ALCL cells which were seeded at a density of 100,000 cells/mL. Cells were left in co-
culture for 48 hours. HEK293FTs were first stably transduced to express Green Fluorescence Protein 
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(GFP) using pJLM1-GFP (Addgene, Cat# 19319) and Puromycin selected at 1 μg/mL, as detailed in 
chapter 2.6. HEK293FTs were then trypsinised and sorted for GFP-positive cells (GFP was co-
transduced into HEK293FTs along with the Notch1 plasmid), following co-culturing with the OP9-DLL1 
cell line, while ALCL cells were then washed off and processed for downstream assays. 
Deriving crizotinib-resistant ALCL cell lines 
Crizotinib-resistant Karpas 299, SUP-M2, SU-DHL-1 and DEL cells were established as described 
previously (Ceccon et al, 2013). Briefly, ALCL cells were seeded at approximately 0.5 x 106 cells/mL. 
Crizotinib (see Table 2.1) was added at a starting concentration of 50 nM, and cells were maintained 
in fresh drug containing medium changed every 48-72 hours. After every two passages at a given 
concentration of drug, the concentration of crizotinib was increased in half-log intervals.  
 
2.2 KRAB-dCas9 Knock-down and Activation 
Two Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems were used: an 
overexpression system (transcriptional activation) and a knock-down system (transcriptional 
inhibition).  
CRISPR Activation 
With respect to transcriptional activation, cells were transduced to express plasmids dCas9-VP64_Blast 
(Addgene, Cat# 61425) and MS2-P65-HSF1_Hygro (Addgene, Cat# 61426), before being selected with 
Blasticidin and Hygromycin (concentrations in Table 2.1, as described in chapter 2.6). Cells were then 
transduced with plasmid sgRNA(MS2)_Zeo (Addgene, Cat# 61427) containing the appropriate 
oligonucleotides (as described in chapter 2.9) and selected with Zeocin (concentrations in Table 2.1).  
CRISPR Knock-down 
With respect to transcriptional inhibition, a lentiviral-based two plasmid system was used: pHR-SFFV-
KRAB-dCas9-P2A-mCherry (Addgene Cat# 60954), and doxycycline-inducible FgH1tUTG (Addgene Cat# 
25307932). DEL, Karpas 299 and SUP-M2 cell lines were transduced (as described in chapter 2.6) to 
express pHR-SFFV-KRAB-dCas9-P2A-mCherry and cells were sorted for expression of mCherry (chapter 
2.8). To knockdown notch1, 2 guide sequences per candidate gene were designed using the Broad 
Institute short guide RNA (sgRNA) Designer (https://portals.broadinstitute.org/gpp/public/analysis-
tools/sgrna-design-crisprai) and introduced into FgH1tUTG using Golden-Gate assembly (as described 
in chapter 2.9). Cells were then transduced to express the cloned FgH1tUTG (chapter 2.6), and cells 
positive for eGFP were collected by Fluorescence-Activated Cell Sorting (FACS) following sorting for 
GFP expression (chapter 2.8). FgH1tUTG transduced cells were cultured with tetracycline-free FBS and 
sgRNA expression induced with 1 µg/mL doxycycline for 24 to 96 hours.  
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Table 2.1: Compounds used in this thesis. Drugs were obtained lyophilized from the manufacturer and 
reconstituted in the appropriate diluent at the maximum tolerated concentration before being 
aliquoted in appropriate volumes and kept at temperatures recommended by the manufacturer to 
minimize freeze/thaw cycles. 
 
2.3 Drug treatments & Growth assays 
ALCL cell lines were treated with various drugs (Table 2.1). Drug treatments were conducted in 96-well 
plates for proliferation assays, whereby drugs were diluted to 10 times the final concentration in RPMI, 
and 10 μL of the diluted drug was added to 90 μL of cells seeded in a 96-well plate. For other assays, 
the stock solution of drug or antibiotic was added directly to the well at the appropriate volume.  
Cell proliferation was mostly measured using a tetrazolium dye (MTT) assay (Sigma-Aldrich, Cat# 
M5655). Cells were seeded at 100,000 cells/mL in 100 μL (or 90 μL for drug treatments, as described 
above) in a 96-well plate (ThermoFisher Scientific, Cat# AB-2396). After a suitable incubation period, 
Reagent Category number Concentration Application 
GSI 1 Abcam, Cat# ab145891 Variable Therapeutic 
BMS-906024 Sigma-Aldrich, Cat# 0018 Variable Therapeutic 




DEL (100 μg/mL) 
Karpas 299 (100 μg/mL) 
SU-DHL1 (80 μg/mL) 





DEL (10 μg/mL) 
Karpas 299 (10 μg/mL) 
SU-DHL1 (5 μg/mL) 
SUP-M2 (10 μg/mL) 
Selection marker 
Hygromycin Invivogen, Cat# ant-zn-1 
DEL (200 μg/mL) 
Karpas 299 (200 μg/mL) 
SU-DHL1 (125 μg/mL) 
SUP-M2 (200 μg/mL) 
Selection marker 
Puromycin Sigma-Aldrich, Cat# 8833 
DEL (500 ng/mL) 
Karpas 299 (1 μg/mL) 
SU-DHL1 (1 μg/mL) 
SUP-M2 (1 μg/mL) 
Selection marker 
Methotrexate Sigma-Aldrich, Cat# A6770 Variable Therapeutic 
crizotinib Sigma-Aldrich, Cat# PZ0191 Variable Therapeutic 
ceritinib 
MedChem Express, Cat# 
HY-15656 
Variable Therapeutic 
DMSO Sigma-Aldrich, Cat# D8418 





Thiazolyl Blue Tetrazolium Bromide was added to a final concentration of 1 mg/mL. After a further 4 
hours of incubation at 37⁰C, Sodium Dodecyl Sulphate (SDS) in suspension (Sigma-Aldrich, Cat# 75746) 
was added to a final concentration of 10% w/v to dissolve the formazan crystals that have formed.  
Cells were incubated for 4 hours at 37⁰C, before absorbance was measured at 570 nm using a 
SpectraMax i3 plate reader. Samples were analysed in technical and biological triplicates.  
Alternatively, cell proliferation was measured using the RealTime-Glo kit (Promega, Cat# G9711) to 
measure more than one time-point. Reagents were first incubated at 37⁰C before cells were seeded at 
100,000 cells/mL in a 96-well plate, following which Real-Time Glo reagents were added to a final 
concentration of 1X following the manufacturer’s instructions. Luminescence was then measured 
using a SpectraMax i3 plate reader at 24, 48 and 72 hours, following the manufacturer’s instructions. 
Samples were analysed in technical and biological triplicates.  
 
2.4 Apoptosis and Cell Cycle Assays 
Apoptosis assay 
1 million cells were harvested by centrifugation at 100 g for 5 min at 4⁰C. Cells were washed in Annexin 
V (AV) Binding Buffer (ThermoFisher Scientific, Cat# V13246), before being resuspended in 100 μL of 
AV solution (Annexin V (Biolegend, Cat# 640920) diluted 1:20 in AV Binding Buffer). Cells were 
incubated in the solution for 30 min at room temperature, in the dark, before being washed with AV 
Binding Buffer. Finally, cells were resuspended in 250 μL of Propidium Iodide (PI) (Propidium Iodide 
(Sigma-Aldrich, Cat# P4864) diluted 1:1000 in AV Binding Buffer). Stained cells were then immediately 
analysed using FACS, with a BDBioscience FACSCalibur. Samples were analysed in technical and 
biological triplicates. 
Cell cycle assay 
To assess the fraction of cells in each stage of the cell cycle, 1 million cells were washed in cold 
Phosphate-Buffered saline (PBS) and collected by centrifugation at 100 g for 5 min at 4⁰C before 
resuspension in 400 μL 70% ethanol, by adding the ice cold ethanol dropwise, while vortexing the cells 
at high speed before a final incubation on ice for 45 min. Cells were then washed once in PBS after 
being collected by centrifugation at 2000 g for 5 min at 4⁰C. Finally, cells were resuspended in a PI 
solution (PI diluted 1:1000, supplemented with 100 μg/mL RNAse A (Sigma-Aldrich, Cat# 
10109142001)) and incubated 10 min at room temperature before immediately being analysed using 





2.5 siRNA and shRNA expression silencing 
siRNA Nucleofection 
ALCL cell lines were nucleofected with small interfering RNA (siRNA) (siRNA Silencer Select, 
ThermoFisher Scientific, Cat# 4392420, Assay # 108983, or Cat# AM4611 for scrambled siRNA) using 
Amaxa Solution V (Lonza, Cat# VCA-1003), according to the manufacturer’s instructions, using an 
Amaxa Nucleofector. Samples were analysed in biological triplicates.  
ALCL cell lines were cultured in 12-well plates in 2 mL of medium to reach a density of 0.5 million 
cells/mL. Cells were collected by centrifugation at 90 g for 10 min at room temperature, and were 
resuspended in 100 μL of Amaxa Solution V (Lonza, Cat# VCA-1003), before transfer to an Amaxa 
cuvette (Lonza, Cat# VCA-1003) along with 30 pmol siRNA suspended in 2 μL RNAse-free water (siRNA 
Silencer Select, ThermoFisher Scientific, Cat# 4392420, Assay # 108983, or Cat# AM4611 for scrambled 
siRNA), and nucleofection with an Amaxa Nucleofector (Lonza, Cat# AAB-1001) using programme A-
030. Cells were then resuspended in 1 mL of RPMI medium, in a 12-well plate. Subsequent experiments 
were conducted 24 hours post Nucleofection.  
shRNA silencing 
ALCL cell lines were transduced with shRNA constructs (detailed in chapter 2.6, constructs are in Table 
2.2), and cells successfully transduced were selected on incubation in media containing the relevant 
antibiotic (Table 2.1). Following 96 hours of selection, RNA was extracted as detailed in Chapter 2.7 to 
verify gene silencing, following which cells were cultured in fresh, antibiotic-free media for 
downstream applications. 
 
2.6 Lentiviral production & Transductions 
HEK293FTs were seeded at 50% confluency 1 day before transfection. The plasmid of interest was co-
transfected with plasmids pMD2.G (Addgene Cat# 12259, kind gift from Didier Trono), and psPAX2 
(Addgene Cat# 12260, kind gift from Didier Trono) using TransIT-293 (MirusBio Cat# MIR 2700). A mix 
of 19.2 μL TransIT-293, 1.52 μg of envelope plasmid PMD2.G (Addgene, Cat# 12259), 2.38 μg of 
packaging plasmid psPAX2, and 2.7 μg of the expression plasmid (see Table 2.2) was first prepared in 
500 μL of Opti-MEM medium (ThermoFisher Scientific, Cat# 31985062), and incubated at room 
temperature for 15 min. The mix was then added to cells.  
Supernatant was collected 54 hours after transfection; the media was harvested, and cell debris was 
removed by centrifugation at 100 g for 5 min. The virus-containing media was then frozen down at -
80⁰C until required or used immediately for transduction.  
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ALCL cell lines were cultured in T25-flasks (Corning, Cat# 430641) in 5 mL of medium, to a density of 
0.5 million cells/mL. Cells were then treated with medium containing viral particles at a MOI of less 
than 0.7. Following transduction (24 hours), cells were either selected by adding antibiotic to the media 
for 4 days (See Table 2.1) or sorted based on expression of the relevant fluorescent protein. In any 
case a negative control of untransduced cells helped to confirm that the transduction was successful.  
 






Plasmid Addgene Reference (if applicable) 
Selection 
protein/antibiotic 
psPAX2 12260 - 
PMD2.G 12259 - 
FgH1tUTG 70183 EGFP 
dCas9-VP64_Blast 61425 Blasticidin 
MS2-P65-HSF1_Hygro 61426 Hygromycin 




pLJM1-EGFP-Notch1 - Puromycin 
LentiCas9-Blast 52962 Blasticidin 
LentiGuide-Puro 52963 Puromycin 









NPM-ALK shRNA Obtained from Roberto Chiarle (Piva 
et al, 2006) 
- 
pIND_puro_ALK Obtained from Liam Lee Puromycin 
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Name F/R Application Sequence 
NOTCH1: 
sequencing 
of the whole 
cDNA 
Forward Sanger sequencing CTCTGCCTGGCGCTGCTG 
Forward Sanger sequencing GGAAACAACTGCAAGAACGGG 
Forward Sanger sequencing TGTGCCAGTACGATGTGGAC 
Forward Sanger sequencing ATGACCAGTGGCTACGTGTG 
Forward Sanger sequencing CAATGAGTGCGACTCACAGC 
Forward Sanger sequencing GCGTCAATGACTTCCACTGC 
Forward Sanger sequencing ACTGCAAGGACCACTTCAGC 
Forward Sanger sequencing AAAGTGTCTGAGGCCAGCAA 
Forward Sanger sequencing AACAACAGGGAGGAGACACC 
Forward Sanger sequencing CTGCAGCATGGCATGGTAGG 
Forward Sanger sequencing CAGGGCCGACCAGAGGAG 
Forward Sanger sequencing TGCACCCATGGTACCAATCA 
Forward Sanger sequencing ATTCCACGTCTCCGACTGG 
Forward Sanger sequencing ATGCCAAAAAGCTCCTGGG 
Forward Sanger sequencing CCAGATGCGTCCCAAGATGT 
U6 Forward Sanger sequencing AATGACTATCATATGCTTACCG 
F1 Forward Sanger sequencing TCGCTATGTGTTCTGGGAAA 
CMV_F Forward Sanger sequencing CGCAAATGGGCGGTAGGCGTG 
SP6 Forward Sanger sequencing CGATTTAGGTGACACTATAG 
NOTCH1 Forward qPCR TACAAGTGCGACTGTGACCC 
NOTCH1 Reverse qPCR ATACACGTGCCCTGGTTCAG 
JAG1 Forward qPCR GCCGAGGTCCTATACGTTGC 
JAG1 Reverse qPCR CCGAGTGAGAAGCCTTTTCAA 
CAS9 Forward qPCR CCTGCGGCTGATCTATCTGG 
CAS9 Reverse qPCR AGCTGGTTGTAGGTCTGCAC 
HEY1 Forward qPCR GTTCGGCTCTAGGTTCCATGT 
HEY1 Reverse qPCR CGTCGGCGCTTCTAATTATTC 
HES1 Forward qPCR TCAACACGACACCGGATAAAC 
HES1 Reverse qPCR GCCGCGAGCTATCTTTCTTCA 
PPIA Forward qPCR GCTTTGGGTCCAGGAATG 
PPIA Reverse qPCR AGAAGGAATGATCTGGTGGTTAAG 
GAPDH Forward qPCR CTGGGCTACACTGAGCACC 
GAPDH Reverse qPCR AAGTGGTCGTTGAGGGCAATG 
NOTCH1_1 Forward AAACCCCGGGCCCGGCTCCGCGCCC 
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NOTCH1_1 Reverse CRISPR 
Overexpression 
CACCGGGCGCGGAGCCGGGCCCGGG 
NOTCH1_2 Forward AAACCACAGCGCCGCCAGCCAGCCCC 





NOTCH1_1 Reverse AAACACCTCGTGCGGCGAGCGCGG 
NOTCH1_2 Forward TCCCGCGGCGGCATGCCTCCCCAC 
NOTCH1_2 Reverse AAACGTGGGGAGGCATGCCGCCG 
NOTCH1 Forward PCR for cloning ATATATACCGGTATAGCGCGTGTGCGTCCCAGCCC 
NOTCH1 Reverse PCR for cloning CTCTCATTCGAATCAGCGCCGTTTACTTGAAGGCC 
NOTCH1_645 Forward Site-Directed 
Mutagenesis 
GGTCATGGCAGGGGCGCCGTGGAA 
NOTCH1_645 Reverse Site-Directed 
Mutagenesis 
TTCCACGGCGCCCCTGCCATGACC 
NOTCH1_759 Forward Site-Directed 
Mutagenesis 
GTGTTGTGGCAGGGCCCGCCGTTCTGG 
NOTCH1_759 Reverse Site-Directed 
Mutagenesis 
CCAGAACGGCGGGCCCTGCCACAACAC 
MYC Forward qPCR GGCTCCTGGCAAAAGGTCA 
MYC Reverse qPCR CTGCGTAGTTGTGCTGATGT 
DTX1 Forward qPCR GACGGCCTACGATATGGACAT 
DTX1 Reverse qPCR CCTAGCGATGAGAGGTCGAG 
STAT3 Forward qPCR CAGCAGCTTGACACACGGTA 
STAT3 Reverse qPCR AAACACCAAAGTGGCATGTGA 
JAG1 Forward qPCR GTCCATGCAGAACGTGAACG 
JAG1 Reverse qPCR GCGGGACTGATACTCCTTGA 
DLL1 Forward qPCR GATTCTCCTGATGACCTCGCA 
DLL1 Reverse qPCR TCCGTAGTAGTGTTCGTCACA 
NPM-ALK Forward qPCR CTGTACAGCCAACGGTTTCCC 
NPM-ALK Reverse qPCR GGCCCAGACCCGAATGAGG 
NOTCH1 Forward ChIP ATCAACCTGTTCCTCCCCTG 
NOTCH1 Reverse ChIP TTCCCGACTACAAGCGGACT 
IRF4 Forward ChIP CTCTAAACACCGCGGAGAGG 
IRF4 Reverse ChIP CTTTGCAGAGCGTGTAACGG 
Control Forward ChIP ATTCCACCTTGTCCAGCCCT 
Control Reverse ChIP GGTTTTATCCCTCTCCCCGAC 
Table 2.3: Oligonucleotides used in this thesis. ChIP = Chromatin Immunoprecipitation 
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2.7 RNA extraction & Reverse-Transcription-quantitative Polymerase Chain Reaction (qPCR) 
RNA extraction 
TRI reagent (0.5 mL, Sigma-Aldrich, Cat# T9424) was used to thoroughly resuspend cell pellets, in which 
they were incubated for 5 min at room temperature. Chloroform (200 μL) was then added to samples 
before mixing vigorously and another 5 min incubation at room temperature. The different cellular 
components of the samples were then separated by centrifugation at 16000 g for 15 min at 4⁰C, and 
the aqueous phase was transferred to a new Eppendorf tube. 
Nucleic acids were then precipitated in 300 μL Isopropanol and collected by centrifugation at 16000 g 
for 30 min at 4⁰C, followed by a wash in 500 μL 70% ethanol, and finally allowed to air dry to evaporate 
any remaining alcohol. TURBO DNAse (ThermoFisher Scientific, Cat# AM1907) was then used to 
degrade DNA contaminants according to the manufacturer’s instructions, and the reaction was 
stopped by adding the provided Inactivation Buffer.  
Reverse Transcription 
First, a mix of 500 μM deoxynucleotide triphosphate (dNTPs) (ThermoFisher Scientific, Cat# R0191), 50 
ng of random hexamers (ThermoFisher Scientific, Cat# SO142), and up to 13.2 μL RNA, such that all 
reverse transcription reactions had the same amount of input RNA, as measured by nanodrop, were 
incubated at 65⁰C for 5 min. First-Strand Buffer diluted to 1X (ThermoFisher Scientific, Cat# 18080-
093), 50 μM Dithiothreitol (DTT), 50 units of RNAse OUT (ThermoFisher Scientific, Cat# 10777019), and 
60 units of SuperScript III Reverse Transcriptase (ThermoFisher Scientific, Cat# 18080-093) were then 
added before incubation in a thermocycler for 5 min at 25⁰C, 1 hour at 50⁰C and 15 min at 70⁰C (for 
inactivation). A control sample lacking template was included. Finally, 10 μg/mL RNAse A 
(ThermoFisher Scientific, Cat# EN0531), was used to degrade all the RNA using a 20 min incubation at 
37⁰C before the products were diluted 1:10 for quantitative PCR.  
qPCR 
The following mix was prepared: Forward and Reverse primer (Table 2.3) each at 500 nM, PowerUp 
SYBR Green Master Mix (ThermoFisher Scientific, Cat# A25741) diluted to a 1X concentration, DNA 
(varying concentrations depending on the assay), supplemented with nuclease-free water up to a total 
volume of 10 µL. Samples was incubated in an QuantStudio 6 Flex System PCR machine, using the 
following programme: 2 min at 50°C, followed by activation for 10 min at 95°C, then 40 cycles of 15 
seconds at 95°C and 1 min at 60°C; computing the melting curve then consisted of ramping up the 
temperature from 60°C to 95°C and measuring fluorescence at every 0.1 °C increment. The quantity of 
fragments was measured in both biological and technical triplicates. Where possible, primers were 
selected from Primer Bank (https://pga.mgh.harvard.edu/primerbank/) as these have already been 
validated. In other cases, primers were designed using Primer Blast 
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(https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi). SYBR-Green qPCR analysis was then 
performed using the QuantStudio™ 6 Flex Real-Time PCR System in accordance with the 
manufacturer’s protocol. Transcription levels were normalized to expression of the average of 
glyceraldehyde 3-phosphate dehydrogenase (gapdh) and peptidylprolyl isomerase A (ppia) expression. 
 
2.8 Fluorescence-Activated Cell Sorting 
Cells were separated using the NIHR Cambridge BRC Phenotyping Hub’s BDBioscience’s BD FACSARIA 
(AriaIII and Aria-Fusion). OP9 cells were labelled with a fluorescently tagged antibody detecting DLL-1 
to sort for OP9 cells expressing this protein (for antibodies see Table 2.4) in 100 µL FACS Buffer (PBS 
supplemented with 1% BSA) for 30 min at 4⁰C, before being washed twice in FACS Buffer collecting 
cells by centrifugation at 200 g for 5 min at 4°C. In the case of CRISPR, cells were separated according 
to positivity for GFP or mCherry expression, while for and HEK293FT/OP9-DL1 co-cultures, cells were 
stained for Notch1 using a PE-conjugated antibody (see Table 2.4). 
A FACSCalibur (BD) was used to analyse cells stained either for AV-PI or intracellular PI. Cells were first 
plotted by Side-Scatter vs Forward-Scatter to gate on the live cells, followed by Forward-Scatter-Height 
vs -Area to gate on singlets. Cells were then plotted either on an AV vs PI plot to determine the ratio 
of cells which were AV and PI negative, AV positive and PI negative, AV and PI positive, AV negative 
and PI positive, using an unstained control sample to determine the AV and PI negative population. 
Samples were analysed in technical and biological triplicates.  
In the case of Intracellular PI, cells were directly plotted on PI -intensity vs number of events to 
determine the ratio of cells in Sub-G0, G0, G1, S and M phases. Samples were analysed in technical and 
biological triplicates. 
 
2.9 Golden Gate Assembly 
sgRNAs were cloned into the sgRNA expression vector FgH1tUTG (Addgene Cat# 70183, kind gift from 
Marco Herold) as previously described (Joung et al, 2017). Briefly, a pair of 25 nt oligonucleotides (See 
Table 2.3) containing 4-bp overhangs for the forward (TCCC) and complementary reverse (AAAC) 
sequences were designed and generated to enable cloning into the Bsmb-I site following their 
phosphorylation and annealing. 
To clone oligonucleotides into sgRNA backbones, Golden Gate assembly was used. Oligonucleotides 
were first annealed and phosphorylated, by mixing 10 μM each of the Forward and Reverse 
oligonucleotides, 10 Units T4 Polynucleotide Kinase (ThermoFisher Scientific, Cat# EK0031), and T4 
Ligation Buffer diluted to 1x (NEB, Cat# M0202), topped up with nuclease-free water to a total volume 
of 10 μL. The mixture was incubated in a thermocycler for 30 min at 37⁰C, then 5 min at 95⁰C, before 
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the temperature was decreased to 25⁰C at 5⁰C per min. Products were diluted 1:10 for golden gate 
assembly. The Golden Gate assembly itself consisted 1 mM DTT (ThermoFisher Scientific, Cat# R0861), 
0.1 mg/mL Bovine Serum Albumin (BSA, ThermoFisher Scientific, Cat# AM2616), T4 Ligase Buffer 
diluted to 1X, 1 ng/μL of the backbone plasmid, 10 units of BsmBI (NEB, Cat# R0580), 400 units of T4 
DNA Ligase (NEB, Cat# M0202), and 1 μL of the diluted, annealed oligonucleotides as described above, 
topped with up nuclease-free water to a total volume of 25 μL. The mix was cycled in a thermocycler 
for 15 cycles of 5 min at 37⁰C followed by 5 min at 20⁰C before 2 μL of the product was transformed 
(as detailed in 2.12) and sequenced to verify that the oligonucleotides were cloned as expected using 
a H1-Tet primer. 
 
Name Provenance Application Quantity used 
PE-conjugated DLL-1 ThermoFisher Scientific, Cat# 
12-5767-80 
FACS 0.2 μg 
Notch1 BioLegend, Cat# 629105 FACS 0.4 μg 
Notch1 Biolegend, Cat# 629101 Western Blot 1:500 
α-tubulin Sigma-Aldrich, Cat# T9062 Western Blot 1:2500 
HRP anti-rabbit IgG CiteAb, Cat# P0161 Western Blot 1:10000 
HRP anti-mouse IgG CiteAb, Cat# P0448 Western Blot 1:10000 
phospho-ALK (Tyr1278) 
Cell Signaling Technology, Cat# 
6941S 
Western Blot 1:1000 
ALK 
Cell Signaling Technology, Cat# 
3633S 
Western Blot 1:1000 
STAT3 
Cell Signaling Technology, Cat# 
4904SS 
Western Blot 1:1000 
STAT3 
Cell Signaling Technology, Cat# 
9139 
ChIP 3 μg 
GFP Abcam, Cat# ab290 ChIP 3 μg 
Notch1 eBioscience, Cat#14578581 IHC 1:80 









2.10 notch1 Cloning & Site-Directed Mutagenesis 
notch1 plasmid cloning 
The full-length notch1 complementary DNA (cDNA) was obtained from the Aster lab (Harvard Cancer 
Center), already cloned into the backbone pCDNA3 plasmid (Addgene, Cat# 2092). 
To clone the notch1 gene into the viral vector-containing plasmid pLJM1-EGFP, 1 μg of pLJM1-EGFP 
(Addgene, Cat# 19319) was digested with 10 units of AgeI-HF (NEB, Cat# R3552) and 10 units of BstBI 
(NEB, Cat# R0519) in 1X CutSmart Buffer (NEB, Cat# R3552 or R0519) in a total volume of 25 μL in 
nuclease-free water for 4 hours at 37⁰C. The product was then loaded into a 1% Agarose gel, the 
relevant band excised and purified using a Monarch DNA Gel purification kit (NEB, Cat# T1020S) 
according to the manufacturer’s instructions.  
Second, the notch1 cDNA fragment was amplified from the pcDNA3 plasmid vector using the following 
mix: 1 unit Q5 Polymerase (NEB, Cat# M0491S), 1X Q5 Polymerase Buffer, 1X GC enhancer 200 μM 
dNTPs, 500 nM of each forward and reverse primer, 1 ng of the notch1-containing plasmid, and 
nuclease-free water to a total volume of 50 μL. The mix was incubated in a thermocycler using the 
following programme: 30 seconds at 98⁰C followed by 35 cycles of 7 seconds at 98⁰C and 8 min at 
72⁰C, followed by a final extension of 10 min at 72⁰C. The products were separated by gel 
electrophoresis and purified as described above. The forward and reverse primers (see Table 2.3) were 
designed to include the first and last 20 nucleotides of the notch1 cDNA respectively, with the 6 
nucleotide recognition sites of AgeI and BstBI at each end, followed by 6 nucleotides randomly chosen 
to optimize the primer melting temperature (so as to reach the lowest melting temperature possible, 
while achieving similar melting temperatures for both oligonucleotides). 
Finally, the ligation mix of 25 ng of digested pLJM1-EGFP, 100 ng of the notch1 fragment, 10 units of 
T4 DNA Ligase (NEB, Cat# M0202) in 1X T4 Ligation Buffer, nuclease-free water up to a total volume of 
20 μL was incubated at 16⁰C overnight. The ligated products were then transformed as described in 
2.12. 
Site-Directed Mutagenesis 
Primers for site-directed mutagenesis were designed using Agilent’s online tool 
(https://www.genomics.agilent.com/primerDesignProgram.jsp) and are detailed in Table 2.3. A mix of 
100 ng of the plasmid vector, 2 units Pfu turbo DNA Polymerase (ThermoFisher Scientific, Cat# 
EP0571), DNA Polymerase Buffer diluted to 1X (ThermoFisher Scientific, Cat# EP0571), 125 ng of each 
forward and reverse primer and 200 μM dNTP mix, with nuclease-free water up to a total volume of 
50 μL was prepared. 
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The mix was incubated in a thermocycler at 95⁰C for 30 seconds, then for 14 cycles of 30 seconds at 
95⁰C, 1 min at 55⁰C, and 24 min at 68⁰C. After the cycle was completed, 10 units of DpnI (ThermoFisher 
Scientific, Cat# FD1703) was added, and the reaction mix was incubated at 37⁰C for 1 hour, to digest 
the parental plasmid. The product (2 μL) was then transformed into XL-10 Gold bacteria (Agilent, Cat# 
200314) as described in 2.12, after which the plasmid DNA extracted and sequenced to verify the 
presence of the desired mutation. For sequencing primers used, see Table 2.3. The concept for site-












Figure 2.1: Site-Directed Mutagenesis methodology. The parental strain containing the nucleotide to 
be mutated is replicated using primers containing the mutation, before the methylated parental strand 
is digested to leave only the unmethylated, mutated daughter plasmid.  
 
2.11 droplet digital PCR 
Fractional abundance of mutations was analysed using BioRad’s ddPCR suite of machines: the QX200 
Droplet Generator, the PX1 PCR Plate Sealer, the C1000 Touch Thermal Cycler, and the QX200 Droplet 
Reader. 
First, 70 μL of Droplet Generation Oil for Probes (Biorad, Cat# 1863005), and a mix of 1X ddPCR mix for 
Probes (no dUTP) (Biorad, Cat# 1863023), 1X of Fam/Hex ddPCR Mutation Assay (Biorad, Cat# 
10049047, Assay # dHsaMDS123542085), made up to a final volume of 20 μL with nuclease-free water 











(Biorad, Cat# 1864008), and loaded into the droplet generator before 40 μL of the droplet mix was 
transferred into a 96-well plate, which was sealed with a pierceable foil seal (Biorad, Cat# 181404), 
and sealed using the Plate Sealer. Plates were then loaded into the Thermal Cycler, and incubated 
using the following cycle: 10 min at 95⁰C, 40 cycles of 30 seconds at 94⁰C, 1 min at 53⁰C, followed by 
a 10 min inactivation step at 98⁰C.  
Plates were then loaded into the Droplet Reader, and samples were read. Results were analysed using 
the Biorad QuantaSoft Analysis Pro software. Samples were analysed in technical duplicates.  Controls 
included a no template control, and both positive and negative controls for each of the two probes. 
 
2.12 Transformation & Plasmid Extraction 
Plasmids were transformed using NEB Stable E. coli (NEB, Cat# C3040), with the following protocol – 
except for transformation of the full-length notch1 cDNA-containing plasmid which was conducted 
using Agilent’s XL10-Gold Ultracompetent cells (Agilent, Cat# 200314), using the manufacturer’s 
protocol. 
NEB stable E. coli (50 μL) were incubated for 30 min on ice with 2 μL of the DNA to be transformed. 
The mix was then subject to a heat-shock at 42⁰C for exactly 30 seconds, before incubating for 5 min 
on ice. The mix was then supplemented with 200 μL of Super Optimal Broth with Catabolite repression 
(SOC) medium (ThermoFisher Scientific, Cat# S1797), before incubating at 30⁰C, on a shaking plate 
(220 rpm) for 1 hour. The bacteria were then plated on 100 μg/mL Ampicillin (ThermoFisher Scientific, 
Cat# A9518)-containing Lysogeny Broth (LB) agar plates and incubated overnight at 30⁰C. 
A single colony was then isolated from the agar plate and propagated in LB supplemented with 100 
μg/mL Ampicillin overnight at 30⁰C, on a shaking plate (220 rpm). The plasmids were then extracted 
from the bacteria using Qiagen’s Plasmid Mini or Maxi Kit depending on the output amount required 
(Cat# 12123 and 12162, respectively), following the manufacturers’ instructions. Samples were then 
sent of sequencing at the University of Cambridge Department of Biochemistry using the 








Oligonucleotides were ordered from Sigma-Aldrich suspended in water at a concentration of 100 μM.  
Sequencing primers were designed using the Primer Basic Local Alignment Search Tool (BLAST) online 
tool (Ye et al, 2012). For a complete list of primers used, see Table 2.3. Sequencing primers were 
designed to obtain PCR products approximately 500-800 base pairs in length. Primer GC content was 
restricted to 40-60%, and primer length was 17-22 base pairs. Primers for qPCR were primarily taken 
from the Primer Bank database of validated primers (Spandidos et al, 2010). See relevant Methods 
sections for the design of other oligonucleotides. 
 
2.14 Western Blotting & Antibodies 
Cells were collected by centrifugation at 100 g for 5 min at 4⁰C before washing once in cold PBS, and 
resuspending in Pierce Radioimmunoprecipitation Assay (RIPA) buffer (Thermo Scientific, Cat# 89900) 
supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, Cat# 78441), 
and incubated on ice for 30 min. Centrifugation was then conducted at 16000 g for 10 min at 4⁰C to 
remove cell debris. The protein content in the supernatant was determined using a Qubit protein assay 
(ThermoFisher, Cat# Q33211), according to the manufacturers’ instructions. Finally, samples were 
diluted in Laemlli Buffer (10% SDS, 50% Glycerol, 25% β-Mercaptoethanol, 0.03% Bromophenol Blue 
and 200 mM Tris at pH 7) to generate solutions containing equivalent concentrations of proteins, 
before boiling at 100⁰C for 5 min.  
Samples were loaded onto a TGX 10% Acrylamide Gel (Bio-Rad Cat# 161-0173), prepared according to 
the manufacturer’s instructions (incorporating 0.1% TEMED (National Diagnostics, Cat# EC503), and 
0.03% Ammonium Persulfate (Bio-Rad, Cat# 161-700)) along with 2 µL of protein ladder (ThermoFisher 
Scientific, Cat# 26619). The gel was immersed in Running Buffer (25 mM Tris-HCl at pH 7, 200 mM 
Glycine, 0.1% SDS) at 70 V until the dye front reached the bottom of the gel. Proteins were transferred 
onto a 0.45 µm nitrocellulose membrane (Immobilon, Cat# IPVH00010) in 1X Transfer Buffer (Bio-Rad, 
Cat#10026938) using the Bio-Rad Trans-Blot Turbo system (7 min at 25 V and 1.3 A). The membrane 
was then incubated in 5% BSA (Acros Organics, Cat# 240405000) w/v in Wash Buffer (50 mM Tris-HCl 
at pH 7, 150 mM NaCl and 0.1% Tween-20) for 1 hour at room temperature. Membranes were then 
exposed to primary antibody overnight at 4⁰C in 3% BSA w/v in Wash Buffer (antibodies are detailed 
in Table 2.4). The membrane was then washed in Wash Buffer three times for 10 min, before being 
exposed to HRP-conjugated secondary antibody in 3% BSA w/v in Wash Buffer (see antibodies and 
concentrations in Table 2.4) for 1 hour at room temperature. The membrane was again washed in 
Wash Buffer three times for 10 min. Finally, proteins were visualised following exposure to HRP 




2.15 Patient samples 
Patient tumour tissues and matched peripheral blood DNA were obtained following informed 
patient/parental consent according to both the Declaration of Helsinki and local guidelines from the 
following institutions; Children’s Cancer and Leukaemia Group tissue bank, Nottingham, UK; Institut 
Universitaire du Cancer Toulouse, France; University Hospital Brno, Czech Republic; Biobank of the 
Medical University of Graz, Austria; Belarusian Centre for Paediatric Oncology, Hematology and 
Immunology, Minsk, Belarus; Justus-Liebig University, Giessen, Germany; Our Lady’s Children’s 
Hospital, Crumlin, Ireland (Table 2.5). All tissues were obtained and processed with full ethical approval 
(NHS Research ethics committee reference numbers 07/Q0104/16, 06/MRE04/90 and 
08/H0405/22+5). 
Only samples from patients presenting with systemic ALCL (not cutaneous, for e.g.) were used for this 
study.  Table 2.5 summarizes the clinical data.  
 


















5-year EFS known 79 
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Immunohistochemistry was performed on formalin-fixed paraffin-embedded (FFPE) sections with the 
conventional avidin–biotin–peroxidase method (Vector Laboratories, Cat# SP2001). In brief, heat 
antigen retrieval was performed using citrate buffer at pH 6.1.  Endogenous peroxidases were 
quenched by incubating sections in 3% H2O2 in PBS for 10 min. Sections were incubated in primary 
antibodies diluted in 1% BSA in PBS at 4°C (Table 2.4) overnight followed by incubation with biotin-
conjugated secondary antibodies at room temperature for 1 hour. Sections were then incubated with 
Horseradish Peroxidase (HRP) using IDtect Super Stain System–HRP (following the manufacturer’s 
protocol; Empire Genetics, Cat# ID851007) and developed under visual control using the AEC substrate 
kit (BD Pharmingen, Cat# 551015). Hemalaun counterstaining was performed before mounting 
coverslips with AquaTex (Merck, Cat# 108562). Sections were washed with PBS 3 times for 20 min at 
room temperature between every step. Stained slides were assessed by an experienced pathologist 
(blindly with respect to clinicopathological parameters and patient outcome). Quantification of the 
slides was determined using the histoscore system: stained slides were scored for both the intensity 
and percentage of positively staining cells (0 negative, 1+ weak, 2+ moderate and 3+ strong staining). 
Positive staining was considered 2+ if present in >1% of cells. The Histoscore was then calculated by 
multiplying the intensity by the percentage of positively stained cells.  The Kaplan-Meier method was 
used to compute the EFS or OS, while the statistical differences between patient groups was derived 
using the log-rank test using the PRISM software. 
 
2.17 DNA extraction & Sanger sequencing 
DNA Extraction 
To extract DNA from cell lines, frozen or FFPE tumour samples, the Qiagen’s DNeasy Blood & Tissue Kit 
(Cat# 69504) was used according to the manufacturers’ instructions. The only modification on the 
manufacturer’s protocol was the elution of DNA (in 20 μL of DNAse-free water) three times 
consecutively into separate Eppendorf tubes to ensure all DNA had been eluted from the column.  
Sanger Sequencing  
DNA fragments were amplified using a solution of 5 units of DeamTaq polymerase (ThermoFisher 
Scientific, Cat# EP0702), Polymerase Buffer diluted to 1X, 100 μM dNTP mix (ThermoFisher Scientific, 
Cat# R0191), 200 nM of each Forward and Reverse primers (Table 2.3), and 1 ng of template DNA 
(where PCRs failed due to poor quality DNA, input amount was increased to 20 ng), topped up with 
nuclease-free water to a total volume of 25 μL. The programme used was; 1 min at 95⁰C, followed by 
35 cycles of 30 seconds at 95⁰C, 30 seconds at 64⁰C, and 45 seconds at 72⁰C, followed by a final 
extension of 10 min at 72⁰C.  
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Primer dimers and other contaminants were removed from the reactions using 0.5 μL ExoSAP-IT 
(ThermoFisher Scientific, Cat# 78200.200), 3.5 μL of 10X GeneAmp PCR Buffer II (ThermoFisher 
Scientific, Cat# N8080010), and 1.5 μL of the PCR product as detailed above. This mix was incubated 
for 15 min at 37⁰C, followed by 15 min at 80⁰C. 
PCR products were then labelled using the BigDye Terminator v3.1 Cycle Sequencing Kit (ThermoFisher 
Scientific, Cat# 4337455), using a mix of 0.35 μL of BigDye, 1.75 μL of the provided sequencing buffer, 
0.4 μM of the Forward primer, and 2 μL of nuclease-free water, which, added to the previous 5.5 μL of 
ExoSAP-IT product, led to a total volume of 10 μL. This mix was incubated in a thermocycler for 1 min 
at 95⁰C, followed by 25 cycles of 20 seconds at 96⁰C,15 seconds at 50⁰C, 1 min at 60⁰C, before a one-
off 4 min incubation at 25⁰C.  
Samples were then purified prior to sequencing using the Dynabead Sequencing clean-up kit 
(ThermoFisher Scientific, Cat# 66101) whereby 13 mL of 96% Ethanol was added to a fresh bottle of 
Dynabeads before 20 μL of Dynabead solution was added to each sequencing reaction. Samples were 
mixed and incubated at room temperature for 5 min. The samples were then collected by 
centrifugation at 500 g for 10 seconds before placing on a magnetic plate (ThermoFisher Scientific, 
Cat# 12331D) for 1 min, before being subject to centrifugation upside-down at 100 g for 10 seconds to 
remove supernatant. Next, 100 μL of 85% ethanol was added to wash the samples before incubating 
at room temperature for 5 min. Samples were then collected by placing on a magnetic plate for 1 min 
before being subject to centrifugation upside-down again. The samples were allowed to air-dry for 10 
min before adding 30 μL of nuclease-free water and mixing thoroughly, incubating at room 
temperature for 5 min and placing on the magnetic plate for 1 min. Finally, 25 μL of the eluant was 
transferred to a MicroAmp sequencing plate (ThermoFisher Scientific, Cat# N8010560). Samples were 
sequenced using a 48 capillary ABI 3730 DNA sequencer (ThermoFisher Scientific). Sanger traces were 










2.18 Whole Exome Sequencing 
DNA was extracted from patient tissue or blood (chapter 2.17). Only samples of fresh frozen tissue 
with a high tumour content (>90%) as determined by a histopathologist were sent for exome 
sequencing. Samples were sent either to the University of Ha’il (Kingdom of Saudi Arabia), or to the 
Washington State University sequencing core (United States) for library preparation and whole exome 
sequencing in two different batches (see Table 2.6). Sequencing files are available online at the 














Crescenzo et al; 
SRP044708 
SureSelect 50 
Mb All Exon kit 
Illumina 
HiSeq 2000 
Yes + 7 






Yes for 4 of 5 + 5 
Samples from ALCL99 
sequenced previously, 





No + 13 
Table 2.6: WES Sequencing and library preparation detail from fresh frozen tumour tissue. 
 
2.19 Bioinformatic analysis (full pipeline detailed in Chapter 3) 
Briefly, reads were analysed using FastQ, before quality trimming was performed to remove any base 
pair at the end of each read with a quality score below 30. Reads from these and the 18 de novo 
sequenced samples were aligned to a reference genome (version hg38) using Burrows-Wheeler 
Alignment (‘bwa-mem’ version 0.7.12-5) employing default settings; duplicates were marked and 
removed using Picard (version 2.5.0). SNVs (Single-Nucleotide Variants) were called using CaVEMan 
(Turinsky et al, 2008) (version 1.9.5) and InDels (Insertions and Deletions) using Pindel (Ye et al, 2009) 
(version 0.2.5b8), following which SNVs and InDels were annotated using Annovar (Wang et al, 2010). 
Variants contained in any of the 11 matched peripheral blood samples were filtered out from all 
samples. Variants identified as present in the population at a frequency of > 0.1% as determined by 
dbSNP (build 148) and the 1000 Genome project (phase 3 release) were also filtered out. Variant Effect 
Prediction scores were compiled using prediction software CADD (Kircher et al, 2014), FATHMM 
(Shihab et al, 2013), LRT (Chun & Fay, 2009), MutationAssessor (Reva et al, 2011), MutationTaster 
(Stenson et al, 2009), SIFT (Vaser et al, 2016), PROVEAN (Choi et al, 2012) and Polyphen (Ramensky et 
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al, 2002). Variants predicted to be benign based on this compiled score and the MetaLR/MetaSVM 
databases were filtered out. 
Mutational signatures were derived with the ‘deconstructSigs’ R package (Rosenthal et al, 2016). 
 
2.20 Chromatin Immunoprecipitation-sequencing & ChIP-qPCR 
Browser Extensible Data (BED) files were downloaded from the GSE archive (accession GSE117164 
(Menotti et al, 2019) for STAT3 ChIP-seq, GSE104261 (Choi et al, 2017) and GSE29600 (Wang et al, 
2011a) for NOTCH1 and NOTCH3). Files were sorted using BEDTools (‘sort’), then converted into 
BEDGraph using BEDTools (‘genomecov’), and then into BigWig track files using UCSC’s 
‘bedgraphToBigWig’. The genome browser tracks were visualized in IGV (v2.3.92). 
ChIP-qPCR analysis for Notch1 was performed with 10 million ALCL cells per sample using an anti-
STAT3 (Cell Signalling, Cat# 9139) or anti-GFP antibody (Abcam, Cat# ab290). Following treatment with 
1 µM crizotinib or dimethyl sulfoxide (DMSO) for 3 hours suspended in RPMI 1640 supplemented with 
10% FBS, 1 x 107 cells were fixed with 0.75% formaldehyde for 15 min using orbital shaking at room 
temperature. Subsequently, glycine was added to a final concentration of 125 nM and cells were 
incubated for 5 min at room temperature. Next, cells were washed twice with cold PBS, collected by 
centrifugation at 100 g for 5 min at 4°C and flash frozen using liquid nitrogen and stored at -80 °C until 
use. Cell pellets in which DNA had been cross-linked as detailed above were lysed in 650 μL ChIP lysis 
buffer (50 mM HEPES-KOH pH 7.5, 140 mM NaCL, 1 mM EDTA pH8, 1% Triton X-100, 0.1% Sodium 
Deoxycholate and 0.1% SDS) supplemented with cOmplete™ Mini EDTA-free Protease Inhibitor 
Cocktail (Roche, Cat# 11836170001) at the manufacturer’s indicated concentration, followed by 
sonication for a total of 10 min using 30 seconds on/off pulses. Immunoprecipitation reactions were 
performed overnight with 3 μg STAT3 or GFP antibodies rotating at 4 °C. Next, antibodies and 
chromatin were captured on 50 μL of Protein G Dynabeads (Thermo Scientific, Cat# 10004D) for 2 
hours at 4 °C. Following capture, the bead-chromatin complexes were  washed three times in Low Salt 
Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH 8.0, 150 mM NaCL), followed by 
three washes in High Salt Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl at pH 8, 500 
mM NaCL), two washes in Lithium Chloride Buffer (0.25 M LiCL, 1% NP-40, 1% Sodium Deoxycholate, 
1 mM EDTA, 10 mM Tris-HCl at pH 8) and two final washes in TE Buffer (10 mM Tris pH 8.0, 1 mM 
EDTA). DNA was eluted into 200 μL elution buffer (1% SDS, 100 mM NaHCO3), RNA was digested using 
2 μL RNase A (10 mg/mL, Roche, Cat# 10109169001) at 37 °C for 30 min, before reversing cross-linking 
by incubating at 65°C for 2 hours with 2 μL proteinase K (20 mg/mL, Thermo Scientific, Cat# EO0491). 
De-cross-linked DNA was purified with a Zymo DNA Clean and Concentrator-5 kit (Zymo research, Cat# 
D4003) according to the manufacturer’s instructions. ChIP and input DNA were analysed by SYBR-
Green qPCR performed using a QuantStudio™ 6 Flex Real-Time PCR System in accordance with the 
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manufacturer’s protocol using qPCR primers (Table 2.3) from a published ChIP-seq dataset (Menotti 
et al, 2019). 
 
2.21 Microarray analysis 
Microarray files were downloaded from the GSE archive (accession GSE5827 (Sanchez-Martin et al, 
2017), GSE104261 (Choi et al, 2017) and GSE29600 (Wang et al, 2011a)) and analysed using NCBI’s 
GEO2R online pipeline (Wilhite & Barrett, 2012), by creating a group for samples treated with vehicle 
control (DMSO), and another for samples treated with GSI. The top 250 hits (according to adjusted p-
values) were then extracted from GEO2R; hits present in at least two of the three datasets were 
retained for display on a heatmap. 
 
2.22 Statistical analyses and Graphing 
All experiments were executed in biological triplicates. The MTT, RealTimeGlo, Apoptosis, Cell Cycle 
and qPCR assays were additionally conducted in technical triplicates. Unless indicated otherwise, all 
plots are representative of the mean of the biological replicates, while the error bars represent the 
standard deviation. Two-tailed t-tests were used to calculate the p-value when comparing two samples 
(multiple comparisons were corrected using the Holm-Sidak method); when comparing more than two 
samples, two-way ANOVA was used (again, multiple comparisons were corrected using the Holm-Sidak 
method). The log-rank test was used to compute the statistical difference between sub-groups of 






3. DNAseq analysis of 25 ALK+ ALCL patient samples 
 
3.1 Introduction 
ALK fusion proteins induce the activation of several downstream signalling pathways involved in the 
oncogenesis of ALCL. Beyond this however, as mentioned previously, no published study has shown 
further significant genetic abnormalities in ALK+ ALCL. Indeed, there is little literature about the 
genomics of ALCL beyond the papers published by Youssif et al., Salaverria et al., and Crescenzo et al. 
Youssif, Salaverria and colleagues performed array comparative genomic hybridization on ALK+ ALCL 
and recorded a few gains and losses, though by and large found the genome to be stable, as large-
scale studies of paediatric cancers have also shown (Gröbner et al, 2018). Some years later, Crescenzo 
and colleagues looked at the genome of ALK- ALCL in more detail, performing WES, and showed that 
a sub-section of ALK- ALCL patients presented with mutations of the JAK/STAT3 pathway, as well as 
chimeras involving transcription factors NFκB2 and Nuclear Receptor Corepressor 2 (NCOR2), and 
tyrosine kinases ROS1 and Tyrosine Kinase 2 (TYK2). Indeed, these discoveries proved to have potential 
therapeutic implications, as inhibition of the JAK/STAT3 pathway was shown to inhibit cell growth both 
in ALK- ALCL cell lines and mouse models. This chapter presents data regarding the genome of ALK+ 
ALCL from 18 tumours sequenced within this project combined with data from 7 samples of published 
cases of ALK+ ALCL (Crescenzo et al, 2015). The bioinformatic processing and the results we obtained 
from this analysis are presented in this chapter. 
 
3.2 Whole Exome Sequencing 
The genomic data analysed in this thesis is composed of three separate datasets (Table 2.6); 
sequencing data for the first set of samples, composed of 7 adult ALK+ ALCL with matched peripheral 
blood, were retrieved from an online repository as detailed in chapter 2 (Crescenzo et al, 2015). Two 
further datasets were produced from patient samples, which were sequenced in individual batches 
resulting in a range of read lengths and coverage (Figure 3.2.1, Table 3.1). These two batches of 
samples were derived from tumour tissue banked within the CCLG paediatric cancer tissue bank, most 
isolated from children entered into the ALCL99 trial (Table 2.5, Table 2.6) and therefore receiving a 










Sample Name Average number of reads Average Length of reads (bp) Coverage 
S1 4.96E+07 75 176.7 
S2 1.60E+07 75 57.2 
S3 4.68E+07 75 156.0 
S4 1.69E+07 75 59.7 
S5 4.20E+07 75 149.9 
S7 4.26E+07 75 152.4 
S9 2.21E+07 75 73.6 
S11 2.45E+07 75 87.3 
S12 5.48E+07 75 195.3 
S13 2.32E+07 75 82.5 
S14 4.96E+07 75 176.7 
S15 1.33E+07 75 44.3 
S16 4.96E+07 75 176.7 
S18 6.41E+07 100 284.8 
S23 3.68E+07 100 163.4 
S23B 8.05E+07 100 357.9 
S26B 6.06E+07 100 269.39 
S26 4.21E+07 100 187.02 
S28B 6.96E+07 100 309.39 
S28 5.73E+07 100 156.00 
S28n 5.69E+07 100 252.9 
S28nB 6.53E+07 100 290.2 
S31 3.87E+07 100 172.1 
S31B 5.99E+07 100 266.1 
S32 4.21E+07 100 187.0 
S32B 3.70E+07 100 164.3 
S57B 5.29E+07 100 235.07 
S57 5.14E+07 100 228.53 
S67B 5.38E+07 100 156.00 
S67 5.03E+07 100 223.40 
S71B 5.17E+07 100 229.95 
S71 5.44E+07 100 241.77 
S75B 5.08E+07 100 225.83 
S75 4.74E+07 100 210.48 
S90B 3.80E+07 100 156.00 
S90 2.07E+07 100 92.04 
Table 3.1: Initial WES output. Detail of the number of reads, read length and coverage obtained for 
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Figure 3.2.1: Schematic of the patient samples used in this study. This includes not only the patient 
samples analysed by WES but also the patient samples then used for validation of the variants as 






3.3 Bioinformatic processing 
Following sequencing, the FastQ files were analysed using FastQC for quality control; a representative 
samples’ read length distribution is shown (Figure 3.3.1A), with a vast majority of reads along the 
expected size (as detailed in Table 3.1), and a long tail of shorter reads. Some of the reads were of too 
low a quality to process further (as defined by an average quality score under 30; Figure 3.3.1B). Reads 
were therefore trimmed using ‘fastx_quality_trimmer’, by removing all calls with individual quality 
scores inferior to 30, starting from the end of the read, until reaching a call with a score of 30 or above. 
The result of this quality trim is displayed (Figure 3.3.2), which had the main effect of increasing the 
mean, and upper and lower quartile quality scores of the end of the reads. Trimming also caused an 
increase in the average quality score (by both decreasing the amount of reads with a low-quality score 
and increasing the amount of reads with a high score; Figure 3.3.3). The shortest reads were also 
removed (any reads under 50 nucleotides in length were removed). 
 
Figure 3.3.1: Make-up of a representative read obtained from WES. Read length distribution (A) and 
Average, upper and lower quartile Quality scores (B) for each individual call. 
 
Figure 3.3.2: Post-trim average, upper 
and lower quartile Quality scores for 






Figure 3.3.3: Number of reads for a 
given average read quality score. 
 
The Burrows-Wheeler Alignment algorithm (Li & Durbin, 2009) (‘bwa mem’ version 0.7.12-5) was used 
to align reads to the reference sequence of the human genome (version hg38), which was indexed 
using the Burrows-Wheeler alignment tool, using default algorithm settings. The output of this was a 
collection of aligned files in the SAM format (‘Sequence Alignment Map’) which were translated into 
the BAM format (‘Binary-compressed SAM file’) using SAMtools (Li et al, 2009) to optimize storage 
space and speed up downstream processing of aligned files. These aligned files were then sorted and 
indexed (still using SAMtools), after which duplicate reads were removed and reads around known 
Insertion and Deletion (InDel) loci were realigned (using Picard’s ‘MarkDuplicates’, 
‘RealignerTargetCreator’ and ‘IndelRealigner’), again using default algorithm settings (McKenna et al, 
2010).  
The coverage of the human exome was computed for each aligned file thus obtained. The average 
coverage for each file is presented (Table 3.1). There was relatively wide disparity between file 
coverage, though this is to be expected as the libraries and sequencing have different sources, and 
since the input DNA was of varying quality (some having derived from FFPE tissues; Table 3.1). 
However, coverage of the exons is satisfying, as shown using the example of the notch1 gene of one 
representative patient sample (Figure 3.3.4). 
InDels and SNVs were then called using two separate software packages; Pindel (Ye et al, 2009) and 
CaVEMan (Turinsky et al, 2008). With respect to Pindel, InDels on all chromosomes were called, and 
the same reference genome as above was used. A configuration file containing the required data 
(sample type and insert size) was required, as detailed in the software’s manual. The output was then 
translated to the VCF format (‘Variant Call Format’) for downstream processing. All files were called in 
parallel to increase call accuracy – the output for all samples is saved in a single VCF file containing all 











Figure 3.3.4: Coverage of a representative sample. Coverage is displayed for the gene notch1, for which 
exons are indicated in grey and UTR in orange. 
 
With respect to CaVEMan, samples were called (where possible) against their peripheral blood 
counterparts to screen out germline variants (though each peripheral blood sample was called for SNVs 
using CaVEMan as well to analyse germline variants). CaVEMan requires the same reference genome, 
along with BED file (‘Browser Extensible Data’) defining non-exonic regions to be ignored. A file was 
compiled using all the intergenic regions as determined by the University of California Santa Cruz 
Genomics Institute. As opposed to Pindel, CaVEMan requires a number of steps for variant calling; 
setup, splitting (the files to be called into segments to be analysed), creating files for each segment 
and merging these, before finally calling variants. The resulting output was also in the VCF format, with 
one file per segment. Files were concatenated into a single file along with the corresponding result file 
for Pindel. As expected, a number of variants were found, for example those found in the locus of 
notch1 (Figure 3.3.5). 
These results were annotated using Annovar (Wang et al, 2010). The VCF files were converted to the 
Annovar input format using ‘convert2annovar.pl’, separating out all samples of the Pindel results file, 
and each of the CaVEMan results files. For each sample, the Pindel and CaVEMan results files were 
concatenated so each sample could be annotated individually. Annovar’s ‘table_annovar.pl’ function 
was then used to annotate variants (both single nucleotide and indels), against the human genome 
(build hg38) as a reference. The variants were annotated against the refGene (build 77) (San Lucas et 
al, 2012), Catalogue of Somatic Mutations in Cancer (COSMIC, build 78) (Tate et al, 2019), AVSNP (build 
147) and dbSNP (build 148) databases – while refGene was used as an Annovar gene-based annotation 
to describe the genes on which each variant was identified, the remaining databases were all filter-
based variant annotation databases. Variants were also annotated against a number of variant 
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prediction databases: SIFT (Vaser et al, 2016), Polyphen (Ramensky et al, 2002), LRT (Chun & Fay, 
2009), MutationTaster (Stenson et al, 2009), MutationAssessor (Reva et al, 2011), FATHMM (Shihab et 
al, 2013), PROVEAN (Choi et al, 2012), MetaSVM and MetaLR (Dong et al, 2015), CADD (Kircher et al, 
2014), dbSNP (Sherry, 2001), 1000Genome (phase 3 release) (The 1000 Genomes Project Consortium,  
2015), ExAc (Lek et al, 2016) and Clinvar (Landrum et al, 2016). 
 
 
Figure 3.3.5: Variants in a locus of the notch1 gene in three representative samples. Coverage is 
indicated on a scale of 0 to 364X by the amplitude, representing the number of reads covering a 
particular locus. Colourful stacks of lines represent potential variants identified throughout the stack of 
reads at a certain locus. Coverage varied by sample as displayed here. 
 
Variants identified as part of intronic, intergenic, untranslated regions or immediately upstream or 
downstream of a gene were filtered out, as none of the variant databases contained sufficient 
information to annotate these – particularly in terms of likelihood of them being pathogenic. 
Synonymous single nucleotide variants were also filtered, as unlikely to produce any significant 
biological changes. Highly variable genes with a low likelihood of pathogenicity were also screened out 
at this stage using published literature (Shyr et al, 2014). Following this, variants identified in any of 
the 11 matched peripheral blood samples were removed from all the other samples, to exclude 
germline variants. 
Variants were then screened based on pathogenicity, using annotated variant effect prediction scores. 
Variants were filtered in two sets; those present in the MetaSVM and/or MetaLR databases, and those 
present in neither. Indeed, MetaSVM and MetaLR collate data from eleven function prediction 
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algorithms, three conservation prediction algorithms and four ensemble scores (Details can be found 
in Dong et al, 2015). Variants predicted to be damaging both by MetaSVM an MetaLR were retained, 
while others were filtered out. For variants not in the MetaSVM/MetaLR databases, custom scores 
combining 8 Variant Effect Prediction software programmes (SIFT, Polyphen, LRT, MutationTaster, 
MutationAssessor, FATHMM, PROVEAN, CADD) were derived: scores from each were translated to a 
0-1 scale and averaged out, following which only variants with scores in the 10th most damaging 
percentile or above were retained.  
The final filter eliminated SNPs identified as present in 0.1% or more of the population, as determined 
by dbSNP, the 1000 Genome and ExAc databases (variants annotated as present in the general 
population at a frequency of > 0.1% in any of the three databases were removed). A list of variants 
identified in at least 10% of our ALCL cohort is presented in Appendix I.  
 
3.4 The ALCL genome: first insights 
Having obtained a list of variants, the first step was to mine the data for insights as to the genomic 
make-up of ALCL. First, the average number of mutations per sample for each of the three sequencing 
cohorts was analysed, but no significant difference was found (as determined by One-way Anova; 
Figure 3.4.1), thereby eliminating the possibility of batch effects. However, there was a slight 
correlation between patient age and the number of mutations, whereby adult patients had more 
mutations than paediatric patients (Figure 3.4.2A). In fact, there is a small difference in the average 
number of mutations between the two groups (Figure 3.4.2B). This is in line with published literature: 
meta-analysis of paediatric cancers have consistently shown fewer somatic mutations than in adult 
cancers (Gröbner et al, 2018). Copy-number variations were also studied (only in samples for which 
we held matched peripheral blood; data not shown), but not copy-number variant (greater than 10000 















Figure 3.4.2: Correlation between number of mutations and patient age. A. Number of mutations for 
each patient, in order from the highest to the lowest number of variants identified per patient, colour-
coded by age (paediatric < 19, adult ≥ 19). B. Average and standard deviation of the number of 
mutations per patient for the paediatric (n=16; age <19) and adult (n=9; age 19 and over) cohorts 
(***p<0.0001; unpaired Student’s T-test). 
 
Across all patients, the distribution of variants per chromosome is far from linear, though it correlates 
very closely with the number of genes per chromosome (Figure 3.4.3). This suggests a relatively silent 
genome, without high mutational loads on particular genes or loci since variants are spread evenly 
across chromosomes and are not specifically targeted at a few loci. Interestingly the distribution of 
somatic and germline variants per chromosome varies (Figure 3.4.4). 
 
 
Figure 3.4.3: Mutational load 
per chromosome. Correlation 
between the number of genes 
per chromosome and the 
mutational burden per 
chromosome (expressed as 
the number of mutations per 


















Figure 3.4.4: Mutational load 
per chromosome of germline 





3.5 Genomic signatures indicative of relapse risk 
Considering the types of variants detected across all patients, 39.4% were non-synonymous SNPs, 
followed by frameshift and non-frameshift deletions, and splice variants (24.1%, 10.8% and 10.6% 
respectively) (Figure 3.5.1A). The distribution of variant types found in germline patients is markedly 
different, with a vast majority of non-synonymous SNVs (89.3%) crowding out all other types of 
variants (Figure 3.5.1B). Since frameshift variants almost invariably lead to loss of function of a protein, 
as opposed to non-frameshift deletions, this chimes with the ability of germline cells to avoid major 
mutational events, as opposed to cancer cells, which would have lost replication quality control.  
Our analysis compares favourably with other studies of the paediatric and adult germline genomic 
landscape (Huang et al, 2018; Zhang et al, 2015): of the published pathogenic variants identified both 
adult and paediatric patients, one was identified in the eleven matched germline DNA samples 
analysed; a non-synonymous SNV in adenomatous polyposis coli (apc) (identified by Zhang et al. in a 
paediatric cohort) on Chromosome 5. Both studies identified similar variant rates in cancer patients 












Figure 3.5.1: Distribution of variant types for the somatic mutations identified. Data are divided into 
variants identified in germline (A) or somatic (B) samples. Distribution of variant type averaged for 





Looking at the types of variants identified amongst patient samples reveals great variance (Figure 
3.5.2) – looking at the three sequencing cohorts again eliminates any batch effects (Figure 3.5.3). 
Interestingly, patients that are known to have relapsed (n=9) have a significantly higher proportion of 
non-synonymous SNVs than patients who did not (n= 9; p<0.0001), suggesting that the genetic make-
up of patients may reveal differences in terms of prognosis (Figure 3.5.4). Unfortunately, NGS is not 
quite yet a suitable biomarker, as its cost is still high on a per-patient basis, and it remains a time-
intensive technique that still lacks in the way of standardization of protocol and bioinformatic 
processing, which can lead to large differences in the results observed. Nonetheless, it remains 
interesting that the genomic constitution of patient tumours may correlate with the likelihood of 
relapse, and in this case may underscore the oncogenic relevance of cumulating single-nucleotide 
polymorphisms, as opposed to InDels. 
 
Figure 3.5.2: 
Proportion of each 











Figure 3.5.3: Proportion of each variant per patient, by sequencing cohorts. Three sequencing cohorts 
are separated out: the two sequencing cohorts processed in this study, and the sequencing files 





Figure 3.5.4: Proportion of each variant type 
according to relapse occurrence. Average and 
standard deviation of the proportion of variant 
type per patient, separated out between 
patients who did (n=9) or did not (n=9) relapse 
(****p<0.0001; T-tests corrected for multiple 
testing using the Holm-Sidak method) (in both 
cases this includes only patients for whom we 




3.6 Mutational Signatures of ALCL 
Different mutational processes lead to unique patterns of mutations, and the advent of large-scale 
genomic data has allowed the identification of a growing number of these so-called ‘mutational 
signatures’ (Alexandrov et al, 2013). The mutational signature of the eleven paediatric samples for 
which sequenced matched peripheral blood DNA was analysed using the R package ‘deconstructSigs’, 
looking for matches with published mutational signatures (Alexandrov et al, 2013). The fraction for 
each of the 96 variant types for the eleven samples in this cohort is shown (Figure 3.6.1). The fractions 


















Figure 3.6.2: Mutation signature 
for patient S57. These were 
derived from the variant types 
displayed in Figure 3.8.1. 
 
Analysis of data generated from the eleven patient tumours (Figure 3.6.3) showed that signature 1 
alone contributes to at least half of the identified somatic mutations (Alexandrov et al, 2013). 
Interestingly, signature 1 is based on the prevalence of C>T transitions at NpCpG trinucleotides and is 
associated with spontaneous deamination of 5-methyl-cytosine (Helleday et al, 2014). Signature 3 has 
its roots in homologous recombination DNA double strand break repair deficiency (Alexandrov et al, 
2013) and is usually associated with breast cancer 1 and 2 (brca1 and brca2) mutations in ovarian, 
breast and pancreatic cancers, so its manifestation in ALCL is more surprising. Signature 26 is also 
associated with a DNA repair mechanism, although in this case DNA mismatch repair, hinting that a 
breakdown in DNA repair mechanisms in ALCL could account for disease pathogenesis, which fits well 
with the fact that Signature 1 is associated with an increasing tumour burden with age. The aetiology 
of Signature 12 is as yet unknown. There was no difference between adult and paediatric patient 
mutational signatures suggesting common mechanisms.  
Comparable patterns were found when comparing signatures to the COSMIC signature database (Tate 
et al, 2019) (data not shown). Our analysis compares with other pan-paediatric cancer studies which 
have also found signature 1 in a majority of samples, and signature 3 in some samples (Gröbner et al, 
2018; Ma et al, 2018). 
 
  
Figure 3.6.3: Main 
mutation types 








3.7 Identification of the most prominent variants  
Beyond these insights into the constitution of the genome of ALCL, variants and mutated genes 
themselves were also analysed (Figure 3.7.1). These data show that the most commonly identified 
variants in both adult and paediatric cases are found in the following genes: trna-yw synthesizing 
protein 1 homolog b (tyw1b), potassium voltage-gated channel subfamily member 18 (kcnj18), mir1-
1hg and defensin-β 132 (defb132) while the most frequently mutated genes are kcnj18, protein 





























Figure 3.7.1: Heatmap of the most commonly mutated genes detected. Individual results for each 
patient presented as a heatmap for genes found to be mutated in at least a quarter of patients. The 
right-hand side panel shows the percentage of patients presenting with at least one variant of the 
indicated gene. Paediatric and adult patients are separated and ordered from youngest to oldest (at 
date of diagnosis). 
0%    25%    50%   75%    100% 
Paediatric     Adult 
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Voltage-gated potassium ion channels, such as that encoded by kncj18 have received increasing 
interest as a therapeutic target, in cancers particularly, although their roles are still controversial and 
ill-defined (Reviewed in Serrano-Novillo et al, 2019). Little is known about the role of mir1-1hg, a 
microRNA precursor gene. The other variants detected, tyw1b and defb132 are equally understudied 
but are thought to encode proteins that hypermodify the guanosine component of the tRNA complex 
and a defensin involved in the immunological response to microorganisms respectively (Noma et al, 
2006; Hollox & Armour, 2008). 
Phosphodiesterase biology has been implicated in cancers before, starting with lymphocytes in 
leukemic mice in the 1980s (Weiss & Winchurch, 1978), to its role in angiogenesis and the interplay 
between lymphomas and the microenvironment more recently (Suhasini et al, 2016), which may 
explain the frequent mutations found in genes of this pathway such as pde3dip. Other metabolic 
pathways such as serine biosynthesis are implicated here, as exemplified by frequent mutations in 
psph, a gene and pathway which has also previously been implicated in T-cell malignancies (Kampen 
et al, 2019).  
Perhaps the least surprising hits identified in this study are the frequent mutations in tyro3, a receptor 
tyrosine kinase and emerging oncogene of which the signalling cascade shows extensive cross-talk with 
pathways important to ALCL pathobiology such as PI3K, Akt and JAK/STAT (Reviewed in Smart et al, 
2018), as well as notch1, which has been implicated in ALCL pathogenesis previously (see Chapter 1.7). 
In order to further define identified mutations in genes that may be important towards the 
















3.8 Gene Set Enrichment Analysis: The Notch pathway  
To further investigate the likelihood of pathways being of systemic importance to ALCL, Reactome 
network clustering was conducted (Fabregat et al, 2018). Figure 3.8.1 illustrates the main interactions 
of mutated genes in the dataset. Clear nodes appear around tp53, g-protein sub-unit γ2 (gng2) as well 
as small clusters around notch1 and c-terminal binding protein 2 (ctbp2), indicating proteins that 
interact with a number of the other mutated genes. tp53 is not unexpected as p53 has been reported 
to play a key role in ALCL pathogenesis (Cui et al, 2009). As mentioned previously, the Notch pathway 
is of marked importance in T-cell biology (Osborne & Minter, 2007) particularly in the developing 
thymus which is proposed as the origin of ALK+ ALCL (Malcolm et al, 2016), and has previously been 
implicated in the pathogenesis of ALCL (Jundt et al, 2002). GNG2 is another node which given the 
central importance of G-proteins and the centrosome in cellular biology is not an unexpected finding: 
many proteins interact with these sub-units. Clearly the most frequently affected pathways in this 
dataset are very different from those presented previously (Figure 3.7.1), suggesting that the main 
mutated genes may not be the ones that are of the most systemic importance in ALCL (Figure 3.8.1 
and Figure 3.8.2). However, genes such as tp53 or gng2 are neither frequently mutated nor presenting 
with frequent variants (Figure 3.7.1), indicating that mutation of pathways may be more relevant than 
individual genes. 
The main mutated nodes were cross-checked by Gene-Set Enrichment Analysis (GSEA), which could 
help identify vital pathways in ALCL, since biologically relevant pathways should be enriched more 
heavily with variants than others (Figure 3.8.2). All genes which were mutated in at least a tenth of the 
32 patients were included in the GSEA. Two different software programmes were used; DAVID (Huang 
et al, 2009) for protein domains, and Reactome (Fabregat et al, 2018) for pathway analysis. Reactome 
analysis combined 5 different databases: IPA (Qiagen), PantherDB (Mi et al, 2017), KEGG (Goto et al, 
1997), the National Institute for Health’s Protein Interaction Database and Reactome’s own database. 
Analysis of protein domains with DAVID used four different databases, GO (The Gene Ontology 
Consortium, 2019), Seq-Feat (National Centre for Biotechnology Information, US), SMART (Letunic & 
Bork, 2018) and InterPro (Mitchell et al, 2019). The number of databases in which each pathway or 
domain was found to be enriched are displayed along with p-values and the number of genes in the 
pathway, plotted using ggplot2 in R (Figures 3.8.2 and Figure 3.8.3). 
This analysis showed the gene set to be enriched in T-cell Receptor (TCR) signalling pathway genes 
across all five databases used, along with genes of the Notch pathway (Figure 3.8.2). The TCR signalling 
pathway is perhaps not surprising, as it is one of the main signalling pathways in T-cell biology; it has 
previously been shown that NPM-ALK can substitute for key TCR-induced distal signalling pathways 
and silencing of proximal proteins has been shown in ALCL (Ambrogio et al, 2009; Turner et al, 2007). 
Other less significant hits such as the G-protein-coupled receptor (GPCR) signalling pathway, calcium 
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signalling or neurotransmission are also unsurprising considering the hits already identified in kcnj18 
(a calcium-regulated potassium synaptic channel), gng2 (part of the G-protein complex) and others.  
Analysis of domains frequently present in the mutated genes revealed an enrichment in proteins with 
EGF-like or Calcium ion binding domains (Figure 3.8.3), two features of the Notch protein. Interestingly, 
3 of the 4 identified notch1 variants are found within the EGF-like calcium binding domain of Notch1 





















Figure 3.8.1: Reactome Network Clustering Analysis. Nodular interaction plot showing connections 
between variants. The plot was designed using Reactome. Arrows indicate activating interactions, 






Figure 3.8.2: GSEA of the mutated genes using Reactome and five databases. Scatter plots of the 
pathways found to be enriched in the dataset, displaying the number of databases in which each hit 
was found to be enriched, along with the (-)log10 of the p-value of the software in which each hit is 
found to be most enriched, and the corresponding number of genes involved.  
 
 
Figure 3.8.3: GSEA of the mutated gene domains using DAVID and four databases. Scatter plots of the 
domains found to be enriched in the dataset, displaying the number of databases in which each hit was 
found to be enriched, along with the (-)log10 of the p-value of the software in which each hit is found to 
be most enriched, and the corresponding number of genes involved.  
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3.9 Hit validation in a larger cohort of patient tumours 
Given the importance of the Notch pathway to T cell biology, the most frequent variants detected in 
notch1 (T349P and T311P) were validated in a larger patient cohort (Table 2.5).  
Of the 25 ALK+ ALCL tumour samples analysed by WES, 24% presented with Notch1 variant T349P 
while 12% had Notch1 variant T311P. Of the extended cohort of 78 samples (including 18 of the 
samples previously analysed by WES with a total of 55 ALK+ ALCL, and 23 ALK- ALCL as described in 
Figure 3.2.1); the variant T349P was validated in 12% of patients (n=78; 15% of ALK- patients and 9.3% 
of ALK+ patients) (Figure 3.9.1). Variant T311P was found in 7.6% of patients (n=78; 10.2% of ALK+ 
patients, none in ALK- patients) (Figure 3.9.2). Interestingly, the overall incidence of patients with at 
least one mutation of the EGF-like domain in which these variants were found is cumulatively 18% (14 
of 78 patients).  
 
 
Figure 3.9.1: Sanger chromatogram 




Figure 3.9.2: Sanger chromatogram 





There was therefore no significant difference in incidence of Notch1 mutations between ALK+ ALCL or 
ALK- ALCL, nor was there a significant difference between adult and paediatric ALCL patients (Table 
3.9). Overall, there is a slight difference in the 5-year OS and EFS between patients that are wild-type 
for T349 and T311, and those that present with at least one of the two mutations (a difference of just  
over 9 months and 6 months, respectively for OS and EFS). Interestingly, the difference is much more 
significant for adult and ALK- ALCL patients, though generally patient number prevents a more solid 
analysis of this data, which therefore remains largely anecdotal.  
 





































n = 57 n = 11 n = 13 n = 3 n = 27 n = 5 n = 45 n = 8 n = 12 n = 3 
OS 
(years) 
4.4 3.6 4.2 1.7 4.4 2.9 4.5 4.3 4.5 1.7 
EFS 
(years) 
2.6 2.1 4 1.7 4.2 3.2 2.3 2.2 3.6 1.7 
Death 
(%) 
25% 36% 38% 67% 26% 20% 18% 25% 50% 67% 
Relapse 
(%) 
61% 55% 38% 0% 52% 60% 67% 75% 42% 0% 
 
Table 3.9: Detail of the Notch1 status of our validation cohort. The Notch1 mutation status at T311 and 
T349 (WT: Wild-Type) of the patients in our validation cohort is detailed here, broken down by ALK+ 
and ALK- ALCL patients, and adult and paediatric ALCL patients. In addition, the assorted clinical data 
is detailed, with the 5-year Overall Survival (OS), 5-year Event-Free Survival (EFS), and proportion of 




















3.10 digital droplet PCR 
Finally, we investigated the possible presence of sub-clonal T349P mutations using digital droplet PCR 
technology, which first uses a lipid-based technology to separate out different clones of a sample of 
DNA (one per droplet), before PCR-amplifying the clone contained in each droplet using two different 
fluorescently-tagged probes, corresponding either to the wild-type or mutated allele of the variant 
studied (in this case, T349P). This technology requires a certain amount of optimisation, to determine 
the optimal amount of input DNA, the optimal PCR cycle (and melting temperature). This optimisation 
manifested itself in the total number of droplets (though the manufacturer claims that up to 20,000 
droplets can be generated and created, we achieved an average of around 15,000 after optimisation, 
though some runs were far less successful; Figure 3.10.1), and the difference in amplitude between 
droplets negative or positive for either of the probes (this helps determine the count of positive or 




Figure 3.10.1: Optimisation. (A) ddPCR plot of clones expressing the wild-type (green) or T349P mutated 
allele (blue) – droplets negative for the fluorophore measured are coloured grey, for four different 
samples, before protocol optimisation. Each dot represents one droplet (one clone), and its position on 
the Y-axis represents the intensity of fluorescence that emanates from the droplet.  (B) Number of 
droplets before and after protocol optimisation, as measured by Fluorescence-Activated droplet sorting 
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We were able to use the wild-type and mutated Notch1 cDNA plasmids as negative and positive 
controls to verify that the probes worked as intended (Figure 3.10.2). Though the technology is in 
theory capable of detecting as little as one clone, it is generally accepted that at least three positive 
droplets are required to rule out false positives. Our data (Figure 3.10.3) however shows that we did 
not need to test the limit of detection of the technology, as our patient samples were clearly either 
positive or negative for mutation T349P, and none of the samples we tested (n=60) appeared to 







 Negative controls            Positive controls                  Negative controls          Positive controls  
 
Figure 3.10.2: Positive and negative controls. ddPCR plot of clones expressing the wild-type (green) or 
T349P mutated allele (blue) – droplets negative for the fluorophore measured are coloured grey, for 
four samples, showing two negative controls and two positive controls for the Wild-type (A) and 
mutated (B) allele. Each dot represents one droplet (one clone), and its position on the Y-axis represents 
the intensity of fluorescence that emanates from the droplet. The pink line is the threshold for droplets 







            
              Sample 1                          Sample 2                                    Sample 1                         Sample 2 
Figure 3.10.3: Example of samples showing a lack of sub-clonal mutations. ddPCR plot of clones 
expressing the wild-type (green) or T349P mutated allele (blue) – droplets negative for the fluorophore 
measured are coloured grey, for four samples, showing two samples each with a Wild-type (A) and 
mutated (B) allele. Each dot represents one droplet (one clone), and its position on the Y-axis represents 
the intensity of fluorescence that emanates from the droplet. The pink line is the threshold for droplets 







In this chapter, DNA extracted from 18 ALK+ ALCL patient samples was assessed by WES and analysed 
alongside 7 previously published samples, using a custom-designed bioinformatic pipeline. The 
genomic constitution of the ALCL DNA, both paediatric and adult was analysed, and it was determined 
that, as suggested by a larger meta-analysis, paediatric tumours on average present with slightly less 
variants than adult tumours – although it is unusual to be able to study this in a cancer that manifests 
in both adults and children. The genome of ALCL patients remains fairly silent, with an absence of 
consistent copy-number variations or large InDels, and largely absent frequent mutations and hyper-
mutated genes, bar those described in this chapter.  
 
It would be interesting to ask whether the trend is similar for germline mutations, which could be 
expected to bear more of the responsibility for tumourogenesis in paediatric patients compared to 
adults – although research so far has shown little difference (Huang et al, 2018; Zhang et al, 2015). 
Indeed, though we did not find any significant insertions, deletions or copy-number variations in our 
eleven matched peripheral blood patient samples, our analysis was fine-tuned for the detection of 
somatic mutations, and thus it would be worth analysing these samples using a more targeted 
bioinformatic pipeline. Nonetheless, comparing the germline variant list we obtained with published 
large-scale studies points to probable pathogenic variants in the germline of three patients: S23,  S66 
and S74, presenting with a non-synonymous SNP in tp53 (SNP ID rs1042522) and another two in brca2 
(SNP ID COSM4984873 and rs80359165) respectively (Zhang et al, 2015). 
 
Looking at tumour signatures, signatures 1, 3, 12 and 26 were the most common in our analysis, with 
Signature 1 by far the biggest contributor. Our analysis compares with other pan-paediatric cancer 
studies which have also found signature 1 in a majority of samples, and signature 3 in some samples 
(Gröbner et al, 2018; Ma et al, 2018). The fact that signature 1 (based on the prevalence of C>T 
transitions at NpCpG trinucleotides associated with spontaneous deamination of 5-methyl-cytosine) is 
associated with age might explain the slight correlation we found between mutational burden and age, 
as also shown by Gröbner et al. Signature 3 was also detected in all 11 patient samples, a signature 
with its roots in homologous recombination DNA double strand break repair deficiency (Alexandrov et 
al, 2013). This suggests that DNA damage repair mechanisms might be impaired in these children, 
predisposing them to ALCL, perhaps through germline mutations. Interestingly, this signature is 
strongly associated with germline and somatic brca1/2 mutations, of which we found two potential 
pathogenic ones in our patients (along with other germline brca1 and brca2 mutations in other 
patients, less likely to be pathogenic). Signatures 12 and 26 are both consistent with repair by 
transcription-coupled nucleotide excision repair, and though the aetiology of Signature 12 remains 
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unknown, that of signature 26 is linked with defective mismatch repair – all in all, pointing to an 
increased likelihood of DNA damage, and possibly defective repair mechanisms, which may or may not 
lead to an accumulation of mutational burden with age, as signature 1 and our data may suggest. 
 
While we also attempted to correlate some of the genetic features back to clinical outcomes and 
markers, our sample size is too small to be able to conclusively determine much that can be taken 
forward. Indeed, it is possible that the effect we see, correlating relapse with the type of variants found 
is merely a by-product of another mechanism, such as a particular type of DNA damage or repair 
defect. Nonetheless, the fact that we found this correlation is important as it indicates that, at the 
genomic level, there is a significant difference between patients who relapse, versus those who don’t. 
It may be that the larger proportion of non-synonymous SNPs cluster in certain genes or loci, for 
example, which we were not able to analyse with the facilities available.  
 
The biologic importance of some of the mutated genes and affected pathways were then identified by 
GSEA and other methods. The two signalling pathways most significantly enriched in variants are the 
T-cell receptor signalling and Notch signalling pathways.  These findings are somewhat unsurprising,  
given the importance of both these signalling pathways in T cell biology – indeed, there is increasing 
evidence suggesting cross-talk between the two pathways in T cells (Steinbuck et al, 2018). In addition 
to this, deregulation of Notch signalling has been identified as heavily prominent in several leukaemia 
and lymphomas (Gain-of-function mutations in Notch1; perhaps most so in T-ALL, where 50 to 60% of 
patients present with such mutations (Weng et al, 2004; Breit et al, 2006; Aster et al, 2011)). All this 
evidence suggested to us that Notch1 and the signalling pathway in which it resides is likely to be of 
importance to ALCL.  
 
Indeed, two of the main mutations detected in notch1 (of four mutations identified by WES) were 
validated in a wider cohort of almost 80 patients, whereby a fifth of the samples presented with at 
least one of the Notch1 variants. We described a novel gain-of-function mutation in the extracellular 
EGF-like domains of Notch1. Though in other cancers most of these mutations are in the intracellular 
domains of the protein, some are also found in the extracellular domain: cutaneous and lung squamous 
cell carcinoma patients also present with Notch1 mutations, a number of which are located in the 
extracellular EGF-like domains, though only one of these has been studied in any level of depth, and is 
predicted to lead to loss-of-function (Wang et al, 2011b). Indeed, T349P and T311P are thought to 
manifest in other tumour types, such as primary central nervous system lymphoma (Bruno et al, 2014), 
chronic myelomonocytic leukaemia (Mason et al, 2016), chronic lymphocytic leukaemia (Ljungström 
et al, 2016), T-ALL (Neumann et al, 2015), and squamous cell carcinoma (Martin et al, 2014). Though 
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none of these publications validate the presence of Notch1 T349P, it is unlikely for the variant to be 
present as an artefact or false-positive in all five publications. Finally, despite evidence suggesting that 
other Notch mutations have been found in cancers at sub-clonal frequencies (Minervini et al, 2016), 
we show that this was not the case for mutation T349P in ALCL.  
 
We have therefore analysed the genome of ALCL, and found it to be fairly stable, as ALCL literature 
suggests. Having found evidence that the Notch pathway may be hypermutated and considering 
evidence from the literature concerning Notch1 in ALCL, we decided to validate the two main variants 
found in Notch1. Since we were able to prove that about 20% of patients present with at least one 
Notch1 variant in the extracellular domain of the protein, we then decided to investigate the functional 











In a wild-type state, members of the Notch family of receptors are activated by one of five ligands; 
Jag1, Jag2, DLL1, DLL3 or DLL4 (Figure 4.1.1). Notch activation is regulated by post-translational 
modification of both the Notch receptor and the Notch ligand – as well as proximity of the Notch-
expressing cell and the ligand-expressing cell, which is why the tumour microenvironment, and the 
presence of ligand-expressing endothelial cells are increasingly understood to be significant when 
studying the role of Notch signalling in cancer (Reviewed in Meurette & Mehlen, 2018; Bray, 2016). 
Notch is a heavily conserved signalling pathway in most organisms, underscoring its biological 
importance – and mutations of the Notch family of genes is often associated with oncogenic events. 
Indeed both independent studies and the COSMIC database have shown that the negative regulatory 
region and the PEST sequence of the Notch family of proteins are the target of a large number of 
mutations, across many cancer types (Wang et al, 2011b; Forbes et al, 2008), though it has been noted 
previously that a number of mutations are also found in the EGF-like repeats, even though these have 
rarely been investigated for their functional consequences to the protein (Mutvei et al, 2015; Wang et 
al, 2011b; Rebay et al, 1991). In the previous chapter, two mutations in the extracellular EGF-like 
domain of Notch1 were detected in ALCL. The functional significance that these mutations may have 
on the activity of Notch1, and therefore the significance these mutations may have in ALCL biology are 
described here. 
 
Figure 4.1.1: Schematic showing the interaction of Notch and its ligand. The Notch receptors are 
composed of the following domains; Epidermal Growth Factor-like repeats (EGF), Negative Regulatory 
Region (NRR), LIN12/Notch Repeats (LNR), Heterodimerization Domains (HDC and HDN), RBP-Jκ 
Association Molecule (RAM), Ankyrin Repeats (ANK), Polypeptide enriched in proline, glutamate, serine 
and Threonine (PEST) – and the Notch ligands (in this example, DLL) activate the Notch receptors using 
the Amino-Terminal (NT) and delta-Serrate-LAG2 (DSL) domains. (Modified from Bray, 2016). 
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4.2 Defining Notch1 mutations T349P and T311P 
The most frequent notch1 variant identified in this study, is at position 1045 of the notch1 coding 
sequence, in the 6th of 34 exons, changing an Adenosine to a Cytosine, leading to a change in the 349th 
amino acid from Threonine into Proline. The 6th exon encodes one of the numerous EGF-like domains 
which make up the extracellular domain of Notch1. Notch1 T349P was predicted to be a function-
altering mutation by variant effect prediction software including SIFT (which gave it a score of 0.01), 
Polyphen (which gave the variant a score of 0.999), FATHMM, LRT, MutationTaster, PROVEAN, and the 
MetaLR and MetaSVM databases (Adzhubei et al, 2010; Kumar et al, 2009; Chun & Fay, 2009; Schwarz 
et al, 2014; Choi et al, 2012). Similarly, the T311P variant was scored as being damaging by all the same 
software, except for Polyphen (which gave it a score of only 0.181 as opposed to 0.012 by SIFT).  
Notably, the loss of Threonine leads to the potential loss of O-linked Glycosylation. O-linked 
Glycosylation or Fucosylation of Notch1’s EGF-like domain has been demonstrated to promote Notch 
signalling and regulate binding to its ligand in some cases (Schneider et al, 2018; and reviewed by 
Stanley & Okajima, 2010 and; Pakkiriswami et al, 2016). In addition, Proline is one of the few extremely 
rigid amino acids known to force a change of confirmation in tertiary structure, and interestingly often 
forces a change in β-sheet structure (each EGF-like domain is made up of 4 β-sheets among other 
secondary structures). Molecular studies have shown specific EGF-like domains to be necessary but 
not sufficient for Notch-ligand binding in the presence of Calcium ions (Chillakuri et al, 2012), indicating 
that nearby calcium-binding is likely to be involved in ligand binding. To note, bioinformatic analysis 
identified two more variants in nearby EGF-like domains, and one in Lin12/Notch repeat domain 2. 
Notch1 variant T311P is also found in the 6th exon, at position 1193 of the coding sequence, with 
similarly an Adenosine mutated into a Cytosine leading to a change from Threonine into a Proline, 
resulting in a predicted loss of O-linked Fucosylation on one of the EGF-like domains of the extracellular 
portion of Notch1. 
Furthermore, the COSMIC database shows that T311 and T349 are the two most frequently reported 
mutated amino acids at the presumed Notch1/Jag1 interface across a range of cancers (including 
chronic myelomonocytic leukaemia (Mason et al, 2016), chronic lymphocytic leukaemia (Ljungström 
et al, 2016), T-ALL (Neumann et al, 2015), rhabdomyosarcoma (Kohsaka et al, 2014) and squamous cell 
carcinoma (Martin et al, 2014)) (Figure 4.2.1). These two variants were also validated as present in a 




Figure 4.2.1: COSMIC variant frequencies. 
Frequency at which select Notch1 mutations at 
the Notch/ligand interface are reported in the 
COSMIC database. 
4.3 Molecular Dynamics of Notch1 mutations 
Since Notch1 amino residues T349 and T311 are present at the Notch/ligand interface, in silico 
modelling was performed to predict the effects of the mutation on protein conformation and ligand 
binding. The predicted conformational change was modelled using a combination of previously 
published structures of Notch1 and Jag1 and structural predictions using machine learning to predict 
structure and reconcile the various crystal structures used (Figure 4.3.1). Specifically using a structure 
of Notch1’s extracellular EGF-like domains 8 to 12 bound to its ligand (Luca et al, 2017) (PDBID 5UK5) 
allowed detailed analysis of the Notch1/Jag1 interface (Figure 4.3.2 and Figure 4.3.3).  
 
 
Figure 4.3.1: Detail of sources of protein conformation modelling. A mix of published datasets in the 
protein database (PDB) and predictions (Model) were used to compute the full Notch1 and Jag1 
structures, the amino acids which were obtained from published datasets or models are detailed here. 























































Figure 4.3.2: Full-length modelling of the Notch1 protein bound to Jag1. Binding of Notch1 to Jag1, 
showing enlarged images of amino acid residues T349 and T311. The molecules are presented in their 
secondary (spirals represent α-helices and arrows β-sheets) and tertiary conformations (the semi-
transparent surface outline), with the side-chains of residues T311 and T349 presented as stick 

















A cartoon representation of the Notch1 domain containing residues T349 and T311 is shown, 
displaying Hydrogen bonds in black, and a nearby Calcium ion as a sphere (Figure 4.3.3). The two β-
sheets are anchored to each other by Hydrogen bonds, two of which are dependent on Threonine 349 
and 311, and one of which will be lost when replaced by a Proline residue.  
Mutations T349P and T311P are predicted to displace the β-sheets due to both the bulkier side-chain 
of Proline (as compared to Threonine) and due to the loss of a stabilizing Hydrogen bond (Figure 4.3.4). 
However, the remaining Hydrogen bonds seem sufficient to avoid a more drastic change in 
conformation. Superimposition of wild-type and mutated Notch1 (Figure 4.3.5) clearly show the 
displacement of the β-sheets that mediate ligand binding, and the possible displacement of the nearby 
Calcium ion as well. Although residues T349 and T311 are not in physical contact with the Notch1 
ligand, a change in Notch1’s conformation is still seen that may modulate ligand binding.  
 
 
Figure 4.3.3: Enlarged locus of Notch1 residues T349 and T311 within the Notch1/Jag1 interface . The 
wild-type molecules are presented in their secondary (helices represent α-helices and arrows β-sheets) 
confirmation, with the side-chains of residues T311 and T349 presented as stick cartoons and Hydrogen 
bonds modelled as black dotted lines, while Calcium ions are purple spheres. Notch1 is the upper chain, 







Figure 4.3.4: Detailed conformational changes at the Notch1/Jag1 interface . The molecules (wild-type 
Jag1 and mutated Notch1) are presented in their secondary (helices represent α-helices and arrows β-
sheets) conformation, with the side-chains of residues T311 and T349 presented as stick cartoons and 
Hydrogen bonds modelled as black dotted lines, while Calcium ions are purple spheres. Notch1 is the 





the Wild-type and 
mutated Notch1. 
Wild-type Notch1 is 
shown in green, the 
mutated chain in 
red, and T349 is 








Changes in Gibbs-free energy created by the two variants were then computed in order to determine 
what impact the mutations are likely to have on protein folding. Defining 𝚫𝚫𝐆 as the change in Gibbs-
free energy and 𝚫𝐆 as steady-state Gibbs-free energy, 𝚫𝚫𝐆 was calculated as follows:  
𝚫𝚫𝐆 = 𝚫𝐆(𝐰𝐢𝐥𝐝𝐭𝐲𝐩𝐞)− 𝚫𝐆(𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧) 
SDM (Pandurangan et al, 2017) and mCSM (Pires et al, 2014) analyses predicted that neither T311P 
and T349P would significantly change protein stability (|ΔΔG|<1; Figure 4.3.6); mCSM protein-protein 
interaction analysis predicts a negligible change in ΔΔG (|ΔΔG|<0.5 kcal/mol) of the Notch1-ligand 
binding interaction (Figure 4.3.7). Other online variant confirmation prediction software including 
DynaMut predicted similar negligible changes (stabilizing ΔΔG<1) (Rodrigues et al, 2018). These data 
suggest that since there is little quantifiable change in Gibbs-free energy caused by the two mutations, 




Figure 4.3.6: Quantifying the changes in Gibbs-free energy released by T349P and T311P. Analyses by 
SDM (A) and mCSM-stab (B) for all the Notch1 variants found in COSMIC that are at the protein-ligand 
interface (T311P and T349P mutants are coloured orange).  
 
 
Figure 4.3.7: mCSM-protein-protein-interaction 
analysis. Analyses for all the Notch1 variants 
found in COSMIC that are at the protein-ligand 









4.4 Investigating in vitro models to study Notch1 mutations 
Notch1 is expressed at high levels in ALCL cell lines (Jundt et al, 2002), which fits with data showing 
that Notch1 is highly expressed in patient tumours (more on this in Chapter 5). However, of all the cell 
lines evaluated, none express the notch1 variants detected in the patient samples (data not shown). 
Hence, in order to functionally evaluate the consequences of these mutations to the proteins encoded, 
attempts were made, using CRISPR-Cas9 technology, to engineer T349P and T311P Notch1 into ALCL 
cell lines. The Cas9 expression plasmid pSpCas9(BB)-2A-GFP (Addgene; Cat# 48138) was expressed into 
ALCL cell lines using nucleofection, after failed attempts to insert the plasmid into ALCL cell lines using 
the latest generation of LipofectamineTM; Lipofectamine 3000 (Thermo Fisher Scientific, Cat# 
L3000001; Figure 4.4.1). Indeed, previous experience has shown suspension T-cell derived lines to be 
resistant to liposome-based transfection technology, although we had hoped that the latest iteration 
of LipofectamineTM may have overcome this issue, as the manufacturer’s promotional material 
suggests. 
Instead, we proceeded with electrical current-based nucleofection using Amaxa’s NucleofectorTM (now 
owned by the Lonza Group).  Optimisation suggested that programmes A030 and G016 produced the 
best results, in terms of balancing toxicity of the technique and electroporation of the plasmid into the 
cell lines. Sorting using the plasmid’s GFP marker allowed to select for nucleofected cell lines 
expressing Cas9, protein and mRNA expression of which was verified using Western Blotting (Figure 
4.4.1 and Figure 4.4.2) and RT-qPCR (data not shown). Following this, single-stranded Donor 
Oligonucleotides (ssODN) and sgRNA were designed to mediate cleavage and homology-directed 
repair of the notch1 gene to introduce the variants we identified. Unfortunately, it soon became clear 
that nucleofection of these oligonucleotides for transient expression was too toxic to ALCL cell lines 
already stressed by the expression of Cas9, and transfection had already proven to be impossible. 
Stable expression of the sgRNA and ssODN using viral transduction was investigated, but well-
documented concerns for significant off-target mutations (Pattanayak et al, 2013) should cell lines 
stably express both Cas9 and sgRNA for the months required for downstream experiments led us to 
abandon this approach. Putting the off-target effects aside, ssODN could not, at the time, be 
transduced into cell lines, as they could not be expressed by a simple plasmid, and thus would require 
nucleofection regardless, which has proven both too toxic and to have too low a transfection efficiency 
for this approach to work – particularly since cells would have to be grown out from single clones to 
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Figure 4.4.1: FACS plots of Cas9 nucleofection and transfection. ALCL cell lines were transfected, using 
Lipofectamine, with either an empty vector (A) or a GFP-Cas9-expressing plasmid (B) or electroporated 
using Nucleofection, with the same empty vector (C) or GFP-Cas9 construct (D) and analysed for GFP 
expression using FACS (representative FACS plots are shown). 
 
 
Figure 4.4.2: Validating Cas9 
expression. Western Blot 
validating Cas9 protein 
expression in electroporated 
ALCL cell lines. Blots are 




4.5 Notch1 T349P confers a proliferative advantage to cells in which it is expressed  
An expression plasmid containing the whole length notch1 cDNA (Li et al, 2008) was mutated by site 
directed mutagenesis to carry the variants T349P and T311P. Due to the high basal expression levels 
of Notch1 in ALCL cell lines, an alternative cell line was chosen in which to express the Notch1 mutants 
in order to assess their functional consequences. 
Unfortunately, B- and T-cell lines all have high basal levels of notch1, as do many other cell lines and 
therefore the HEK233FT cell line, a well-characterized, easy-to-use, and easy-to-transfect with proven 
low-to-absent endogenous levels of notch1 expression was employed (Figure 4.5.1) (Petit et al, 2002; 
Oh et al, 2010). Wild-type or mutated Notch1 plasmids were transfected into HEK293FT cells, and 
protein levels visualised by Western Blot to verify expression and activation of both full-length Notch1 
and the activated ICN (Figure 4.5.1). In addition, mRNA expression levels of the proteins were assessed 
by RT-qPCR to verify that levels of expression were not significantly different between cells expressing 
the wild-type and mutated Notch1 plasmids (Figure 4.5.1). 











Figure 4.5.1: Validation of ectopic Notch1 expression in HEK293FTs following transfection. (A) 
Expression of the indicated proteins according to Western Blot, blots are representative of three 
biological replicates. EV = Empty Vector, WT = Wild-type. (B) Fold expression of notch1 mRNA in 
HEK293FTs expressing either a Wild-Type (WT) or mutated Notch1 over an Empty Vector control, as 
measured using RT-qPCR. 
 
In order to assess the functional consequences of the mutations, Notch1 mutants T349P and T311P 
were expressed in HEK293FT cells and cell proliferation monitored by the RealTimeGlo assay (Figure 
4.5.2). The T349P mutant led to a significant increase in cell proliferation at 72 hours, as compared to 
both the empty vector control and the HEK293FTs stably transfected with the wild-type cDNA of 
notch1. These data suggest that the T349P Notch1 mutant, confers a survival advantage to the cells in 
which it is expressed in the absence of exogenously-applied ligand. 
 
 
Figure 4.5.2: Proliferative effect of the Notch1 
mutations. Proliferation of HEK293FTs 
expressing either an Empty Vector, Wild-Type 
(WT) or mutated Notch1, as measured by the 








In keeping with a proliferative advantage, cells expressing the mutant forms of Notch1 also showed 
increased transcript levels of the transcriptional targets of Notch1 activity, hes1 and hey1, suggesting 
that Notch1 is transcriptionally active in these cells (Figure 4.5.3). These data confirm the previously 











Figure 4.5.3: Expression levels of Notch1 downstream genes. Fold expression of hes1 (A) or hey1 (B) in 
HEK293FT cells expressing either Wild-Type (WT) or mutated Notch1 compared to an Empty vector, as 
measured by RT-qPCR (*p<0.05; **p<0.01; n=3).  
 
 
4.6 Interplay between Notch1 T349P and its ligand, DLL1 
Since in silico modelling suggested that T349P and T311P could mediate binding to the Notch1 ligand, 
assays were conducted to determine whether the increase in cell proliferation observed was 
dependent on binding to the Notch1 ligand. HEK293FT cells expressing wild-type or mutant notch1 
were co-cultured with either the wild-type OP9 cell line or OP9 cells expressing the Notch1 ligand DLL1. 
The OP9-DLL1 system is a widely used as a means to activate Notch1 activity, often to promote 
differentiation of immune cells (Zúñiga-Pflücker, 2004; Holmes & Zúñiga-Pflücker, 2009). Here, OP9-
DLL1 cells were used both to activate the exogenously expressed Notch receptor in HEK293FTs using 
a co-culture protocol followed by sorting on Notch1 (Figure 4.6.1 and Figure 4.6.2) - or to activate the 








































Figure 4.6.1: Summary of the co-culture method. This cartoon describes the method we used here to 
express DLL1 in the OP9 cell line, Notch1 (wild-type or mutated) in the HEK293FT cell line, and how the 
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Figure 4.6.2: Sorting of the OP9-DLL1 and Notch1-expressing-HEK293FT co-culture. HEK293FT cells 
transfected with an empty vector (A), wild-type (B), T349P-notch1 (C) or T311P-notch1 (D) were 
separated by flow cytometry according to Phycoerythrin (PE) staining (cells were stained using a 
Notch1-PE conjugated antibody). Plots are representative of three biological replicates.  
 
 




There was no discernible difference in proliferation between cells co-cultured with wild-type OP9, or 
OP9-DLL1 cells (Figure 4.6.3). In other words, while the Notch1 mutations T349P and T311P provided 
a growth advantage, the co-culture did not. In keeping with this observation, there was no increase in 
expression of the Notch1 downstream target genes hes1 and hey1 (Figure 4.6.4). This suggests that 







Figure 4.6.3: Cell proliferation upon co-culture 
with OP9 cells presenting the Notch1 ligand, 
DLL1. Proliferation of HEK293FTs expressing 
either an Empty Vector (EV), Wild-type (WT) or 
mutated Notch1, co-cultured with either wild-
type (WT-OP9) or DLL1-expressing OP9 (OP9-
DLL1) cells, as measured by an MTT assay. 





Figure 4.6.4: Expression levels of Notch1 target genes when co-cultured with OP9-DLL1 cells. Fold 
expression of hes1 (A) and hey1 (B) in HEK293FTs expressing either Wild-Type (WT) or mutated Notch1 
over an Empty vector, when co-cultured with a Wild-Type (WT-OP9) or DLL1-expressing (OP9-DLL1) 





Interestingly, increased transcription of endogenously-expressed DLL1 was observed on expression of 
the mutant forms of Notch1 compared to wild-type protein suggesting that the mutant proteins might 
themselves lead to transcription of ligand in an autonomous fashion (Figure 4.6.5). We did, as a 
positive control, test that presenting the Notch ligand to ALCL cells increased expression of Notch 
target genes and found that this was indeed the case (see chapter 6.6).  
  
Figure 4.6.5: Expression of the Notch ligand DLL1 
in HEK293FT cells. Cells expressing either Wild-
Type (WT) or mutated Notch1 compared to an 
Empty vector control, when co-cultured with 
either Wild-Type (WT-OP9) or DLL1-expressing 
(OP9-DLL1) OP9 cell lines as measured by RT-




In this chapter the functional consequences of Notch1 mutants T349P and T311P were investigated:  
although these variants have previously been identified, they have never before been characterised.  
Threonine bases within the EGF-like domains are post-translationally modified by O-linked 
Glycosylation which is necessary for ligand-dependent Notch1 signalling (Stanley & Okajima, 2010; 
Pakkiriswami et al, 2016; Haines & Irvine, 2003). In contrast, Proline is one of the few extremely rigid 
amino acids, known to result in a change in tertiary structure, often forcing a change in β-sheet 
conformation (each EGF-like domain is made up of 4 β-sheets among other structures). To note, our 
bioinformatics analysis identified two more variants in EGF-like domains 8 and 31, as well as one in the 
Lin12/Notch repeat domain 2. In addition, it has been shown that EGF-like domains 8 to 12 are 
important for Notch1 binding to its different ligands (Luca et al, 2017; Rebay et al, 1991). Because of 
all this data and literature, we theorize that the variant identified here might modulate ligand binding.  
 
In parallel, calcium signalling is thought to be dysregulated in ALCL (Rust et al, 2005), but studies have 
also shown that Calcium ions play an important role in Notch ligand binding (Rand et al, 2000). Indeed, 
binding of the Calcium ions may modulate the tertiary structure of Notch1 and thus effect ligand 
binding affinity (Cordle et al, 2008), thereby modulating Notch1 downstream signalling (Raya et al, 
2004). In addition to this, we have shown through GSEA that not only are calcium signalling genes 
hypermutated, but that a number of proteins with calcium ion binding domains are mutated as well 
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(Figure 3.8.2 and Figure 3.8.3). It therefore seems possible that calcium signalling and the presence of 
calcium ions for binding of Notch1 to its ligand is important in determining the effect of T349P and 
T311P. Indeed, it may be that these variants only modulate Notch ligand binding by effecting calcium 
ion binding, though unfortunately we did not have the facilities to test this hypothesis. Ultimately, it’s 
likely that only such an assay as crystallography could verify this, though it remains questionable 
whether the biological question and implications are worth investing in such a time- and resource-
intensive technique.  
 
As explained then, we posited that these mutations in the extracellular EGF-like domains of the Notch1 
receptor may modulate the binding of Notch1 with its ligands – however, in silico data did not suggest 
that these variants force conformational changes that lead to a significant change in Gibbs-free energy. 
While modelling the strength of ion binding is also a possibility, this would require a high-resolution 
crystal structure of the binding of the calcium ions to the relevant extracellular domains of Notch, 
which is not available, hence we could not proceed with such modelling.  In addition, it should be said 
that crystal structures seldom feature post-translational modification, as the proteins are expressed 
ectopically in specialty strains of yeast or bacteria. As a result, the Notch1 and Jag1 proteins modelled 
here may well lack important modifications, including some notorious ones such as Glycosylation or 
Fucosylation, which would be lost in the mutated protein. Research has shown that these 
modifications are important to the interaction between Notch and its ligands – indeed removing 
certain Fucosylation sites inhibited Notch1 signalling (Schneider et al, 2018). 
 
Since the computer modelling left us with little clues as to the functional consequences of variants 
T311P and T349P in ALCL, the variants were studied in vitro in both the presence and absence of 
Notch1 ligand. Full-length Notch1 was expressed in the HEK293FT cell line as it has low endogenous 
levels of expression compared to ALCL and other lymphoma cell lines. This replaced CRISPR-based 
protocols to engineer the variants into ALCL cell lines, for the reason delineated in this chapter. Ideally, 
we would have studied these mutations in ALCL, particularly since using an alternative non-T cell 
cancer cell line is too far removed from the model we would prefer to use. In particular, it’s unclear 
whether the ectopic expression we induced would lead to the activation of the same pathways that 
Notch1 would signal through in ALCL. Among other reasons, this is due to the possible absence in 
HEK293FTs of pathways with which Notch1 cross-talks in ALCL, examples of which are given in Chapter 
5. Overexpressing the Notch1 plasmid, wild-type or mutated, in ALCL, would leave the strong, 
endogenous wild-type Notch1 in place, and evidence from digital droplet PCR suggests that the 
fractional abundance of mutated Notch1 mRNA in such a system is below 25%, which we did not 
believe was sufficient to study the two Notch1 mutations. Furthermore, as detailed in Chapters 5 and 
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6, ALCL are addicted to Notch1 expression, so knocking out the notch1 gene to then express the ectopic 
plasmid was not an option either, as cells would have died following knocking out of the endogenous 
copy of the gene.  
 
Expression of the Notch1 T349P mutation led to an increase in cellular proliferation in this system, 
concurrent with increases in expression of hes1 and hey1, two genes immediately downstream of 
Notch1. In keeping with the lack of effects on ligand-receptor interaction predicted in silico, activating 
the Notch1 receptor using the co-culture OP9-DLL1 system did not induce a growth advantage to 
T349P or T311P Notch1 mutant-expressing cells, although this may be because HEK239FT cells 
endogenously express Notch ligands (Mumm et al, 2000; Oh et al, 2010), or because the mutant 
Notch1 proteins promote expression of Notch ligands in HEK293FT cells. Our positive control, detailed 
in chapter 6.6, shows that presenting the Notch ligand to ALCL cells significantly increased expression 
of Notch1 target genes, indicating that the co-culture concept is viable, as suggested by the large 
amount of literature using this exact system. It is also possible that, as two sets of adherent cell lines, 
HEK293FTs and OP9-DLL1 cells may not grow close enough or at the right orientation for Notch1 and 
its ligand come into contact, as opposed to co-culturing OP9-DLL1 cells with suspension ALCL cells. 
However, growing both OP9-DLL1 and HEK293FT should provide sufficient confluency and coverage to 
ensure that a majority of the Notch1 receptors come into contact with their ligand – indeed it seems 
more likely, as the literature suggests, that HEK293FTs express the Notch ligand endogenously. If that 
is indeed the case, most of these experiments would need to be attempted using a different cell line 
than HEK293FTs, although few ubiquitous cell lines are documented as having low endogenous levels 
of Notch1, making this a difficult endeavour.  
 
Therefore, it remains unclear whether the Notch ligand is in any way responsible for the functional 
effects of T349P and T311P. It remains a possibility that the Notch ligand expressed in HEK293FTs 
results in a perpetually activated Notch1 when exogenously expressed in HEK293FTs, a theory given 
credence by Figure 4.5.1, which shows the presence of activated, intracellular Notch1 in HEK293FTs 
cultured on their own. This is more likely than the possibility of T349P promoting ligand-independent 
activation of the Notch receptor, as such an effect would only really be expected by a loss-of-function 
mutation in the negative regulatory region of Notch1, responsible for exactly that: preventing ligand-
independent activation of Notch1. Indeed, mutations have been observed in T-ALL doing just that: 
activating Notch1 by disrupting the activity of the negative regulatory region (Weng et al, 2004). Due 
to the apparent systemic importance of Notch signalling in ALCL, and since we show here that Notch1 
can affect cell proliferation, we decided to investigate the importance and role of the Notch pathway 
in ALCL.  
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5. The Notch pathway in ALCL 
 
5.1 Introduction 
Binding of the Notch receptor to one of its ligands leads to proteolytic cleavage of Notch; first at a site 
in the Negative Regulatory Region (NRR) by the A-Disintegrin and Metalloprotease (ADAM) family of 
proteases, leading to Notch Extracellular Truncation (NEXT), which sheds the extracellular domain of 
Notch but leaves the intracellular domain tethered to the cell membrane. This first cleavage changes 
the conformation of Notch, rendering it a target for γ-secretases. Proteolysis by γ-secretase releases 
the ICN, except in cases where the PEST or Heterodimerization domains are mutated, in which case 
the ICN is cleaved without the required conformational change from the extracellular domains, as only 
observed in some malignancies. Mutations in the negative regulatory region meanwhile lead to ligand-
independent activation of the receptor (Weng et al, 2004). In a healthy setting, signal transduction by 
the ICN is tightly regulated as demonstrated by its short half-life and the fact that it is quickly targeted 
for proteasomal degradation by an ubiquitin ligase (Tsunematsu et al, 2004; Fryer et al, 2004). The ICN 
is then transported to the nucleus by means so far unknown, where the ICN RAM and ANK domains 
bind to a CSL (CBF1, Suppressor of Hairless, Lag-1) transcription factor: RBP-Jκ (Lubman et al, 2007; 
Friedmann et al, 2008). This complex then displaces transcriptional repressors to promote expression 
of a number of target genes, though it is not altogether clear what promoter sequences the 
Notch/RBP-Jκ complex has a strong affinity for and therefore binds to.  
While the role of Notch1 signalling is still hotly debated, particularly in developmental biology, it clearly 
has a key role to play in T cell biology, as laid out in chapter 1. It is therefore of no surprise that Notch1 
has been shown to play an oncogenic role in a number of T cell malignancies, in particular in ALCL 
(Kamstrup et al, 2014). Indeed, recent evidence from our lab suggests that NPM-ALK may induce 
Notch1 expression in T cell development and tumour formation (Malcolm et al, 2016). Therefore, in 
this chapter the relevance of the Notch1 pathway in ALCL is investigated, as well as its relationship 
with NPM-ALK signalling. 
To study this, we used widely accepted and used in vitro model cell lines derived from tumour tissue 
of ALCL patients, mostly from the most common sub-type (anaplastic, large-cell), they are Karpas 299 
(‘K299’), SU-DHL (more than one type exists; SU-DHL1 will be used in this thesis), SUP-M2 and DEL, 
indeed these are the cell lines used throughout this thesis to model ALCL tumours (Fischer et al, 1988; 
Barbey et al, 1990; Morgan et al, 1989; Epstein & Kaplan, 1974). These ALCL cells lines all present with 
the NPM-ALK translocation and are not significantly different from each other, safe for Karpas 299 
which have been shown to behave differently on a biochemical level, probably due to additional 
mutations of the PTEN and p53 pathways (Turturro et al, 2001). 
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5.2 Silencing notch1 in ALCL cell lines leads to a decrease in proliferation 
We first attempted to silence the expression of notch1 using siRNA. The effect was limited, though we 
still observed a statistically significant 8.3%, 10.4%, and 12.8% decrease in notch1 expression, 
respectively in Karpas 299, DEL and SUP-M2 cell lines, as measured by qPCR (Figure 5.2.1). This led to 
a limited, though again statistically significant decrease in proliferation, as measured by MTT (Figure 
5.2.2). However, as inhibition of gene expression was at the limit of detectability by qPCR, we decided 
to validate these data using another technique. 
  
Figure 5.2.1: notch1 expression in siRNA-treated 
ALCL cells, as measured by qPCR. Fold expression 
of notch1 in ALCL cells nucleofected with siRNA 
targeting notch1, calculated as fold scrambled 
siRNA, and measured by qPCR 48 hours following 





Figure 5.2.2: Proliferation of ALCL cell lines under 
siRNA-mediated notch1 silencing. Proliferation 
of ALCL cells nucleofected with siRNA targeting 
notch1, measured by MTT at 48 hours following 
nucleofection of the siRNA, compared to 




We then attempted to confirm these results using a two-plasmid KRAB-dCas9 CRISPR inactivation 
construct (Gilbert et al, 2014). This protocol uses a sgRNA to direct dCas9 fused to a transcriptional 
repressor (KRAB) to the promoter of a particular gene; in this case notch1. The decrease in expression 
of notch1 was greater than observed with siRNA; of two sgRNAs tested, the second showed statistically 
significant 31.6%, 41.4% and 30% decreases in notch1 expression in DELs, Karpas 299s, and SUP-M2s 
respectively, as compared to a non-targeting sgRNA (Figure 5.2.3). This led to statistically significant 
decreases in proliferation of 19.6%, 19.5% and 28% at 48 hours, respectively in DEL, Karpas 299 and 




Figure 5.2.3: CRISPR-inactivation of notch1 
expression, as measured by qPCR. Fold 
expression of notch1 in ALCL cells transduced 
with Notch1-silencing sgRNA, calculated as fold 
change over non-targeting (NT) sgRNA, and 
measured by qPCR 48 hours following 





Figure 5.2.4: The effect on proliferation of 
CRISPR-inactivation-mediated notch1 silencing. 
Proliferation of ALCL cells transduced with 
sgRNA targeting Notch1, measured by MTT 48 
hours following nucleofection, calculated as 
fold-change over non-targeting (NT) sgRNA 










Figure 5.2.5: shRNA silencing of notch1 expression, as seen at the transcript and protein level. Cells 
were transduced with 2 shRNA targeting Notch1 or a non-targeting (NT) control shRNA. (A) Western 
Blot showing decreased expression of the activated, ICN in ALCL cell lines.  Blots are representative of 
three biological replicates. (B) Fold expression of notch1 in ALCL cells transduced with Notch1-silencing 






For added certainty, we proceeded with shRNA silencing of notch1 expression using lentiviral 
expression plasmids, and were able to verify a decrease in expression of at least 50% across 2 shRNA 
and 3 cell lines at both transcript and protein levels (Figure 5.2.5). This in turn led to a significant 
decrease in cell proliferation at 48 hours, as measured by MTT in all 3 cell lines and for 2 shRNA (Figure 
5.2.6). It is therefore clear that ALCL cell lines are addicted to notch1 expression to proliferate. 
  
 
Figure 5.2.6: Proliferation of ALCL cell lines under 
shRNA-mediated notch1 silencing. Proliferation 
of ALCL cells transduced with shRNA targeting 
Notch1, measured by MTT calculated as fold-
change over non-targeting (NT) shRNA (*p<0.05; 






5.3 The decrease in proliferation observed upon notch1 silencing is due to apoptosis. 
To investigate the effect of silencing notch1 in ALCL cell lines, we first measured the expression levels 
of Notch1’s transcriptional targets hes1 and hey1; they were also downregulated upon notch1 silencing 
by shRNA (Figure 5.3.1). To identify the mechanics leading to decreased cell viability, apoptosis was 
assessed following staining of cells for AV and PI.  A significant increase in the percentage of cells 
staining positive for Annexin V (AV) and/or Propidium Iodide (PI) was observed suggestive of cell death 
via apoptosis (Figure 5.3.2). Cells were also stained with intracellular PI to identify any changes in cell 
cycle. Representative FACS plots show the effect of notch1 shRNA in SUP-M2: there is a significant shift  
to sub-G0, indicating that cells are entering apoptosis (Figure 5.3.3). This shift was quantified; a 
significant decrease in the G0-G2 population and a significant increase in the sub-G0 population is 
observed in all three cell lines when transfected with shRNA (Figure 5.3.3). We can therefore 
confidently conclude that ALCL cell lines are addicted to notch1 expression, and that silencing this gene 


















Figure 5.3.1: Expression of hes1 and hey1 upon shRNA silencing of Notch1. Fold expression of hes1 (A) 
and hey1 (B) in ALCL cells transduced with Notch1-silencing shRNA, calculated as fold change over non-
targeting (NT) shRNA, and measured by qPCR (*p<0.05; **p<0.01; ***p<0.001; n=3). 
 





Figure 5.3.2: AV-PI staining of shRNA-
transduced ALCL cell lines. Representative FACS 
plots of ALCL cells were transduced with a 
control non-targeting shRNA (A) or a Notch1-
targeting shRNA (B-C) and stained for AV and 
PI. (D) Quantification of cells staining for AV 
and/or PI (*p<0.05; ***p<0.0001; n=3). 
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Figure 5.3.3: Cell cycle analysis of ALCL cells after notch1 shRNA silencing. ALCL cells were transduced 
with a control non-targeting shRNA (A) or a Notch1-targeting shRNA (B), permeabilised and stained 
for intracellular PI. FACS plots are representative of three technical and biological replicates. 
Quantification of cells in either G0 to G2 phases (C) or sub-G0 (D) (NS=not significant; *p<0.05; 
**p<0.01; ***p<0.0001; n=3). 
 
5.4 Notch1 promotes myc and dtx1 expression in ALCL 
To determine the signalling cascade downstream of Notch1, we made use of published microarray 
data of the T-ALL cell line CUTLL-1 that examines the effects of GSI treatment on gene expression (Choi 
et al, 2017; Sanchez-Martin et al, 2017; Wang et al, 2011a). The differential expression of the top hits 
present in at least two of three published datasets was computed - hes1 and hey1 are found, along 
with dtx1, a known regulator of the Notch pathway (suggesting a feedback mechanism), and other hits 
such as myc (Figure 5.4.1). Using qPCR, we confirm that, in ALK+, ALCL cell lines DEL, SU-DHL and SUP-
M2, silencing notch1 by shRNA leads to a significant decrease in both myc and dtx1 signalling (Figures 
5.4.2), suggesting that Notch1 in ALCL signals through a number of pathways beyond hes1 and hey1, 
including myc, an important oncogenic signalling pathway in and of itself. Analysis of previously 














2011a) confirms that Notch1 and 3 bind at these gene loci, binding which disappears upon GSI 
treatment (Figure 5.4.3). Unfortunately, no such dataset exists for ALCL. 
 
Figure 5.4.1: Microarray analysis of Notch1 
downstream targets. Analysis of microarray 
data from three separate publications of the T-
ALL cell line CUTLL-1, representing the fold-
change in expression of the top 250 target genes 
(assessed by adjusted p-values) in the presence 
of GSI (over a vehicle control: DMSO); analysing 
previously published data (Choi et al, 2017; 











Figure 5.4.2: Validation of Notch1 downstream targets, as measured by qPCR . Fold expression of myc 
(A) and dtx1 (B) in ALCL cell lines transduced with Notch1-silencing shRNA, calculated as fold change 




Figure 5.4.3: ChIP-seq 
data of Notch binding 
loci in T cell-derived 
malignancies. Analysis 
of published ChIP-seq 
data from two separate 
publications of the T-
ALL cell line CUTLL1, 
looking at Notch1, and 
Notch1 binding at the 
loci of myc and dtx1, 
treated with vehicle 
control (DMSO; upper 
track) or GSI (lower 
track) (Choi et al, 2017; 












5.5 Inhibition of NPM-ALK leads to a decrease in notch1 expression 
To study the interplay between Notch1 and NPM-ALK in ALCL, we first attempted to determine 
whether NPM-ALK induces expression of Notch1. NPM-ALK activity was inhibited by incubation with 
the ALK/ROS/cMet inhibitor crizotinib (Figure 5.5.1) or expression silenced with a specific doxycycline-
inducible shRNA (using a lentiviral expression plasmid; Figure 5.5.3). In both cases, a significant 
decrease in transcripts for Notch1 and its transcriptional targets hes1 and hey1 was observed (Figure 
5.5.2 and Figure 5.5.4), suggesting that Notch1 transcription is promoted by NPM-ALK expression and 
activity – indeed, in the case of NPM-ALK silencing by shRNA, the expression of hey1 was completely 
inhibited (Figure 5.5.4). 
 
 
Figure 5.5.1: Validating crizotinib treatment 
using Western Blotting. ALCL cells were treated 
with 20nM crizotinib for 72 hours, and levels of 
the indicated proteins were measured by 












Figure 5.5.2: The impact of crizotinib treatment on various genes, as measured by qPCR . ALCL cell lines 
were treated with 20nM crizotinib for 72 hours, and expression levels of notch1 (A), hes1 (B) and hey1 
(C), calculated as fold change over vehicle control (DMSO), as measured by qPCR (*p<0.05; **p<0.01; 
***p<0.0001; n=3). 
 







Figure 5.5.3: Validating NPM-ALK shRNA silencing. Cells were transduced with doxycycline-inducible 
shRNA targeting NPM-ALK or a non-targeting (NT) control shRNA and treated with 1 μM doxycycline 
for 48 hours. (A) Western Blot validating silencing of NPM-ALK protein in ALCL cell lines. Blots are 
representative of three biological replicates. (B) Fold expression of npm-alk in ALCL cells transduced 
with NPM-ALK-silencing shRNA, calculated as fold change over non-targeting (NT) shRNA, and 
measured by qPCR (***p<0.0001; n=3). 
 







Figure 5.5.4: The impact of NPM-ALK silencing on various genes’ expression. Cells were transduced with 
doxycycline-inducible shRNA targeting NPM-ALK or a non-targeting (NT) control shRNA and treated 
with 1 μM doxycycline for 48 hours. Fold expression of notch1 (A), hes1 (B) and hey1 (C) in ALCL cells, 





B A C 
 
111/172 
5.6 Modest increases in notch1 expression are observed on ectopic expression of NPM-ALK 
NPM-ALK was expressed ectopically using plasmid pIND_puro_ALK in the HEK293FT cell line, and in 
ALK- ALCL cell lines Jurkat and Mac2A, and this was validated both at the protein and transcription 
level (Figure 5.6.1). An approximate two-fold increase in expression of notch1 transcripts detected in 
HEK293FT, Jurkat and Mac2A cell lines ectopically expressing npm-alk was observed, with the highest 
levels seen in HEK293FT cells, which may be due to the already high basal levels of Notch1 expression 
in Jurkat and Mac2A cell lines (Figure 5.6.2). These results are modest and were not tested at the 
protein level. We also investigated the effect of ectopic NPM-ALK expression on Notch1 targets hes1 




Figure 5.6.1: Validating ectopic NPM-ALK 
expression. Cells were transduced with an npm-
alk expression plasmid or an empty vector 
control. Fold expression of npm-alk in various cell 
lines is presented, calculated as fold change over 





Figure 5.6.2: The effect of ectopic NPM-ALK 
expression on Notch1. Cells were transduced 
with an npm-alk expression plasmid or an empty 
vector control. Fold expression of notch1 in 
various cell lines is presented, calculated as fold 
change over empty vector, and measured by 















Figure 5.6.3: The effect of ectopic NPM-ALK expression on Notch1 targets. Cells were transduced with 
an NPM-ALK expression plasmid or an empty vector control. Fold expression of hes1 (A) and hey1 (B) 
in various cell lines is presented, calculated as fold change over empty vector, and measured by qPCR 
(*p<0.05; **p<0.01; ***p<0.001; n=3). 
 
5.7 ChIP-seq analysis reveals that NPM-ALK may regulate Notch1 through STAT3 
A positive feedback loop has previously been described between Notch1 and STAT3 (Hildebrand et al, 
2018). Since STAT3 is one of the major downstream signalling pathways of NPM-ALK activity, we 
investigated whether NPM-ALK-promoted expression of notch1 was mediated through the STAT3 
pathway. To do so, published ChIP-seq data (Menotti et al, 2019) of STAT3 binding sites in the ALCL 
cell lines SU-DHL1 and JB6 treated with either crizotinib or a vehicle control (DMSO) were analysed. 
These data show a significant decrease in binding of STAT3 at the notch1 gene in crizotinib-treated 
cells as compared to vehicle control (DMSO)-treated cells (Figure 5.7.1). These data were validated by 
performing ChIP-qPCR; a significant decrease in binding of STAT3 at the notch1 gene upon crizotinib 

































 Figure 5.7.1: STAT3 binding at the Notch1 gene. Analysis of previously published ChIP-seq data, looking 
at binding of STAT3 to the notch1 gene in SU-DHL1 or JB-6 cell lines treated with a vehicle control 














Figure 5.7.2: ChIP-qPCR validation of 
the ChIP-seq analysis. ChIP-qPCR 
binding of STAT3 and GFP proteins at 
the notch1 gene, or at a negative 
control intergenic region, in SUP-M2 
cells treated with either a vehicle 
control (DMSO) or crizotinib (300 
nM) for 6 hours, as determined by 
qPCR (***p<0.0001; n=3), expressed 
as percentage of the total input. 
 
5.8 Silencing STAT3 leads to a decrease in notch1 expression 
To validate the hypothesis that STAT3 upregulates notch1 expression, stat3 was silenced employing 
specific shRNAs (using lentiviral expression plasmids) in ALCL cell lines. Knock-down in expression both 
at the transcript and protein levels were verified (Figure 5.8.1). As theorized, transcript levels of 






Figure 5.8.1: STAT3 shRNA-mediated silencing in ALCL cell lines. Cells were transduced with 1 of 2 shRNA 
targeting STAT3 or a non-targeting (NT) control shRNA. (A) Western Blot validating silencing of STAT3 
protein in ALCL cell lines. Blots are representative of three biological replicates. (B) Fold expression of 
stat3 in ALCL cells transduced with STAT3-silencing shRNA, calculated as fold change over non-















Figure 5.8.2: The effect of STAT3 silencing on the Notch pathway. Fold expression of notch1 (A), hes1 
(B) and hey1 (C) in ALCL cells transduced with STAT3-silencing shRNA, calculated as fold change over 
non-targeting (NT) shRNA, and measured by qPCR (*p<0.05; **p<0.01; ***p<0.001; n=3). 
 
5.9 Discussion 
As detailed previously, data informed our hypothesis that the Notch1 pathway is of systemic 
importance in ALCL, and that there is some cross-talk between Notch1 signalling and that of NPM-ALK, 
the driving oncogene in ALK+ ALCL. notch1 expression was first silenced in ALCL cell lines, to determine 
the most essential functions of the signalling pathway. As laid out in the previous chapter, ALCL cell 
lines, suspension T-cells, are mostly impervious to lipid-based transfection, while electroporation-
based technology such as Lonza’s Nucleofection protocol is highly toxic to cells. Though we attempted 
to electroporate siRNA into ALCL lines – they are easier to electroporate than shRNA constructs due to 
their much shorter size, and at the time significantly cheaper than shRNA – we did not manage to find 
a satisfying balance between significant notch1 silencing and toxicity of an intense electroporation 
protocol, which explains the very modest decrease in expression, stretching the limit of sensitivity of 
qPCR technology. CRISPR-based knock-down was the next step, as opposed to CRISPR knock-out, which 
is known to cause off-target mutations - and thus any effect seen using this technique is more likely to 
be due to Notch1 silencing rather than any off-target effect caused by knock-out CRISPR technology. 
Again unfortunately, the effect was relatively limited, with a <50% decreased of notch1 expression, 
and only a relatively small effect on proliferation – and no other observable effect on cell physiology 
such as migration or morphology. Expression of notch1 was therefore silenced using transduction of 
shRNA expression constructs into the genome of the cell lines using lentiviral-based technology, 
causing a significant decrease in proliferation, suggesting that ALCL cell lines depend on Notch1 
signalling for growth. The expression of Notch1 target genes hes1 and hey1 was measured along with 
B A C 
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notch1 as a proxy for Notch1 activity, to be certain that the effect seen at the transcriptional level 
translated to Notch1 activity at the protein level – though protein level of activated, intracellular 
Notch1 could have been assessed by western blotting, reverse-transcription quantitative PCR was used 
for its quantitative output and reliability.  
 
We then showed that silencing Notch1 in ALCL triggers apoptosis, as seen by AV and PI staining, and 
the fact that cells were largely in the sub-G0 phase of the cell cycle. Caspase protein expression was 
not measured (another conclusive protocol to prove that apoptosis has been triggered), nor was 
Notch1 expression rescued to show that the effect is reversible and indeed due to Notch1 signalling, 
and not any off-target effect. However, considering that we silenced Notch1 by three different means, 
and proceeded with chemical inhibition of the receptor in Chapter 6, we deemed this evidence 
conclusive enough. These, instead, are all future experiments that would be worth undertaking – in 
particular rescuing Notch1 expression following silencing. 
 
Looking at signalling downstream of Notch1 we hypothesize that two targets beyond hes1 and hey1 
are myc and dtx1, expression of which is upregulated by Notch in T-ALL cell lines. Unfortunately, no 
such microarray data (in the presence and absence of Notch1) exists in ALCL, and so this is the closest  
data we could use to narrow down the potential list of downstream targets. Regardless, identifying 
myc and dtx1 is not particularly surprising, as a multitude of studies have shown this in T-ALL or 
lymphoma (Weng et al, 2006; Gekas et al, 2016; Sharma et al, 2007). Indeed Notch mutations are 
known to induce myc expression in T-ALL (Chiang et al, 2016) raising the question of whether we should 
have looked at myc expression when studying Notch1 T349P. Equally, it is unclear whether these 
findings would translate into ALCL: not only are these data from T-ALL, but they were taken from cell 
lines treated with GSI, which is not a specific inhibitor. Indeed, GSIs are far from specific to the Notch 
pathway, with γ-secretases targeting a whole host of proteins for cleavages, including E-cadherin, 
VEGF, Type I Interferon Receptor and the Insulin Growth Factor Receptor (IGFR), as well as a number 
of Voltage-gated potassium channels, interestingly (Reviewed in Haapasalo & Kovacs, 2011) 
 
To answer the first question, previous publications have shown c-myc to be of importance in ALCL 
pathobiology; indeed some cell lines are addicted to the myc oncogene (Lollies et al, 2018; Weilemann 
et al, 2015). We were able to validate these data, by showing a significant decrease in myc expression 
upon Notch1 silencing in ALCL cell lines suggesting that that these data are not simply due to off-target 














































pSTAT3 relocates to the






own this evidence may explain why notch1 silencing triggers apoptosis: Notch1 silences c-myc, itself 















Figure 5.9.1: Schematic representation of our proposed model. We propose that NPM-ALK recruits 
JAK3, which phosphorylates STAT3, which in turn binds to and promotes expression of the notch1 
gene, although NPM-ALK can also by-pass JAK3 and phosphorylates JAK3 on its own. 
 
Cross-talk between NPM-ALK and Notch signalling in ALCL was then studied. Silencing npm-alk led to 
a significant decrease in notch1 expression, and this was equally true when chemically inhibiting NPM-
ALK activity using the TKI crizotinib. Though less clear-cut, we also suggest that the opposite is true as 
well: increasing npm-alk expression upregulates notch1 expression. Given that NPM-ALK is known to 
signal through a few well-established mediators such as JAK/STAT, PLC-γ, PI3K, Akt and ERK/MAPK, we 
hypothesized that one of these proteins was responsible for the cross-talk between NPM-ALK and 
Notch1. In particular, Notch1 and STAT3 signalling are known to interact (Wu et al, 2017) and indeed 
in different settings STAT3 upregulate notch1 expression (Li et al, 2014). To test whether NPM-ALK 
effects notch1 expression via STAT3 in ALCL, we looked at published ChIP-seq datasets in ALCL cell lines 
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treated with TKIs or vehicle controls and found STAT3 to bind at the notch1 gene. We were able to 
validate this using ChIP-qPCR. We therefore show that STAT3 binds at the notch1 gene, and that this 
binding can be modulated using small molecule inhibitors. Given that STAT3 is one of the major 
downstream signalling pathways of NPM-ALK, it is therefore very likely NPM-ALK upregulates notch1 
via STAT3 (proposed model depicted in Figure 5.9.1). In confirmation, silencing stat3 expression led to 
a significant downregulation of notch1 transcription as a result.  
 
We are therefore confident that the Notch signalling pathway in ALCL is central to its pathobiology. 
We have identified cross-talk between Notch1 and NPM-ALK and elucidated its mechanism. The next 
logical step is to assess the therapeutic potential of the Notch pathway in ALCL; validate that the known 
anti-Notch1 drugs are as efficient as the literature suggests, study whether they are effective in an 





6. Notch1 as a Therapeutic Target in ALCL 
6.1 Introduction 
Morgan discovered the notched wing phenotype in fruit flies more than a hundred years ago, in 1917 
(Morgan, 1917). It took over half a century, until the late 1980s and early 1990s, for genomic 
translocations to be identified in T-cell malignancies, and to be implicated in the pathobiology of the 
diseases. Soon it became apparent that these translocations were mutating the human homolog of 
notch, first called tan-1 (Raimondi et al, 1987; Ellisen et al, 1991). Nowadays, the Notch pathway is 
implicated in a number of different disorders (Reviewed in Andersson & Lendahl, 2014). A century on, 
there is therefore increasing interest in targeting the Notch pathway therapeutically, particularly as far 
as oncology is concerned. 
γ-secretases are membrane-bound proteases formed of four proteins (Presenilin, Nicastrin, Pen2 and 
Aph1) which cleave a number of targets, including Notch (Reviewed in Selkoe & Wolfe, 2007). The 
existence of various isoforms of these component proteins points to the possibility of complex 
regulation of γ-secretases, thus adding another layer of fine-tuning to the already complex process of 
Notch activation. γ-secretases were the first molecules to be targeted as part of Notch therapies, with 
the first γ-secretase inhibitor (GSI; MK-0752) being trialled in 2006 in T-ALL patients in the USA 
(Deangelo et al, 2006). Despite evidence that the GSI MK-0752 was able to reduce tumour size, 
gastrointestinal toxicity was such that treatment had to be discontinued in this trial; and indeed, newer 
generation GSIs resulted in the same toxicity; they were not specific enough to target the γ-secretases 
expressed in T-cells. Nevertheless, they remain accessible and useful compounds for studies of Notch 
performed in vitro. In addition, promising new types of compounds targeting Notch itself, or its ligands, 
are being developed, leading to a renewed interest in using Notch as a therapeutic target.  The 
existence of various isoforms of these component proteins suggest complex layers of regulation of γ-
secretases, thus adding another layer of fine-tuning to the already complex process of Notch activation 
In ALCL more specifically, a first publication showed that twelve ALCL patients presented with high 
levels of Notch1 expression (out of twelve tested), and that cells of the tumour microenvironment  
were expressing Jagged1, which drove Notch1 activity and, in turn, tumour growth (Jundt et al, 2002). 
The high expression of both Notch1 and Jagged1 was confirmed in a further twelve patients with 
primary cutaneous ALCL in a subsequent publication (Kamstrup et al, 2008). A final paper on this topic 
shows varying expression levels of Notch1 in 10 ALK+ ALCL and 9 ALK- ALCL patients, and suggested 
that inhibition of Notch1 by GSIs led to apoptosis in the ALCL cell line Karpas 299 (Kamstrup et al, 
2014). In this chapter the utility of Notch1 as a therapeutic target in ALCL is investigated. In addition, 
the effectiveness of GSIs in ALK- ALCL is studied, using not only two ALK- ALCL cell lines, FEPD and 
Mac2A, derived from ALK- ALCL patient tumours (del Mistro et al, 1994; Davis et al, 1992), but also the 
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CD4 and CD8-negative T cell leukaemia cell line Jurkat (immortalization described in Schneider et al, 
1977; followed by phenotyping in Gillis, 1980). 
 
6.2 Chemical inhibition using γ-Secretase Inhibitors of Notch1 
A number of small molecular inhibitors are available to target Notch1, hence cell lines were exposed 
to different Notch1 inhibitors starting with GSI I, which has been proven to inhibit growth of the ALCL 
cell line Karpas 299 (Kamstrup et al, 2014). The efficacy of GSI I was first verified by assessing the 
protein levels of ICN by Western Blot, to verify inhibition of Notch1 cleavage, and therefore activity 
(Figure 6.2.1). The effect of GSI I in ALK+ and ALK- ALCL cell lines was tested, both confirming the effects 
seen previously and showing that γ-secretase inhibitors targeting Notch1 have the same effect in ALK- 
ALCL cell lines (Figure 6.2.2). Staining cell lines for AV and PI demonstrated a significant increase in 
cells positive for both AV and PI when treating four different ALK+ ALCL and two different ALK- ALCL 
cell lines with GSI I for 48 hours (Figure 6.2.3) – indicating the pro-apoptotic effect of Notch1 inhibition.  
This result was verified by staining ALCL cell lines treated with GSI I with intracellular PI, to assess the 
proportion of cells in each phase of the cell cycle, and a significant increase in the proportion of cells 
in the sub-G0 fraction was detected, indicating again that the cells are dying (Figure 6.2.4). It should 




Figure 6.2.1: Validating the efficacy of GSI 
treatment in ALCL cell lines. Cells were 
treated with 1 μM GSI I or a vehicle control 
(DMSO) for 48 hours, and the protein levels 
of the activated, intracellular domain of 
Notch1 was measured by Western Blot. 






















Figure 6.2.2: Proliferation of GSI-treated ALCL 
cell lines. ALK+ (A) and ALK- (B) ALCL cells were 
treated with varying amounts of GSI I or a vehicle 
control (DMSO) for 48 hours, and (C) 
proliferation of these cells was measured using 












Figure 6.2.3: AV-PI staining of GSI-treated ALCL cell lines. Representative FACS plots of ALCL cells were 
treated with (A) a vehicle control (DMSO) or (B) 1 μM of GSI I for 48 hours and stained for AV and PI. 





































Figure 6.2.4: Intracellular PI staining of ALCL cells treated with 1 μM GSI I. Representative FACS plots of 
ALCL cells were treated with (A) a vehicle control (DMSO) or (B) 1 μM of GSI I for 48 hours and stained 
for intracellular PI. Quantification of cells in either G0 to G2 phases (C) or sub-G0 (D) (***p<0.0001; 
n=3). 
The compounds PF-03084014 (NCT02299635) from Pfizer, and BMS-906024 (NCT03691207) from 
Bristol-Myers Squibb both currently under  study in various clinical trials, including paediatric pre-
clinical trials were also assessed for their activity (Papayannidis et al, 2015; Messersmith et al, 2015; 
Carol et al, 2014; Zweidler-McKay et al, 2014). However, there was no growth inhibition of ALCL cell 






















Figure 6.2.5: Proliferation of ALCL 
cell lines treated with the indicated 
GSIs. ALK+ and ALK- ALCL cells were 
treated with varying amounts of the 
GSIs BMS-906024 or PF-03084014 or 
a vehicle control (DMSO) for 72 
hours, and proliferation of these 
cells was measured using MTT (n=3). 
 
6.3 Sensitivity of mutated Notch1 to γ-Secretase Inhibitors 
To determine whether the Notch1 mutations identified in this study, T349P and T311P modulated 
sensitivity to GSIs, HEK293FT cell lines expressing either an empty vector, wild-type or mutated Notch1 
were treated with GSI I, but no significant difference was found (Figure 6.3.1), indicating that response 
to GSIs is likely independent of these Notch1 mutations. 
  
 
Figure 6.3.1: Proliferation of GSI-treated Notch1-
expressing HEK293FT cells. HEK293FT cell lines 
expressing either an empty vector or wild-type 
(WT) or T349P or T311P-mutated Notch1 were 
treated with varying amounts of GSI I or a vehicle 
control (DMSO) for 48 hours, and proliferation of 
these cells was measured using MTT (expressed 




6.4 Crizotinib-resistant ALCL cell lines are sensitive to γ-Secretase Inhibitors of Notch1 
ALK inhibitors are now being added to frontline therapy (Reviewed by Larose et al, 2019) (eg. Trial 
NCT01979536). Ideally, a single agent ALK inhibitor would provide a less toxic frontline treatment 
approach in the future although resistance would be expected to develop (Sharma et al, 2018; 
Gambacorti-Passerini et al, 2016). Therefore, crizotinib-resistant ALCL cell lines were assessed for their 
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sensitivity to GSI to test whether inhibition of Notch1 is a potential new second-line treatment for 
patients relapsing on crizotinib or related TKIs. Four different cell lines were exposed to various 
quantities of crizotinib to derive TKI-resistant cell lines: K299, resistant to 1 μM, SUP-M2, resistant to 
0.3 μM (Ceccon et al, 2013), DELs, resistant to 0.2 μM and SU-DHL1, resistant to 0.1 μM crizotinib. No 
significant difference in the response of these four cell lines to GSI I, as compared to their wild-type 
counterparts was observed (Figure 6.4.1), indicating that patients relapsing on crizotinib would likely 















Figure 6.4.1: Proliferation of crizotinib-resistant ALCL cell lines exposed to GSI I. Wild-type and 
crizotinib-resistant ALK+ ALCL cell lines were treated with varying amounts of GSI I or a vehicle (DMSO) 
control for 48 hours, and proliferation of these cells was measured using MTT (expressed as absorbance 








6.5 Synergy between γ-Secretase Inhibitors and Tyrosine Kinase Inhibitors 
The combination of TKIs most likely to be approved for use in ALCL with GSIs was investigated. Treating 
ALCL cell lines with a combination of GSI I and crizotinib led to synergistic activity in reducing cell 
proliferation as indicated by a Bliss Independence Index of less than 1 across several concentrations 
and cell lines (Figure 6.5.1). Though we only tested one cell line, this synergy is also observed with the 
combination of GSI I and ceritinib, another ALK TKI, though the synergy was not observed across as 
many combinations of concentrations (Figure 6.5.2). Interestingly, this synergy holds true at 
concentrations below the IC50 of each respective drug (taken to be IC50 = 30 nM for crizotinib, IC50 = 








Figure 6.5.1: Combination treatment of GSI I and crizotinib. BLISS matrix showing the calculated 
combination index obtained on treating the indicated ALK+ ALCL cell lines with crizotinib and GSI I for 
72 hours (using a range of concentrations of 10-50 nM for crizotinib, and 10 nM-2 μM GSI I). A 
combination index of <1 indicates synergy between drugs, 1 indicates additive effects, >1 indicates 
antagonistic effects (average of n=3). Concentration range were taken to include doses on either side 
of the IC50. 
 
Figure 6.5.2: Combination treatment with GSI I and 
ceritinib. BLISS matrix showing the combination index on 
treating the indicated ALK+ ALCL cell lines with ceritinib 
and GSI I for 72 hours (using a range of concentrations of 
5-50 nM for ceritinib, and 500 nM-2 μM GSI I). A 
combination index of <1 indicates synergy between drugs, 
1 indicates additive effects, >1 indicates antagonistic 
effects (average of n=3). Concentration range were taken 





While Pfizer’s compound (PF-03084014) did not affect proliferation or apoptosis on its own in ALCL 
cell lines, it showed synergistic activity when treating ALK+ ALCL cells in combination with the TKI 
crizotinib, as shown in the Bliss Matrix (Figure 6.5.3). Interestingly, the synergy is less marked when 
using K299 cell lines, though this can be explained by the mutational burden in these cell lines and 
crizotinib’s significantly higher IC50 in K299. The drug combination also leads to a significant increase 
in DELs, SUP-M2 and SU-DHL1 staining positive for both AV and PI as well as a significant decrease in 
cells staining for neither – more so than the effect observed when treating the cells with each drug 
separately (Figure 6.5.4). These data suggest that GSI and ALK inhibitors may lead to a better 
therapeutic outcome when used in combination than on their own, and may serve as a second-line 
treatment for ALCL which, at least in children, is currently successfully treated with a combination of 










Figure 6.5.3: Combination treatment of crizotinib and PF-03084014. BLISS matrix showing the 
combination index on treating the indicated ALK+ ALCL cell lines with crizotinib and PF-03084014 for 
72 hours (using a range of concentrations of 10-50 nM for crizotinib, and 100 nM-10 μM PF-03084014). 
A combination index of <1 indicates synergy between drugs, 1 indicates additive effects, >1 indicates 
antagonistic effects (average of n=3). Concentration range were taken to include doses on either side 














































Figure 6.5.4: AV-PI staining of TKI/GSI combination treatment in ALCL cell lines. Representative FACS 
plots of ALCL cells were treated with either (A) a vehicle control (DMSO), (B) 50 nM crizotinib, (C) 2 μM 
PF-03084014 or (D) a combination of both for 72 hours and stained for AV and PI. Quantification of 























6.6 Notch1 activation through ligand binding dampens the efficacy of GSIs.  
To investigate how cell death induced by GSIs in ALCL is modulated on presentation of the Notch1 
ligand, further experiments were conducted. Indeed, as explained in chapter 6.1, the literature 
suggests that some patient tumours may express Notch1 ligands in the tumour micro-environment, 
and that this drives Notch1 expression (Jundt et al, 2002). Therefore, ALCL cell lines were co-cultured 
with the OP9 mouse feeder cell line expressing either an empty vector or the Notch1 ligand DLL1 (OP9-
DLL1). As expected, ALCL cell lines co-cultured with the OP9 cell line and treated with GSIs showed a 
significant decrease in expression of hes1 and hey1, but surprisingly, co-culturing them with the OP9-
DLL1 cell line rescued hes1 and hey1 expression (Figure 6.6.1). These data could suggest that Notch1 
is already activated and therefore GSIs are less effective, as not able to dampen Notch1 signalling, 











Figure 6.6.1: Expression of Notch1 target genes upon ligand presentation. ALCL cell lines were co-
cultured with the OP9 mouse feeder cell line expressing either an empty vector (OP9) or the Notch1 
ligand DLL1 (OP9-DLL1) and treated with either 1 μM GSI I or a vehicle control (DMSO). Fold expression 
of hes1 (A) and hey1 (B) is displayed, calculated as fold change over expression levels in ALCL cells co-
cultured with empty-vector expressing OP9 cells and treated with a vehicle control, and measured by 







The proliferation of ALCL cell lines treated with GSI I co-cultured with OP9-DLL1 and presented with 
the Notch1 ligand resulted in a partial rescue in proliferation (about 75% of the level compared to cells 
treated with a vehicle control; Figure 6.6.2A). Similar results were observed when treating Notch1-
expressing HEK293FTs with GSIs (Figure 6.6.2B). Again, this suggests that presentation of the Notch1 
ligand DLL1 can abrogate some of the effects of GSI in cell lines, though it’s unclear as yet whether 











Figure 6.6.2: Proliferation upon Notch1 ligand presentation. (A) ALCL cell lines were co-cultured with 
the OP9 mouse feeder cell line expressing either an empty vector (OP9) or the Notch1 ligand DLL1 (OP9-
DLL1) and treated with either 1 μM GSI I or a vehicle control (DSMO) for 48 hours. (B) HEK293FT cells 
expressing either an empty vector (EV) or Notch1 were co-cultured with the OP9 mouse feeder cell line 
expressing either an empty vector (OP9) or the Notch1 ligand DLL1 (OP9-DLL1) and treated with either 
the indicated concentrations of GSI I or a vehicle control (DMSO). Proliferation was measured using an 
MTT assay, calculated as fold change over cells co-cultured with empty-vector expressing OP9 cells and 









6.7 Tissue Microarray shows a correlation between Notch1 expression and EFS  
A clinically-annotated FFPE tissue microarray of 89 ALK+ ALCL patients, biopsied at initial presentation, 
was analysed for Notch1 protein expression. Of the 89 patient tumours, 88.8% showed Notch1 staining 
of varying intensity (Figure 6.7.1A). This is consistent with previously published results (Kamstrup et 
al, 2014; Jundt et al, 2002). In over half of the patients, the majority of tumour cells stained positive 
for Notch1, while about a third of patients’ tumours presented with either no Notch1 staining or sparse 
staining (Figure 6.7.1B). Interestingly, patients with little or no Notch1 staining have a significantly 









Figure 6.7.1: Notch1 expression in a wider ALCL patient cohort . A tissue microarray of 89 patient 
samples was stained for Notch1 by immunohistochemistry and is shown as the percentage of patients 
presenting with a given Notch1 staining intensity (A) or a given percentage of tumour cells staining 










Figure 6.7.2: Notch1 expression and Event-Free Survival of ALCL patients. 10-year Event-Free Survival 





6.8 Notch1 expression does not correlate with response to GSI exposure in ALCL cell lines  
To assess whether the strength of Notch1 expression correlates with the response to mainstream 
therapies such as Methotrexate (part of the ALCL99 protocol) or GSIs, a CRISPR-activation system 
(Konermann et al, 2015) was employed to increase notch1 expression in ALCL cell lines: cells were first 
transduced to express Cas9-VP64 and the MS2 enhancer, which are then recruited to a genomic locus 
by the sgRNA, produced by a third plasmid transduced into cell lines, binding to the MS2-stem loops,  
thereby upregulating gene activity. Expression of notch1 using this approach, as measured by qPCR, 
was at its highest level 48 hours post selection of sgRNA-expressing cells (Figure 6.8.1A). Expression 
was verified in biological triplicates and two cell lines, as compared to a non-targeting control sgRNA 
(Figure 6.8.1B). 
These cells were then treated with increasing concentrations of Methotrexate (the commonly used 
chemotherapeutic agent of the ALCL99 therapy) or GSI I, but no significant difference in response, 
when compared to cells transduced with a non-targeting sgRNA was seen (Figure 6.8.2): while the ALCL 
cells that overexpressed notch1 showed a trend towards being more sensitive to GSI I, this did not 









Figure 6.8.1: Validating CRISPR-activation of notch1. Cas9-VP64- and MS2-expressing ALCL cell lines 
were transduced with sgRNA targeting the notch1 promoter or a non-targeting (NT) control sgRNA. (A) 
Fold expression of notch1 in ALCL cells, calculated as fold change over non-targeting (NT) sgRNA, and 
measured by qPCR at the indicated times after selection for sgRNA-expressing cells. (B) Fold expression 
of notch1 in ALCL cells 48 hours post-selection, calculated as fold change over non-targeting (NT) 














Figure 6.8.2: Sensitivity of Notch1-overexpressing cells to methotrexate and GSI I. ALCL cell lines were 
transduced with sgRNA targeting the notch1 promoter or a non-targeting (NT) control and exposed to 
varying amounts of Methotrexate (A) or GSI I (B), or a vehicle control (DSMO) for 48 hours. Proliferation 
was then measured using MTT and is displayed as fold absorbance over the vehicle control (n=3).  
 
6.9 Discussion 
In this chapter, the potential application of Notch1 as a therapeutic target in ALCL, both ALK+ and ALK-
was investigated. Anti-Notch1 drugs, GSIs, showed effectiveness, both in ALK+ ALCL, which has been 
demonstrated previously (Kamstrup et al, 2008), and also in ALK- ALCL, which is a novel finding. Though 
newer generations of GSIs were also assessed, these proved somewhat less effective. Of course, GSIs 
inhibit γ-secretase and not Notch1, so by definition are not specific to the Notch1 signalling pathway, 
although their effectiveness in lymphomas and leukaemia are well-documented, along with the toxic 
gastrointestinal side-effects (Reviewed in Takebe et al, 2014; and Habets et al, 2019). In addition, 
silencing Notch1 more specifically, using shRNA, has by-and-large the same effect as chemical 
inhibition using GSIs, hence suggesting that the effect observed with GSI is largely due to inhibition of 
Notch signalling. However, it is likely that the stronger doses required, particularly in the case of PF-
03084014, to inhibit ALCL tumour growth is due to its much safer toxicity profile, its higher specificity 
and non-competitive mechanism of action (Wei et al, 2010; Samon et al, 2012). Similarly for BMS-
069024 (Zweidler-McKay et al, 2014). Importantly, the fact that these newer generation GSIs are non-
competitive permits a finer tuned targeting, which has allowed pharma companies to design these 
inhibitors more specifically to the γ-secretase used in T-cells, as opposed to Golgi cells. Regardless, this 
finding is particularly important in the context of ALK- ALCL, which typically is associated with a much 
worse prognosis than ALK+ ALCL, and for which the pipeline of potential treatments is not nearly as 




Notch inhibitors more likely, and easier to recruit for, as the potential pool of eligible patients would 
be larger once ALK- ALCL patients are included. 
Though HEK293FT cells expressing the Notch1 variants T349P or T311P were not more or less sensitive 
to chemical Notch1 inhibition than cell lines expressing WT Notch1, ALK+ ALCL cell lines resistant to 
ALK TKIs were just as responsive to GSIs as their wild-type counter-parts. Therefore, Notch1 inhibition 
is likely a viable strategy for both ALK+ ALCL as ALK- ALCL: indeed, though there is general agreement 
within the field that ALK TKIs such as crizotinib or ceritinib have a lot of potential to replace the toxic 
ALCL99 chemotherapy protocol, ultimately resistance is expected to evolve, as with all TKIs (Sharma et 
al, 2018; Gambacorti-Passerini et al, 2016). Therefore, Notch1 inhibition constitutes a viable second-
line therapeutic strategy, but also has synergistic potential as a combination therapy with ALK TKIs. 
The concept of combining ALK TKIs with other therapies is not new, synergy has been shown in pre-
clinical trials with vascular endothelial growth factor (VEGF) inhibitors in solid tumours (Michaelson et 
al, 2019), with heat-shock protein 90 (HSP90) or epidermal growth factor receptor (EGFR) inhibitors in 
non-small cell lung cancer (Zhu et al, 2019; Courtin et al, 2016), or even MYCN and mTOR inhibitors in 
ALK+ neuroblastoma (Berry et al, 2012). Indeed, in ALK+ ALCL more specifically, crizotinib has 
successfully been combined with the mTOR inhibitor everolimus (Xu et al, 2018), while GSI I has been 
combined with the proteasome inhibitor bortezomib (Dang et al, 2019). 
Research presented here therefore fits well in a pattern of investigation of combination therapies. The 
main appeal of combination therapies is to delay – or ideally prevent - emergence of resistance 
(Courtin et al, 2016). Indeed, it is harder for the tumour to select for resistant clones when they would 
have to resist to both treatments simultaneously. Though this is difficult to prove in vitro, anecdotal 
evidence from our lab shows that adding GSIs, even at very low doses, concentrations of TKIs (such as 
crizotinib) that would normally induce resistance (Ceccon et al, 2013), is enough to ensure complete 
cell death in vitro. Ideally, this would be proven in vivo, but there are as of yet few Notch1 inhibitors 
with satisfyingly low levels of toxicity. In cancer patients – including ALCL - a number of trials have been 
started which combined different therapies, showing that this strategy one preferred by clinicians and 
clinical trial committees (Reviewed in Larose et al, 2019 and; Prokoph et al, 2018). That we show the 
potential synergy of a combination of various TKIs and GSIs indicates the strength of this combination 
strategy. Interestingly, this strategy seems least effective in Karpas 299 cells, although this is relatively 
unsurprising: as detailed earlier, Karpas 299 are different from most other cell lines used in this thesis, 
due to significant mutations in such important genes as phosphatase and tensin homolog (pten) and 
tp53 (Turturro et al, 2001). Unfortunately, the strength of Notch1 expression does not seem to 
correlate with response to GSIs, and therefore a conclusive biomarker to predict which patients would 
best react to either GSIs as a stand-alone or GSI and ALK TKIs as a combination therapy is lacking; the 
example of the cell line Karpas 299 would suggest that such a predictive biomarker would be desirable. 
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Regardless, Notch1 expression is predictive of prognosis: strength of expression correlates with EFS of 
patients treated on the ALCL99 protocol or its predecessors (which, it should be said, remain 
remarkably similar since front-line ALCL therapy has progressed very little since its inception (Reviewed 
by Larose et al, 2019)). Though at first, the fact that high Notch1 expression correlates with an 
improved EFS over that found for patients with a poorer EFS seems odd, it is important to remember 
that these patients were treated with the ALCL99 chemotherapy protocol, and as such one would not 
expect Notch1 expression to correlate with treatment response in any way. Though the statistical 
significance is slight (p = 0.046), the number of patients enrolled (respectively for low and high Notch1 
expression n = 56 and n = 33) is large as far as an ALCL study is concerned. Though a number of potential 
biomarkers predictive of prognosis have been mooted for ALCL (Reviewed in Larose et al, 2019), most 
are more invasive than Notch staining of the biopsy at presentation – although new liquid-biopsy based 
technologies are also very promising. Unfortunately, however, the data presented here is insufficient 
to inform future clinical trial biomarkers. Indeed, the effect observed is slight and the functional 
implications are not clear: why does Notch1 staining intensity correlate with EFS, unless for example 
this is just a manifestation of another more relevant clinical biomarker? For example, one would 
imagine that stronger NPM-ALK expression might upregulate Notch1 and therefore lead to the high 
intensity staining observed, while also increasing the likelihood of the host immune system developing 
auto-antibodies to NPM-ALK; indeed there is mounting evidence that auto-antibody titre correlates 
with prognosis (Reviewed by Larose et al, 2019). It could therefore be interesting to compare Notch1 
staining with NPM-ALK expression and auto-antibody titre. 
Notch receptors should ideally not be studied in isolation, indeed in tumours, the microenvironment 
would play a crucial role in modulating signalling of the Notch pathways, as previously shown in ALCL 
(Jundt et al, 2002), but this is a well-documented fact more broadly (Reviewed in Bray, 2016). To study 
this, ALCL cells activated by the Notch ligand DLL1 were treated with GSI I, in an attempt to model a 
more realistic tumour model. The main finding from this experiment was that ligand activation 
attenuates the effect of γ-secretase inhibition, and reassuringly similar results have been observed 
previously, albeit in the context of T cell differentiation: presence of the Notch1 ligand DLL1 expressed 
by OP9 feeder cells reversed the decrease in Notch1 target gene expression caused by γ-secretase 
inhibition (Zhou et al, 2008). However, it is unlikely that the tumour microenvironment would provide 
the 1:1 ligand-to-receptor ratio simulated here, and thus the effect seen is probably amplified 
compared to what would be observed in patients. Ideally, GSIs would be tested in a mouse model of 
ALCL, which is much closer to patient conditions. Nevertheless, this points to an important potential 
caveat of using GSIs as a stand-alone therapy and reinforces the importance of the combination 
treatment with ALK TKIs.  
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To conclude, in this chapter GSIs are shown to be a viable frontline treatment option for ALK+ and ALK- 
ALCL, and in the former case, in combination with ALK TKIs but also as a second line protocol when 







7. Concluding remarks & future work 
 
The genetics underlying ALK+ ALCL remains largely unknown. Being a relatively rare cancer with a 
common, well-characterised driving oncogenic event, little effort has been made to uncover other 
genetic alterations. We therefore sequenced 18 ALK+ ALCL tumours and analysed their genome 
together with 7 previously reported ALK+ cases (Crescenzo et al, 2015) in order to uncover mechanisms 
of pathogenesis, biomarkers and novel therapeutic targets. We revealed that paediatric ALK+ ALCL 
tumours (≤18 years of age) have fewer variants than adult cases in keeping with age-related increases 
in mutational load (Gröbner et al, 2018). However, overall the genome remains largely silent and 
devoid of significant insertions, deletions or copy number variations, also in keeping with previous 
publications (Youssif et al, 2009; Salaverria et al, 2008). Whilst we detected differences between the 
genomes at diagnosis of patients who did and did not go on to relapse, our sample size was too small 
to be able to deduce any firm conclusions as to mutational events that may be predictive of relapse. 
Analysis of a larger number of samples would be the next step, as it may not only help explain the 
difference in prognoses between the two different patient groups, but also lead to the discovery of 
reliable predictive biomarkers to differentiate them, and thus allow tailored, personalized treatment 
strategies. In addition, as mentioned before, we hold limited numbers of samples with matched 
constitutive DNA to be able to study of the germline genomic landscape, which is important to identify 
potential predisposing genetic abnormalities. Therefore, a prospective study would include patient 
samples with matched constitutional DNA as well as patients with a range of prognoses to allow a full 
analysis of genetic abnormalities associated with predisposition and/or risk of relapse/recurrence. 
However, paediatric ALCL is rare and therefore the study described herein utilised all available tumour 
samples. 
 
To identify pathways that are key to ALCL biology, gene set enrichment analysis was employed 
revealing a number of pathways commonly affected by mutation in ALK+ ALCL. Unsurprisingly,  
mutations clustered in genes of the TCR signalling pathway, but another key pathway identified was 
Notch1. Gain-of-function mutations in Notch1 have previously been identified in a number of other 
cancers, most notably in approximately 50 to 60% of T cell Acute Lymphoblastic Leukaemia and 
Lymphoma (Weng et al, 2004; Aster et al, 2011; Breit et al, 2006). However, most of these mutations 
are in the intracellular domains of the protein, with few in the extracellular domains (Wang et al, 
2011b; Vollbrecht et al, 2015; Athanasakis et al, 2014). In contrast, a novel mutation in the 9th EGF-like 
domain of extracellular Notch1 (T349P) was detected in 9.3% of ALK+ ALCL patient tumours analysed 
in this study. Whilst variant effect prediction software indicated these variants to be harmful, t he 
functional significance of these mutations was investigated. We showed the positive impact of T349P 
on Notch1 activity as demonstrated by enhanced cell proliferation when expressed in HEK293FT cells. 
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We theorize that Notch1 T349P could modulate ligand binding (either directly or through modulation 
of calcium binding, particularly as calcium signalling is thought to be dysregulated in ALCL and calcium 
ions play an important role in Notch ligand binding (Rand et al, 2000; Rust et al, 2005). An interesting 
next step here would be sequencing the known loci of genomic mutations of the notch1 gene, as it 
seems likely that ALCL patients might present with some of the previously identified and characterized 
mutations of Notch1. As noted previously, this would fit with data from other T cell malignancies, many 
of which present with Notch1 mutations (Weng et al, 2004). Ideally even, the whole exome of the 
notch1 gene would be sequenced for further mutations.  
 
Notch1 has been identified on the surface of ALCL cells (Kamstrup et al, 2014; Jundt et al, 2002), and 
the genomic location of notch1 has been shown to be amplified in a significant number of ALCL 
paediatric patients (10 of 17 patients; Youssif et al, 2009). notch1 also shows strong expression in a 
great majority of ALK+ ALCL, and about half of ALK- ALCL (Kamstrup et al, 2014; Jundt et al, 2002), as 
well as in cutaneous ALCL patients (Kamstrup et al, 2008) – this in itself may be a manifestation of the 
genomic gains identified in ALCL. Strong notch1 expression has been demonstrated in a number of T-
cell and ALCL cell lines (Jundt et al, 2002). These data, added to our own, point to the importance of 
the Notch pathway in ALCL, and led us to investigate the therapeutic potential. Both this study and 
those cited above suggest however that somewhere around a quarter to a third of ALCL patients 
present with low Notch1 expression, though it is not clear what separates these tumours from others, 
with a significantly stronger expression of Notch1. Presumably, this could be caused by reduced NPM-
ALK activity; indeed the literature suggests that ALK- ALCL tumours are less likely to present with strong 
Notch1 expression (Kamstrup et al, 2014). However, all 89 patients in our tissue microarray are ALK+ 
ALCL so it is also likely that there is inter-tumour variability in the expression of Notch1 in ALCL. A 
combination of NPM-ALK-mediated upregulation of notch1 and amplification of the genomic locus of 
notch1 may explain the variability in expression of notch1 between the 89 patients samples we studied. 
 
Regardless of the presence of Notch1 mutations, Notch1 constitutes a therapeutic target in ALCL, 
independent of ALK status. Suppression of Notch1 expression/activity led to an increase in apoptosis 
in keeping with previous reports, which we replicated in both ALK+ and ALK- cell lines (Jundt et al, 
2002; Dang et al, 2019; Kamstrup et al, 2014). Interestingly, in T-ALL the presence of Notch1 mutations 
has been shown to correlate with response to therapy (Breit et al, 2006), whereby patients with 
activating Notch1 mutations have a more favourable long-term response to treatment (prednisone in 
this case). How this fits with the data presented here and in other studies pointing to Notch1 as an 
oncogene is unclear, indeed the role of Notch1 itself in cancers in general has long been unclear,  with 
evidence showing it to be an oncogene while other studies show it to be a tumour suppressor. 
Ultimately, this likely depends on the tumour type, how Notch1 signalling is regulated, on the types of 
Notch1 ligands which are used for its activation, and on the interplay with transcription factors in the 
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nucleus which mediate downstream signalling in combination with the activated, intracellular domain 
of Notch1. 
 
Efforts to modulate Notch signalling therapeutically have been difficult. Indeed, as highlig hted 
previously, the lack of specificity of most early Notch inhibitors (mostly γ-secretase inhibitors, and not 
Notch inhibitors per se) rendered them too toxic (gastrointestinal issues, mostly) and were therefore 
discontinued. The main problem stemmed from so-called on-target effects: inhibition of Notch 
signalling in the epithelial cells of the gut leads progenitor cells to differentiate into goblet cells over 
enterocytes (Aster, 2009). Considering that these are not off-target effects, the toxicity observed was 
a major issue, as simply fine-tuning the specificity of Notch inhibitors would not solve the problem.  
 
Fortunately, new, inventive approaches that do not attempt to target γ-secretase have yielded 
promising new compounds. Recently, CB-103, a pan-Notch protein-protein inhibitor acting to inhibit 
the Notch transcription factor complex inside the nucleus, thus preventing downstream Notch 
signalling, has shown its efficacy in a number of tumour types in pre-clinical studies (Lehal et al, 2018; 
Weber et al, 2018), and has already progressed to early-phase clinical trials to test its safety profile in 
patients (Perez Garcia et al, 2018; clinical trial IDs NCT03422679 and 2017-001491-35). Another 
mechanism to inhibit Notch that is being considered is to block the interaction of Notch with its ligand. 
For example, competitive inhibitors are being investigated, although unfortunately early studies 
showed little in the way of reduced gastrointestinal toxicity (Briot & Iruela-Arispe, 2015). Different 
attempts have yielded more promising results, demonstrating an increase in goblet cells in mouse 
models, while also showing that this approach reduced angiogenesis in addition to reducing tumour 
growth (Kangsamaksin et al, 2015). The latest iterations of such antibodies seem to show ever-
decreased toxicity in pre-clinical mouse trials without compromising on anti-tumour activity (Masiero 
et al, 2019). As a result, these newer methods of Notch inhibition raise hope that work such as that 
laid out in this thesis will have practical use for patients in the clinic, as toxic chemotherapy is phased 
out from paediatric treatment schedules. 
 
Intriguingly, NPM-ALK has been shown to be sufficient to induce notch1 expression in mouse 
thymocytes (Malcolm et al, 2016), showing that the two signalling pathways are intricately linked in 
ALCL. Not only do we confirm this by silencing npm-alk in ALCL, but we also show that NPM-ALK acts 
through STAT3, which binds to notch1. This could explain why we observed synergistic effects between 
crizotinib and γ-secretase inhibitors in inducing cell death. TKIs of NPM-ALK have been a boon for adult 
ALCL patients, and a potential one for paediatric patients – though unfortunately some patients 
relapse, as with many small molecule inhibitors (Gambacorti-Passerini et al, 2016). For this reason, we 
show here for the first time that resistance to TKIs such as crizotinib do not significantly impact the 
sensitivity of ALCL to γ-secretase inhibitors targeting the Notch pathway. In other words, we show the 
potential of Notch inhibition as a second-line therapy, where TKIs fail (Gambacorti-Passerini et al, 
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2016). In addition, it seems likely that adding a Notch inhibitor to front-line treatment in combination 
with a TKI such as crizotinib would reduce the chances of relapse or resistance developing, particularly 
in cases where resistance develops in the form of mutations to npm-alk (Prokoph, et al., 2019; in 
publication). Further work, in the form of pre-clinical studies such as combination treatments in animal 
models would confirm whether such a therapy schedule does indeed delay relapse significantly.  
 
Importantly, we show the potential of targeting the Notch pathway in the ALK- ALCL setting, which has 
never been tested before. Given the role we found of NPM-ALK in upregulating notch1, it was not clear 
that Notch1 would be as effective a therapeutic target in tumours lacking the ALK translocation, 
although as demonstrated, GSIs are just as effective at impeding the growth of ALK- ALCL. Though we 
did not find that strength of Notch1 expression sensitizes cells to either cytotoxic schedules or GSIs, 
analysis of a large cohort of 89 ALK+ ALCL patients showed that strength of Notch1 protein expression 
retrospectively correlates with Event-Free Survival. Given that dose de-escalation in low-risk ALCL 
patients could reduce toxicity and improve quality of life, as well as decrease long-term risks derived 
from cytotoxic therapies, these data are particularly important and could inform future trial designs.  
We also confirm in a significantly larger cohort that Notch1 is strongly expressed in a large majority of 
ALCL patients. This finding is important in itself as it highlights the potential of Notch inhibitors as a 
therapy: though we showed that stronger expression does not correlate with increased sensitivity to 
GSIs, the inverse is unlikely to be true: ALCL cells that do not stably express Notch1 are unlikely to 
respond to GSIs, thus it is important that a large majority of patients express Notch1 for this treatment 
strategy to be viable. Since the absolute number of ALCL patients is very small compared to many other 
cancer types, it is unlikely that any new treatment strategies only targeting a subset of ALCL patients 
would interest pharmaceutical companies, which typically target larger potential markets. Indeed, the 
fact that ALK- ALCL patients are a potential market for Notch inhibitors would increase their 
attractiveness, particularly since they could be trialled more easily in adult patients, who make up a 
large majority of ALK- ALCL patients, before progressing to paediatric patients.  
 
To conclude, we present here for the first time the genomic landscape of ALK+ ALCL, and use these 
data to demonstrate the importance of the Notch pathway to ALCL pathobiology, as well as the 
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TYW1B 24 chr7:72728896 G1118A W373X stopgain  






























PYGL 16 chr14:50911873 del T  splicing variant  


























TAAR9 13 chr6:132538470 A181T K61X stopgain  











CYP3A5 12 chr7:99672916 T>C  splicing variant  









































MROH5 10 chr8:141494938 C>T  splicing variant  
























TRPT1 9 chr11:64226062 G>C  splicing variant  













































































PPFIA3 7 chr19:49133149 T>G  splicing variant COSM135843 
PTEN 7 chr10:87864104 del T  splicing variant  
MPRIP 7 chr17:17154305 G>T  splicing variant  






















































































NPHP4 6 chr1:5875102 T>A  splicing variant  
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VPS50 5 chr7:93294638 T>G  splicing variant  
BCAP31 5 chrX:153724015 C>A  splicing variant  
TAS2R19 5 chr12:11021672 A900G X300W stoploss  



























































































































































































































































ZFP64 4 chr20:52164759 ins AA  splicing variant  
MTCH2 4 chr11:47622719 G780A W260X stopgain  
RETNLB 4 chr3:108757146 
39 ins 
TAATCCCC 
L14 ins X stopgain  
KCNQ2 4 chr20:63407011 C2168A S723X stopgain  





























DSPP 3 chr4:87615750 3088-3105 del 
1030-




































































































PA2G4 3 chr12:56106718 ins A  splicing variant  
SLC3A1 3 chr2:44301129 del T  splicing variant  
LRRC37A3 3 chr17:64858885 ins A  splicing variant  
IQCK 3 chr16:19717694 G>C  splicing variant  
PIBF1 3 chr13:72835370 ins A  splicing variant  
CSF1 3 chr1:109924191 G>T  splicing variant  
PKD2L2 3 chr5:137936318 A>G  splicing variant  
MAD1L1 3 chr7:2014501 C>A  splicing variant  
PAIP1 3 chr5:43538923 C>T  splicing variant  
DGKZ 3 chr11:46378989 A>C  splicing variant  
PIGQ 3 chr16:582881 A>T  splicing variant  
DOCK8 3 chr9:463655 C5907A Y1969X stopgain 
COSM398289
1 
NPIPB15 3 chr16:74391889 G1141T E381X stopgain 
COSM459287
8 
BAGE4 3 chr21:10414915 A120C X40C stoploss  
 
